Gentiva Health Services (GTIV) 10-K/A 14 Nov 14 2013 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 07, 2014	Jun. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'GENTIVA HEALTH SERVICES INC	'	'
Entity Central Index Key	'0001096142	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	36,766,018	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$293,970,426

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$86,957	$207,052
Accounts receivable, less allowance for doubtful accounts of $10,680 and $8,777 at December 31, 2013 and December 31, 2012, respectively	289,905	251,080
Deferred tax assets, net	28,153	12,263
Prepaid expenses and other current assets	64,746	45,632
Total current assets	469,761	516,027
Note receivable from CareCentrix	28,471	28,471
Fixed assets, net	49,375	41,414
Intangible assets, net	253,727	190,725
Goodwill	383,487	656,364
Other assets	68,647	75,045
Total assets	1,253,468	1,508,046
Current liabilities:	'	'
Current portion of long-term debt	45,325	25,000
Accounts payable	15,659	13,445
Payroll and related taxes	64,857	45,357
Deferred revenue	43,864	37,444
Medicare liabilities	23,894	27,122
Obligations under insurance programs	82,634	56,536
Accrued nursing home costs	22,219	18,428
Other accrued expenses	77,018	66,567
Total current liabilities	375,470	289,899
Long-term debt	1,124,432	910,182
Deferred tax liabilities, net	8,483	41,017
Other liabilities	53,084	33,988
Commitments and contingencies (Note 18)	'	'
Gentiva shareholders' equity:	'	'
Common stock, $0.10 par value; authorized 100,000,000 shares; issued 37,713,302 and 32,009,286 shares at December 31, 2013 and December 31, 2012, respectively	3,771	3,201
Additional paid-in capital	462,262	399,148
Treasury stock, 1,337,882 and 1,260,879 shares at December 31, 2013 and December 31, 2012, respectively	-18,773	-17,852
Accumulated deficit	-758,136	-153,075
Total Gentiva shareholders' equity	-310,876	231,422
Noncontrolling interests	2,875	1,538
Total equity	-308,001	232,960
Total liabilities and equity	$1,253,468	$1,508,046

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivables, allowance for doubtful accounts	$10,680	$8,777
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,713,302	32,009,286
Treasury stock, shares	1,337,882	1,260,879

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Income Statement [Abstract]	'		'		'
Net revenues	$1,726,644		$1,712,804		$1,798,778
Cost of services sold	942,180		908,741		948,455
Gross profit	784,464		804,063		850,323
Selling, general and administrative expenses	-706,227		-655,766		-731,299
Goodwill, intangibles and other long-lived asset impairment	-612,380	[1]	-19,132	[1]	-643,305	[1]
Gain on sale of assets and businesses, net	0		8,014		1,061
Dividend income	0		0		8,590	[2]
Interest income	2,704		2,661		2,686
Interest expense and other	-113,088		-92,608		-91,296
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	-644,527		47,232		-603,240
Income tax benefit (expense)	39,953		-17,251		76,123
Equity in net (loss) earnings of CareCentrix	0		-2,301		68,381
(Loss) income from continuing operations	-604,574		27,680		-458,736
Discontinued operations, net of tax	0		0		8,315
Net (loss) income	-604,574		27,680		-450,421
Less: Net income attributable to noncontrolling interests	-487		-884		-641
Net (loss) income attributable to Gentiva shareholders	-605,061		26,796		-451,062
Total comprehensive (loss) income	-604,574		27,680		-450,899
Basic earnings per common share:	'		'		'
Income (Loss) from Continuing Operations, Per Basic Share	($18.94)		$0.88		($15.14)
Discontinued operations, net of tax	$0		$0		$0.28
Net (loss) income attributable to Gentiva shareholders	($18.94)		$0.88		($14.86)
Weighted average shares outstanding	31,954		30,509		30,336
Diluted earnings per common share:	'		'		'
(Loss) income from continuing operations attributable to Gentiva shareholders	($18.94)		$0.87		($15.14)
Discontinued operations, net of tax	$0		$0		$0.28
Net (loss) income attributable to Gentiva shareholders	($18.94)		$0.87		($14.86)
Weighted average shares outstanding	31,954		30,687		30,336
Amounts attributable to Gentiva shareholders:	'		'		'
(Loss) income from continuing operations	-605,061		26,796		-459,377
Discontinued operations, net of tax	0		0		8,315
Net (loss) income attributable to Gentiva shareholders	($605,061)		$26,796		($451,062)
[1]	The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.
[2]	For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Companybs combined common and preferred ownership of CareCentrix.

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Deficit) [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]	Harden Healthcare Holdings Inc. [Member]
In Thousands, except Share data, unless otherwise specified
Beginning Balance at Dec. 31, 2010	$637,029	$3,080	$372,106	$271,191	$478	($12,484)	$2,658	'
Shares, Beginning Balance at Dec. 31, 2010	'	30,799,091	'	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'	'	'	'
Net (loss) income	-450,421	0	0	-451,062	0	0	641	'
Unrealized loss on interest rate swap, net of tax	-768	0	0	0	-768	0	0	'
Realized loss on interest rate swap	290	'	'	'	290	'	'	'
Total comprehensive income (loss)	-450,899	0	0	-451,062	-478	0	641	'
Income tax benefits associated with the exercise of non-qualified stock options	257	0	257	0	0	0	0	'
Equity-based compensation expense	7,548	0	7,548	0	0	0	0	'
Other non-cash compensation expense	407	0	407	0	0	0	0	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors, shares	'	636,173	'	'	'	'	'	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	7,901	64	7,837	0	0	0	0	'
Acquisition of noncontrolling interest	-320	0	-352	0	0	0	32	'
Distribution to partnership interests	-738	0	0	0	0	0	-738	'
Treasury shares:	'	'	'	'	'	'	'	'
Common stock received from Healthfield escrow	-394	0	0	0	0	-394	0	'
Ending Balance at Dec. 31, 2011	200,791	3,144	387,803	-179,871	0	-12,878	2,593	'
Shares, Ending Balance at Dec. 31, 2011	'	31,435,264	'	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'	'	'	'
Net (loss) income	27,680	0	0	26,796	0	0	884	'
Total comprehensive income (loss)	27,680	0	0	26,796	0	0	884	'
Income tax benefits associated with the exercise of non-qualified stock options	-223	0	-223	0	0	0	0	'
Equity-based compensation expense	7,645	0	7,645	0	0	0	0	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors, shares	'	574,022	'	'	'	'	'	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	3,980	57	3,923	0	0	0	0	'
Acquisition of noncontrolling interest	-1,113	0	0	0	0	0	-1,113	'
Distribution to partnership interests	-826	0	0	0	0	0	-826	'
Treasury shares:	'	'	'	'	'	'	'	'
Common stock received from Healthfield escrow	-4,974	0	0	0	0	-4,974	0	'
Ending Balance at Dec. 31, 2012	232,960	3,201	399,148	-153,075	0	-17,852	1,538	'
Shares, Ending Balance at Dec. 31, 2012	'	32,009,286	'	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'	'	'	'
Net (loss) income	-604,574	0	0	-605,061	0	0	487	'
Total comprehensive income (loss)	-604,574	0	0	-605,061	0	0	487	'
Income tax benefits associated with the exercise of non-qualified stock options	-1,507	0	-1,507	0	0	0	0	'
Equity-based compensation expense	8,210	0	8,210	0	0	0	0	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors, shares	'	891,602	'	'	'	'	'	'
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	3,231	89	3,142	0	0	0	0	'
Issuance of stock in connection with Harden acquisition, shares	'	4,812,414	'	'	'	'	'	'
Issuance of stock in connection with Harden acquisition, value	53,750	481	53,269	0	0	0	0	'
Minority interest capital contribution	1,600	0	0	0	0	0	1,600	'
Distribution to partnership interests	-750	0	0	0	0	0	-750	'
Treasury shares:	'	'	'	'	'	'	'	'
Stock repurchase	-921	0	0	0	0	-921	0	'
Ending Balance at Dec. 31, 2013	($308,001)	$3,771	$462,262	($758,136)	$0	($18,773)	$2,875	'
Shares, Ending Balance at Dec. 31, 2013	'	37,713,302	'	'	'	'	'	'

Consolidated_Statements_Of_Cha1

Consolidated Statements Of Changes In Shareholders' Equity Consolidated Statements Of Changes In Shareholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Statement of Stockholders' Equity [Abstract]	'	'
Treasury stock, shares, acquired	'	605,077
Stock withheld for payroll tax withholdings related to equity-based compensation, shares	77,003	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OPERATING ACTIVITIES:	'	'	'
Net (loss) income	($604,574)	$27,680	($450,421)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'	'
Depreciation and amortization	24,621	26,580	31,032
Amortization of debt issuance costs	14,715	13,300	12,704
Write off of debt issuance cost	16,085	461	3,559
Provision for doubtful accounts	6,730	4,066	8,541
Equity-based compensation expense	8,210	7,645	7,548
Windfall tax benefits associated with equity-based compensation	-119	-88	-192
Goodwill, intangibles and other long-lived asset impairment	612,380	19,132	643,305
(Gain) loss on sale of assets and businesses, net	0	-8,014	-12,536
Equity in net (loss) earnings of CareCentrix, including gain on sale, net of tax	0	2,301	-68,381
Deferred income tax (benefit) expense	-37,048	23,513	-86,367
Changes in assets and liabilities, net of effects from acquisitions and dispositions:	'	'	'
Accounts receivable	910	34,882	-39,542
Prepaid expenses and other current assets	-17,966	-15,447	10,467
Accounts payable	-4,161	832	-2,949
Payroll and related taxes	-1,289	3,275	-2,136
Deferred revenue	-3,719	3,330	-2,273
Medicare liabilities	-3,228	4,142	-8,170
Obligations under insurance programs	12,681	1,560	-6,923
Accrued nursing home costs	1,043	-5,795	-18
Other accrued expenses	5,836	-23,323	-31,642
Other, net	5,998	5,936	-465
Net cash provided by operating activities	37,105	125,968	5,141
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-19,075	-11,779	-19,231
Proceeds from sale of businesses, net of cash transferred	508	9,220	146,315
Proceeds from sale of assets	203	0	0
Acquisition of businesses, net of cash acquired	-359,435	-22,335	-320
Net cash (used in) provided by investing activities	-377,799	-24,894	126,764
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,231	3,980	7,901
Windfall tax benefits associated with equity-based compensation	119	88	192
Proceeds from issuance of debt	817,525	0	0
Borrowings under revolving credit facility	27,000	0	0
Payments of contingent consideration accrued at acquisition date	-1,675	0	0
Repayment of long-term debt	-610,182	-52,943	-63,438
Repurchase of common stock	0	-4,974	0
Debt issuance costs	-15,187	-4,125	-15,460
Minority interest capital contribution	1,600	0	0
Distribution to minority interests	-750	-825	-673
Other	-1,082	-135	-267
Net cash (used in) provided by financing activities	220,599	-58,934	-71,745
Net change in cash and cash equivalents	-120,095	42,140	60,160
Cash and cash equivalents at beginning of period	207,052	164,912	104,752
Cash and cash equivalents at end of period	86,957	207,052	164,912
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'	'
Interest paid	77,898	78,783	78,639
Income taxes paid	$1,057	$4,375	$38,067

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Common stock received from Healthfield escrow, shares	'	'	14,334
Deferred tax (expense) benefit associated with stock compensation deductions	($1.50)	($0.20)	$0.30
Common Stock [Member]	'	'	'
Issuance of stock in connection with Harden acquisition, shares	4,812,414	'	'

Background_and_Basis_of_Presen

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Background and Basis of Presentation	'
	Background and Basis of Presentation
	Gentiva Health Services, Inc. (“Gentiva” or the “Company”) provides home health, hospice, and community care services throughout most of the United States. The Company’s operations involve servicing its patients and customers through (i) its Home Health segment, (ii) its Hospice segment and (iii) its Community Care segment. Discontinued operations represent services provided to patients through the Company's Rehab Without Walls® business and the Company’s homemaker services business in Illinois ("IDOA").
	Effective October 18, 2013, the Company completed the acquisition of certain net assets relating to the home health, hospice and community care businesses of Harden Healthcare Holdings, Inc. ("Harden") pursuant to an Agreement and Plan of Merger dated as of September 18, 2013. Total consideration for the acquisition was $426.8 million, exclusive of transaction costs, consisting of approximately $365.0 million in cash, $53.8 million in shares of Gentiva's common stock and additional contingent consideration of $9.5 million, recorded at estimated fair value of approximately $8.1 million. See Note 5.
	In connection with the acquisition, the Company entered into a new Senior Secured Credit Agreement providing for (i) a six-year $670 million Term Loan B facility, (ii) a five-year $155 million Term Loan C facility and (iii) a five-year $100 million revolving credit facility, which replaced the Company's existing credit agreement. The Company's existing credit agreement was terminated upon consummation of the Harden transaction. The Company utilized a combination of cash on hand and proceeds from the new senior secured term loan facility and a portion of the new revolving credit facility to fund the acquisition consideration, repay all amounts outstanding under Harden's then existing credit facility, which was then terminated, and repay all amounts outstanding under the Company's then existing credit facility, which was then terminated. See Note 13.
	In addition, during 2013 the Company completed three other acquisitions for total cash consideration of $6.1 million. These transactions were done primarily to extend the Company's geographic coverage areas for home health and hospice services.
	A summary of the transactions for 2013, 2012 and 2011 and the consideration paid are as follows (in millions):
	Acquisitions:	Geographic Service Area	Date		Consideration
	Harden Healthcare Holdings, Inc	Nationwide	October 18, 2013		$	426.8
	Appalachian Regional Health Systems	North Carolina	September 30, 2013		2.7
	Wake Forest Baptist Health Care at Home, LLC	North Carolina	August 23, 2013		2.4
	Hope Hospice, Inc.	Indiana	April 30, 2013		1
	Family Home Care Corporation	Washington and Idaho	August 31, 2012		12.3
	North Mississippi Hospice	Mississippi	August 31, 2012		4.7
	Advocate Hospice	Indiana	July 22, 2012		5.5
	Odyssey HealthCare of Augusta, LLC	Georgia	April 29, 2011		0.3
	In addition, during 2012 the Company sold various home health and hospice operations based in Louisiana and Phoenix and sold off its consulting business. A summary of the Company's operations which were sold during 2012 and 2011 are as follows (in millions):
	Dispositions:	Date	Consideration
	Phoenix area hospice operations	November 30, 2012	$	3.5
	Gentiva Consulting	May 31, 2012	0.3
	Louisiana home health and hospice operations	Second Quarter 2012	6.4
	Certain home health branches-Utah, Michigan, Nevada and Brooklyn, New York	Fourth Quarter 2011	1.6
	Furthermore, during 2011 the Company sold its IDOA business based in Illinois and its Rehab Without Walls® business. A summary of these transactions follows (in millions):
	Discontinued operations:	Date	Consideration
	IDOA	October 14, 2011	$	2.4
	Rehab Without Walls®	September 10, 2011	9.8
	The Company considered these business units as operating segments and, as such, the financial results of these businesses were reported as discontinued operations for all periods presented in the Company’s consolidated financial statements.
	During 2011, the Company sold its equity investment in CareCentrix Holdings Inc. The Company recorded accumulated and unpaid dividends on the preferred shares of approximately $8.6 million for the year ended December 31, 2011, which are reflected in dividend income in the Company’s consolidated statement of comprehensive income. The Company also recorded a net gain of approximately $67.1 million, which is reflected in equity in net earnings of CareCentrix, including gain on sale in the Company’s consolidated statement of comprehensive income. See Note 8 for additional information.
	The impact of these transactions have been reflected in the Company's results of operations and financial condition from their respective closing dates. See Note 5 for more information.

Restatement_and_Revision_of_Pr

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]	'
Restatement and Revision of Previously Reported Consolidated Financial Statements	'
	Restatement and Revision of Previously Reported Consolidated Financial Statements
	The Company determined that historically it had incorrectly applied applicable accounting guidance in accounting for its indefinite-lived intangible assets related to closed or consolidated licenses on a pooled basis and did not write-off license costs when the Company closed or consolidated individual operating locations and to correct certain assumptions used in its valuation models for goodwill and indefinite-lived intangibles. The Company has determined it should amortize the full license cost over the period of closure or consolidation.
	The Company determined the impact of this error was material to the 2013 consolidated financial statements, and accordingly, has restated its consolidated balance sheet, consolidated statement of comprehensive loss, consolidated statement of changes in shareholders' equity and consolidated statement of cash flows as of and for the year ended December 31, 2013. The Company also revised its consolidated statement of comprehensive loss and the consolidated statement of cash flows for the year ended December 31, 2011, as well as its consolidated balance sheet and consolidated statement of changes in shareholders' equity for the year ended December 31, 2012. The Company determined the impact was immaterial to the consolidated financial statements for 2011 and 2012.
	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding restated or revised amounts:
		As of December 31, 2013
	Restated Consolidated Balance Sheet (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Intangible assets, net	$	256,282		$	(2,555	)	$	253,727
	Goodwill	390,081			(6,594		)	383,487
	Total Assets	1,262,617			(9,149		)	1,253,468
	Deferred tax liabilities, net	9,825			(1,342		)	8,483
	Accumulated deficit	(750,329		)	(7,807		)	(758,136		)
	Total Gentiva shareholders’ equity	(303,069		)	(7,807		)	(310,876		)
	Total equity	(300,194		)	(7,807		)	(308,001		)
	Total liabilities and equity	1,262,617			(9,149		)	1,253,468
		As of December 31, 2012
	Revised Consolidated Balance Sheet (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Intangible assets, net	$	193,613		$	(2,888	)	$	190,725
	Total Assets	1,510,934			(2,888		)	1,508,046
	Deferred tax liabilities, net	42,165			(1,148		)	41,017
	Accumulated deficit	(151,335		)	(1,740		)	(153,075		)
	Total Gentiva shareholders’ equity	233,162			(1,740		)	231,422
	Total equity	234,700			(1,740		)	232,960
	Total liabilities and equity	1,510,934			(2,888		)	1,508,046
		For the Year Ended December 31, 2013
	Restated Consolidated Statement of Comprehensive Loss (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Selling, general and administrative expenses	$	(701,716	)	$	(4,511	)	$	(706,227	)
	Goodwill, intangibles and other long-lived asset impairment	(610,436		)	(1,944		)	(612,380		)
	Loss from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	(638,072		)	(6,455		)	(644,527		)
	Income tax benefit	39,565			388			39,953
	Loss from continuing operations	(598,507		)	(6,067		)	(604,574		)
	Net loss	(598,507		)	(6,067		)	(604,574		)
	Net loss attributable to Gentiva shareholders	(598,994		)	(6,067		)	(605,061		)
	Total comprehensive loss	(598,507		)	(6,067		)	(604,574		)
	Basic Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Diluted Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
		For the Year Ended December 31, 2011
	Revised Consolidated Statement of Comprehensive Loss (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Selling, general and administrative expenses	$	(730,407	)	$	(892	)	$	(731,299	)
	Loss from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	(602,348		)	(892		)	(603,240		)
	Income tax benefit	75,768			355			76,123
	Loss from continuing operations	(458,199		)	(537		)	(458,736		)
	Net loss	(449,884		)	(537		)	(450,421		)
	Net loss attributable to Gentiva shareholders	(450,525		)	(537		)	(451,062		)
	Total comprehensive loss	(450,362		)	(537		)	(450,899		)
	Basic Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(15.13	)	$	(0.01	)	$	(15.14	)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(14.85	)	$	(0.01	)	$	(14.86	)
	Diluted Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(15.13	)	$	(0.01	)	$	(15.14	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(14.85	)	$	(0.01	)	$	(14.86	)
	Revised Consolidated Statement of Changes in Shareholders' Equity (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Retained Earnings (Deficit), Balance at December 31, 2010	$	272,394		$	(1,203	)	$	271,191
	Net loss	(450,525		)	(537		)	(451,062		)
	Total comprehensive loss	(450,525		)	(537		)	(451,062		)
	Retained Earnings (Deficit), Balance at December 31, 2011	(178,131		)	(1,740		)	(179,871		)
	Total Shareholders' Equity, Balance at December 31, 2010	$	638,232		$	(1,203	)	$	637,029
	Net loss	(449,884		)	(537		)	(450,421		)
	Total comprehensive loss	(450,362		)	(537		)	(450,899		)
	Total Shareholders' Equity, Balance at December 31, 2011	202,531			(1,740		)	200,791
	Restated Consolidated Statement of Changes in Shareholders' Equity (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Retained Earnings (Deficit), Balance at December 31, 2012	$	(151,335	)	$	(1,740	)	$	(153,075	)
	Net loss	(598,994		)	(6,067		)	(605,061		)
	Total comprehensive loss	(598,994		)	(6,067		)	(605,061		)
Retained Earnings (Deficit), Balance at December 31, 2013	(750,329		)	(7,807		)	(758,136		)
Total Shareholders' Equity, Balance at December 31, 2012	$	234,700		$	(1,740	)	$	232,960
Net loss	(598,507		)	(6,067		)	(604,574		)
Total comprehensive loss	(598,507		)	(6,067		)	(604,574		)
Total Shareholders' Equity, Balance at December 31, 2013	(300,194		)	(7,807		)	(308,001		)
	For the Year Ended December 31, 2013
Restated Consolidated Statement of Cash Flows	As Previously Reported			Restatement Adjustments			As Restated
(In thousands)
Net loss	$	(598,507	)	$	(6,067	)	$	(604,574	)
Depreciation and amortization	20,110			4,511			24,621
Goodwill, intangibles and other long-lived asset impairment	610,436			1,944			612,380
Deferred income tax benefit	(36,660		)	(388		)	(37,048		)
	For the Year Ended December 31, 2011
Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			As Revised
(In thousands)
Net loss	$	(449,884	)	$	(537	)	$	(450,421	)
Depreciation and amortization	30,140			892			31,032
Deferred income tax benefit	(86,012		)	(355		)	(86,367		)
The Company has also reflected these corrections as applicable in its consolidated financial statements and also in the condensed consolidating financial statements presented in Note 22. Supplemental Guarantor and Non-Guarantor Financial Information and Note 23. Quarterly Financial Information.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Accounting Policies	'
	Summary of Significant Accounting Policies
	Consolidation
	The Company's consolidated financial statements include the accounts and operations of the Company and its subsidiaries in which the Company owns more than a 50 percent interest. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of the Company's hospice programs, are reported below net income under the heading “Net income attributable to noncontrolling interests” in the Company's consolidated statements of comprehensive income for the years ended December 31, 2013, 2012 and 2011 and presented as a component of equity in the Company's consolidated balance sheets at December 31, 2013 and 2012. All material balances and transactions between the consolidated entities have been eliminated.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The most critical estimates relate to revenue recognition, which incorporates the impact of various revenue adjustments including payment caps under the Medicare program for hospice, the collectibility of accounts receivable and related reserves, impairment tests for goodwill and other indefinite-lived intangible assets, obligations under insurance programs, including workers’ compensation, professional liability, property and general liability and employee health and welfare insurance programs.
	A description of the critical accounting policies and a discussion of the significant estimates and judgments associated with such policies are described below.
	Significant Accounting Policies and Estimates
	Revenue Recognition
	Revenues recognized by the Company are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. In each category described below, the impact of the estimate, if applicable, undertaken by the Company with respect to these elements is reflected in net revenues in the consolidated statements of comprehensive income. See further discussion of the elements below under the heading “Causes and Impact of Change on Revenue.”
	Home Health Episodic Net Revenues
	Under the home health Prospective Payment System (“PPS”) of reimbursement, for Medicare and Medicare Advantage programs paid at episodic rates, the Company estimates net revenues to be recorded based on a reimbursement rate which is determined using relevant data, relating to each patient’s health status including clinical condition, functional abilities and service needs, as well as applicable wage indices to give effect to geographic differences in wage levels of employees providing services to the patient. Billings under PPS are initially recognized as deferred revenue and are subsequently amortized into revenue over an average patient treatment period. The process for recognizing revenue to be recorded is based on certain assumptions and judgments, including (i) the average length of time of each treatment as compared to a standard 60 day episode (ii) any differences between the clinical assessment of and the therapy service needs for each patient at the time of certification as compared to actual experience, as well as (iii) the level of adjustments to the fixed reimbursement rate relating to patients who receive a limited number of visits, are discharged but readmitted to another agency within the same 60 day episodic period or are subject to certain other factors during the episode. Deferred revenue of approximately $43.9 million and $37.4 million, primarily relating to the PPS program, is included under current liabilities in the consolidated balance sheets as of December 31, 2013 and 2012, respectively.
	Hospice Medicare Net Revenues
	Medicare revenues for Hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payer or other reasons unrelated to credit risk.
	In addition, each hospice provider is subject to certain Medicare payment limitations, including an overall payment cap. The Medicare payment cap, which is calculated for each provider by the Medicare fiscal intermediary at the end of the hospice cap period, is determined under the proportional method. The proportional method allocates each beneficiary's Medicare payment cap based on the ratio of the number of days the beneficiary received hospice services from the Company over the total number of days the beneficiary received hospice services from all providers. The Medicare payment cap amount is then further allocated between the hospice cap periods based on the ratio of the number of days the Company provided hospices services during each cap period. The sum of each beneficiary's Medicare cap payment, as determined above, represents the aggregate Medicare payment cap. Medicare revenue paid to a provider during the hospice cap period cannot exceed the aggregate Medicare payment cap. As of December 31, 2013, the Company currently has 2 programs estimated to exceed the Medicare cap limits for the 2014 cap year. The Company has recorded a net hospice Medicare cap credit of approximately $4.6 million in the Company’s consolidated statements of comprehensive income for 2013 and $4.4 million and $4.3 million for estimated cap exposure as a reduction in Medicare revenues in the Company’s consolidated statements of comprehensive income for 2012 and 2011, respectively. As of December 31, 2013 and 2012, approximately $6.5 million and $15.9 million, respectively, is reflected as Medicare liabilities in the Company’s consolidated balance sheets associated with Medicare cap exposures.
	Fee-for-Service Agreements
	Under fee-for-service agreements with commercial payers, certain state and local government payers and patients, net revenues are recorded based on net realizable amounts to be received in the period in which the services are provided. Fee-for-service contracts with commercial payers are traditionally one year in term and renew automatically on an annual basis, unless terminated by either party.
	Medicare Settlement Issues under Interim Payment System
	Prior to October 1, 2000, reimbursement of Medicare home healthcare services was based on reasonable allowable costs incurred in providing services to eligible beneficiaries subject to both per visit and per beneficiary limits in accordance with the Interim Payment System established through the Balanced Budget Act of 1997. These costs were reported in annual cost reports which were filed with CMS and were subject to audit by the fiscal intermediary engaged by CMS. During the third quarter of 2013, the fiscal intermediary finalized its audit of the fiscal 2000 cost reports, which are now being settled by CMS. In connection with the finalized audit and expected settlements, the Company recorded approximately $4.0 million as a positive adjustment to net revenues in the Company's consolidated statement of comprehensive income for the year ended December 31, 2013.
	Settlement liabilities are recorded at the time of any probable and reasonably estimable event and any positive settlements are recorded as revenue in the Company’s consolidated statements of comprehensive income in the period in which such gain contingencies are realized.
	Causes and Impact of Change on Revenue
	For each of the sources of revenue, the principal elements in addition to those described above, which can cause change in the amount of revenue to be realized, are (i) an inability to obtain appropriate billing documentation, (ii) an inability to obtain authorizations acceptable to the payer, (iii) utilization of services at levels other than authorized and (iv) other reasons unrelated to credit risk.
	Revenue adjustments resulting from differences between estimated and actual reimbursement amounts are recorded as adjustments to net revenues or recorded against allowance for doubtful accounts, depending on the nature of the adjustment. These are determined by Company management and reviewed from time to time, but no less often than quarterly. Each of the elements described here and under each of the various sources of revenue can effect change in the estimates. Although it is not possible to predict the degree of change that might be effected by a variation in one or more of the elements described, the Company believes that changes in these elements could cause a change in estimate which could have a material impact on the consolidated financial statements. There have not been any material revisions in these estimates for the periods presented in this report.
	Billing and Receivables Processing
	The Company’s billing systems record revenues at net expected reimbursement based on established or contracted fee schedules. The systems provide for an initial contractual allowance adjustment from “usual and customary” charges, which is typical for the payers in the healthcare field. The Company records an initial contractual allowance at the time of billing and reduces the Company’s revenue to expected reimbursement levels. Changes in contractual allowances, if any, are recorded each month. Changes in the nature of contractual allowances have not been material for the periods presented in this filing.
	“Accounts Receivable” section below further outlines matters considered with respect to estimating the allowance for doubtful accounts.
	Accounts Receivable
	Collection Policy
	The process for estimating the ultimate collection of receivables involves significant assumptions and judgments. The Company believes that its collection and reserve processes, along with the monitoring of its billing processes, help to reduce the risk associated with material revisions to reserve estimates resulting from adverse changes in reimbursement experience, revenue adjustments and billing functions. Collection processes are performed in accordance with the Fair Debt Collections Practices Act and include reviewing aging and cash posting reports, contacting payers to determine why payment has not been made, resubmission of claims when appropriate and filing appeals with payers for claims that have been denied. Collection procedures generally include follow up contact with the payer at least every 30 days from invoice date, and a review of collection activity at 90 days to determine continuation of internal collection activities or potential referral to collection agencies. The Company’s bad debt policy includes escalation procedures and guidelines for write-off of an account, as well as the authorization required, once it is determined that the open account has been worked by the Company’s internal collectors and/or collection agencies in accordance with the Company’s standard procedures and resolution of the open account through receipt of payment is determined to be remote. The Company reviews each account individually and does not have either a threshold dollar amount or aging period that it uses to trigger a balance write-off, although the Company does have a small balance write-off policy for non-governmental accounts with debit balances under $10.
	The Company’s policy is to bill for patient co-payments and make good faith efforts to collect such amounts. At the end of each reporting period, the Company estimates the amount of outstanding patient co-payments that will not be collected and the amount of outstanding co-payments that may be waived due to financial hardship based on a review of historical trends. This estimate is made as part of the Company’s evaluation of the adequacy of its allowance for doubtful accounts. There have not been any material revisions in this estimate for the periods presented in this report.
	Accounts Receivable Reserve Methodology
	The Company has implemented a standardized approach to estimate and review the collectibility of its receivables based on accounts receivable aging trends. The Company analyzes historical collection trends, reimbursement experience and revenue adjustment trends by major payers, including Medicare and other payers, as well as by business lines as an integral part of the estimation process related to determining the valuation allowance for accounts receivable. In addition, the Company assesses the current state of its billing functions on a quarterly basis in order to identify any known collection or reimbursement issues to determine the impact, if any, on its reserve estimates, which involve judgment. Revisions in reserve estimates are recorded as an adjustment to the provision for doubtful accounts, which is reflected in selling, general and administrative expenses for continuing operations and in discontinued operations, net of tax in the consolidated statements of comprehensive income. The provision for doubtful accounts relating to continuing operations amounted to $6.7 million and $4.1 million in 2013 and 2012, respectively. The provision for doubtful accounts relating to continuing operations and discontinued operations amounted to $8.4 million and $0.1 million, respectively, in 2011. The allowance for doubtful accounts at December 31, 2013 and 2012 was $10.7 million and $8.8 million, respectively. Additional information regarding the allowance for doubtful accounts can be found in Schedule II—Valuation and Qualifying Accounts in Item 8. Financial Statements and Supplementary Data of this report.
	Goodwill and Other Indefinite-Lived Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various operating units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to its carrying amount to determine if there is potential impairment of goodwill and other indefinite-lived intangible assets. If the fair value of an reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than the carrying value of its goodwill. To determine the fair value of the Company’s reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies and reasonableness tests, as appropriate.
	The Company is required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. The future occurrence of a potential indicator of impairment, such as, but not limited to, a significant adverse change in legal factors or business climate, reductions of projected patient census, an adverse action or assessment by a regulator, as well as other unforeseen factors, would require an interim assessment for some or all of the Company's reporting units and could have a material impact of the Company's consolidated financial statements. See Note 10 for information on the Company's impairment testing.
	Obligations Under Insurance Programs
	The Company is obligated for certain costs under various insurance programs, including workers’ compensation, professional liability, property and general liability, and employee health and welfare.
	The Company may be subject to workers’ compensation claims and lawsuits alleging negligence or other similar legal claims. The Company maintains various insurance programs to cover this risk with insurance policies subject to substantial deductibles and retention amounts. The Company recognizes its obligations associated with these programs in the period the claim is incurred. The cost of both reported claims and claims incurred but not reported, up to specified deductible limits, have generally been estimated based on historical data, industry statistics, the Company’s specific historical claims experience, current enrollment statistics and other information. The Company’s estimates of its obligations and the resulting reserves are reviewed and updated from time to time, but at least quarterly. The elements which impact this critical estimate include the number, type and severity of claims and the policy deductible limits; therefore, the estimate is sensitive and changes in the estimate could have a material impact on the Company’s consolidated financial statements.
	Workers’ compensation and professional and general liability costs associated with continuing operations were $33.9 million, $21.0 million and $15.1 million for the years ended December 31, 2013, 2012 and 2011, respectively. The Company’s workers’ compensation and professional and general liability costs relating to discontinued operations were approximately $0.5 million for the year ended December 31, 2011. The increase in expense for 2013 relates to overall recent trends of rising healthcare costs and the results from a review, conducted by the Company's third-party claims administrators, of established case loss reserves on all open claims in excess of $10,000 and settlements in excess of established reserves. Other drivers of differences in costs between years relate primarily to the number and severity of claims incurred in each reported period as well as changes in the cost of insurance coverage. Workers’ compensation and professional liability claims, including any changes in estimate relating thereto, are recorded primarily in cost of services sold in the Company’s consolidated statements of comprehensive income. There have not been any material revisions in estimates of prior year costs for the periods presented in this report.
	The Company maintains insurance coverage on individual claims. The Company is responsible for the cost of individual workers’ compensation claims and individual professional liability claims up to $500 thousand per incident that occurred prior to March 15, 2002, and $1 million per incident thereafter. The Company also maintains excess liability coverage relating to professional liability and casualty claims which provides insurance coverage for individual claims of up to $25 million in excess of the underlying coverage limits. Payments under the Company’s workers’ compensation program are guaranteed by letters of credit. The Company believes that its present insurance coverage and reserves are sufficient to cover currently estimated exposures, but there can be no assurance that the Company will not incur liabilities in excess of recorded reserves or in excess of its insurance limits.
	The Company provides employee health and welfare benefits under a self insured program and maintains stop loss coverage for individual claims in excess of $400 thousand for 2013. For the years ended December 31, 2013, 2012 and 2011, employee health and welfare benefit costs associated with continuing operations were $86.6 million, $87.5 million and $93.0 million, respectively. Employee health and welfare benefit costs associated with discontinued operations were $0.7 million for December 31, 2011. Differences in costs between years relate primarily to increased enrollment and the number and severity of individual claims incurred in each reported period. Changes in estimates of the Company’s employee health and welfare claims are recorded in cost of services sold for clinical associates and in selling, general and administrative costs for administrative associates in the Company’s consolidated statements of comprehensive income. There have not been any material revisions in estimates of prior year costs for the periods presented in this report.
	The Company also maintains Directors and Officers liability insurance coverage with an aggregate limit of $60 million.
	Other Accounting Policies
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date three months or less from their date of acquisition to be cash equivalents, including money market funds invested in U.S. Treasury securities, short-term treasury bills and commercial paper. Cash and cash equivalents also included amounts on deposit with several major financial institutions in excess of the maximum amount insured by the Federal Deposit Insurance Corporation. Management believes that these major financial institutions are viable entities.
	The Company had operating funds of approximately $5.5 million and $5.4 million at December 31, 2013 and 2012, respectively, which relate exclusively to a non-profit hospice operation managed in Florida.
	Investments
	During 2011, the Company sold its investment in CareCentrix Holdings Inc. The Company recorded accumulated and unpaid dividends on the preferred shares it held of approximately $8.6 million in 2011, which is reflected in dividend income in the Company's consolidated statements of comprehensive income. The Company also recorded a net gain of approximately $67.1 million, which is reflected in equity in net earnings of CareCentrix, including gain on sale in the Company's consolidated statements of comprehensive income.
	As of December 31, 2013 and 2012, the Company held an investment, at cost, in CareCentrix Holdings Inc. of $0.9 million for shares that it expects to receive in settlement of certain tax amounts owed to the Company as set forth in the stock purchase agreement.
	At December 31, 2013 and December 31, 2012, the Company had assets of $34.7 million and $27.7 million, respectively, held in a Rabbi Trust for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The corresponding amounts payable to the plan participants are equivalent to the underlying value of the assets held in the Rabbi Trust. Assets held in a Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets.
	Debt Issuance Costs
	The Company amortizes deferred debt issuance costs over the term of its credit agreement and senior notes. As of December 31, 2013 and 2012, the Company had unamortized debt issuance costs of $28.3 million and $44.2 million, respectively, recorded in other assets in the Company’s consolidated balance sheets.
	On October 18, 2013, the Company entered into a new senior secured credit agreement and terminated the Company's existing credit agreement. In accordance with applicable guidance, due to changes in certain of the Company's participating lenders under the new credit agreement, the Company performed a debt modification analysis. That analysis resulted in the Company recording a write-off of a portion of its prepaid debt issuance costs of approximately $16.1 million, for the year ended December 31, 2013, which is reflected in interest expense in the Company's consolidated statement of income and capitalized debt issuance costs of approximately $24.2 million, which are being amortized over the life of the New Credit Agreement utilizing an effective interest rate methodology. See Note 11.
	During 2012 and 2011, the Company recorded additional write-offs of prepaid debt issuance costs of approximately $0.5 million and $3.5 million, respectively, in conjunction with various amendments of its former credit facility which are reflected in interest expense in the Company’s consolidated statements of comprehensive income.
	Fixed Assets
	Fixed assets, including costs of Company developed software, are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Leasehold improvements are amortized over the shorter of the life of the lease or the life of the improvement. Repairs and maintenance costs are expensed as incurred. See Note 9 for additional information.
	Accounting for Impairment and Disposal of Long-Lived Assets
	The Company evaluates the possible impairment of its long-lived assets, including intangible assets, which are amortized pursuant to authoritative guidance. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset. See Note 9 and Note 10 for additional information.
	Nursing Home Costs
	For patients receiving nursing home care under a state Medicaid program who elect hospice care under Medicare or Medicaid, the Company contracts with nursing homes for the nursing homes to provide patients’ room and board services. The state must pay the Company, in addition to the applicable Medicare or Medicaid hospice daily or hourly rate, an amount equal to at least 95 percent of the Medicaid daily nursing home rate for room and board furnished to the patient by the nursing home. Under the Company’s standard nursing home contracts, the Company pays the nursing home for these room and board services at the Medicaid daily nursing home rate. Nursing home costs are partially offset by nursing home net revenue, and the net amount is included in cost of services sold in the Company’s consolidated statements of comprehensive income.
	Equity-Based Compensation Plans
	The Company has several stock ownership and compensation plans, which are described more fully in Note 15. The Company accounts for its equity-based compensation plans in accordance with authoritative guidance under which the estimated fair value of share-based awards granted under the Company's equity-based compensation plans is recognized as compensation expense over the vesting period of the award.
	Income Taxes
The Company uses the liability method to account for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted. Deferred income tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Uncertain tax positions must be more likely than not before a tax benefit is recognized in the financial statements. The benefit to be recorded is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. See Note 19 for additional information.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	On July 18, 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, Income Taxes (Topic 740) (ASU 2013-11), which provides final guidance that requires an entity to net its liability for unrecognized tax positions against a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. The provisions of this new guidance are effective as of the beginning of our 2014 fiscal year.  The Company does not expect the adoption of this new guidance to have a material impact on on the Company’s consolidated financial statements.
	On July 27, 2012, the FASB issued ASU 2012-02, Intangibles—Goodwill and Other (Topic 350) (ASU 2012-02), which provides final guidance on impairment of indefinite-lived intangible assets other than goodwill that gives companies the option to perform a qualitative assessment that may allow them to skip the annual two-step test and reduce costs. ASU 2012-02 gives companies the option to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If a company concludes that this is the case, it must perform the two-step test. Otherwise, a company can skip the two-step test. The Company adopted ASU 2012-02 in the first quarter of 2013 and the adoption of ASU 2012-02 did not have a material impact on the Company’s consolidated financial statements.

Acquisitions_and_Dispositions

Acquisitions and Dispositions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions and Dispositions	'
	Acquisitions and Dispositions
	Acquisitions
	During 2013, 2012 and 2011, the Company completed several acquisitions as further described below.
	Harden Healthcare Holdings, Inc.
	Effective October 18, 2013, the Company completed the acquisition of certain net assets relating to the home health, hospice and community care businesses of Harden Healthcare Holdings, Inc. ("Harden") pursuant to an Agreement and Plan of Merger dated as of September 18, 2013. The Company completed the acquisition as an entrance into the community care business, primarily throughout Texas, Oklahoma, Missouri and Kansas, and to expand its geographic coverage for its home health and hospice businesses. Total consideration for the acquisition was $426.8 million, exclusive of transaction costs, consisting of approximately $365.0 million in cash, $53.8 million in shares of Gentiva's common stock and additional contingent consideration of $9.5 million, recorded at estimated fair value of approximately $8.1 million. The contingent consideration includes (i) consulting agreements entered into with Capstar Partners, LLC and another former executive of Harden and (ii) a sub-lease termination agreement entered into with Capstar Investment Partners, L.P. See Note 17 for further information.
	In connection with the acquisition, the Company entered into a new Senior Secured Credit Agreement providing for (i) a six-year $670 million Term Loan B facility, (ii) a five-year $155 million Term Loan C facility and (iii) a five-year $100 million revolving credit facility, which replaced the Company's existing credit agreement. The Company's existing credit agreement was terminated upon consummation of the Harden transaction. The Company utilized a combination of cash on hand and proceeds from the new senior secured term loan facility and a portion of the new revolving credit facility to fund the acquisition consideration, repay all amounts outstanding under Harden's then existing credit facility, which was then terminated, and repay all amounts outstanding under the Company's then existing credit facility, which was then terminated. See Note 13.
	The financial results of Harden are included in the Company’s consolidated financial statements from the acquisition date. The purchase price for the acquisition was allocated to the underlying assets acquired and liabilities assumed based on their estimated fair values at the date of the acquisition. Estimated fair values were based on various valuation methodologies, including market studies and a replacement cost method for fixed assets, an income approach using primarily discounted cash flow techniques for amortizable intangible assets, a cost approach considering both replacement cost and opportunity cost methods for indefinite-lived intangible assets and an estimated realizable value approach using historical trends and other relevant information for accounts receivable and certain accrued liabilities. For certain other assets and liabilities, including accounts payable and other accrued liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the purchase price over the fair value of the net identifiable tangible and intangible assets acquired was recorded as goodwill.
	The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). The primary areas of the preliminary valuation that are not yet finalized relate to the fair values of amounts for income taxes for certain tax carryforwards inclusive of associated limitations and valuation allowances, amounts payable to the former Harden shareholders for utilization of tax carryforwards, and the final amount of residual goodwill. The Company expects to continue to obtain information to assist it in determining the fair values of the net assets acquired at the acquisition date during the measurement period.
	The following table summarizes the fair value of the assets acquired and liabilities assumed as of the acquisition date (in thousands):
		October 18, 2013 (Restated)
	Cash and cash equivalents	$	10,203
	Accounts receivable, net	46,195
	Deferred tax asset	13,589
	Prepaids and other current assets	1,890
	Fixed assets, net	9,476
	Identifiable intangible assets, net	71,215
	Goodwill	331,167
	Other assets	2,889
	Total assets acquired	486,624
	Accounts payable and accrued liabilities	58,563
	Other current liabilities	8,720
	Deferred tax liabilities, noncurrent	590
	Total liabilities, assumed	67,873
	Net assets acquired	$	418,751
	The intangible assets that are subject to amortization are amortized on a straight-lined basis over the estimated useful life of the intangible asset. The valuation of the intangible assets by component and their respective useful life are as follows (in thousands):
		(Restated)
	Restated	Home Health			Hospice			Community Care			Total		Useful
													Life
	Intangible assets:
	Tradenames	$	1,052		$	798		$	11,922		$	13,772	5-10 Years
	Covenants not to compete	490			499			1,029			2,018		2-3 Years
	Medicare licenses and certificates of need	18,001			11,413			26,011			55,425		Indefinite
	Total	$	19,543		$	12,710		$	38,962		$	71,215
	Goodwill of $111.7 million, $103.0 million and $116.5 million, respectively, has been assigned to the Company’s Home Health, Hospice and Community Care segments for reporting purposes. The Company expects approximately 20 percent of the aggregate amount of goodwill and identifiable intangible assets will be amortizable for tax purposes.
	The net revenues of Harden from the acquisition date through December 31, 2013 were approximately $92.6 million and contributed a net loss, net of tax benefit of approximately $7.9 million, including the impact of acquisition related costs. The following unaudited pro forma financial information presents the combined results of operations of the Company and Harden as if the acquisition had been effective at January 1, 2012. The pro forma results for the year ended December 31, 2013 combine the results of the Company for such period and the historical results of Harden from January 1 through October 17, 2013. The pro forma results presented below for the year ended December 31, 2012 combine the results of the Company and the historical results of Harden (in thousands, except per share amounts):
		For the Year Ended			For the Year Ended
		December 31, 2013			December 31, 2012
	Net revenues	$	2,105,562		$	2,188,915
	Net (loss) income attributable to Gentiva shareholders	$	(618,592	)	$	40,748
	Earnings per common share:
	Basic	$	(17.29	)	$	1.15
	Diluted	$	(17.29	)	$	1.15
	Weighted average shares outstanding:
	Basic	35,786			35,321
	Diluted	35,786			35,499
	The unaudited pro forma results above reflect adjustments for (i) interest on debt incurred calculated using the Company’s weighted average interest rate of 7.7 percent, (ii) income tax provision using an enacted tax rate of 40.0 percent, (iii) amortization of incremental identifiable intangible assets and (iv) acquisition and integration costs incurred. The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisition had occurred as of the beginning of the Company’s 2012 reporting period.
	Other Acquisitions
	Appalachian Regional Health Systems
	Effective September 30, 2013, the Company completed its acquisition of the assets and business of Appalachian Regional Health Systems, a provider of home health services with offices in Boone and Newland, North Carolina. Total consideration of $2.7 million, subject to post-closing adjustments, consisted of $2.1 million from the Company's existing cash reserves and $0.6 million held in escrow for certain post closing matters.
	Wake Forest Baptist Health Care at Home, LLC
	Effective August 23, 2013, the Company acquired 60 percent interest in the membership units of Wake Forest Baptist Health Care at Home, LLC for approximately $2.4 million, consisting of $2.2 million in cash and $0.2 million of other assets, and entered into an operating agreement with Wake Forest University Baptist Medical Center to provide home health services in the Winston-Salem, North Carolina geographical area.
	Hope Hospice, Inc
	Effective April 30, 2013, the Company completed its acquisition of the assets and business, pursuant to an asset purchase agreement, of Hope Hospice, Inc., a provider of hospice services located in Rochester, Indiana. Total non-cash consideration of $1.0 million consisted of the assumption of Hope Hospice's outstanding debt and existing liabilities as of the closing date.
	Family Home Care Corporation
	Effective August 31, 2012, the Company completed its acquisition of the assets and business of Family Home Care Corporation, one of the leading providers of home health and hospice services in the Washington and Idaho markets. Total consideration of $12.3 million, excluding transaction costs and subject to post-closing adjustments, was paid at the time of closing from the Company's existing cash reserves.
	North Mississippi Hospice
	Effective August 31, 2012, the Company completed its acquisition of the assets and business of North Mississippi Hospice, a provider of hospice services with offices in Oxford, Southhaven and Tupelo, Mississippi. Total consideration of $4.7 million, excluding transaction costs and a post-closing adjustment of $0.2 million, was paid from the Company's existing cash reserves.
	Advocate Hospice
	Effective July 22, 2012, the Company completed its acquisition of the assets and business of Advocate Hospice, a provider of hospice services located in Danville, Indiana, for consideration of $5.5 million, excluding transaction costs and subject to post-closing adjustments. The consideration included entering into an option purchase agreement with a third party covering membership interests in Advocate Hospice. The consideration was paid at the time of closing from the Company's existing cash reserves.
	Additional consideration of up to $2.0 million is payable under the option agreement if certain earnout conditions are met, which the Company estimated fair value at acquisition date of $1.9 million, on a discounted cash flow basis. At December 31, 2012, the Company estimated the fair value of the contingent consideration at $1.1 million based upon certain average daily census growth targets and recorded an $0.8 million adjustment to the contingent consideration. During the second quarter of 2013, the average daily census growth target was met and the Company paid $1.5 million from the escrow to the sellers and retained $0.5 million in escrow for remaining indemnification provisions under the agreement. As such, the Company recorded a $0.9 million charge to adjust the contingent consideration to fair value, which is reflected in selling, general and administrative expense in the Company's consolidated statements of comprehensive income for the period ended December 31, 2013. During the third quarter of 2013, in accordance with the escrow agreement, an additional $0.2 million was paid to the sellers from the escrow fund.
	Odyssey HealthCare of Augusta, LLC
	Effective April 29, 2011, the Company purchased the outstanding member units representing the noncontrolling interest in Odyssey HealthCare of Augusta, LLC (“Augusta”) for approximately $0.3 million. As a result of the transaction, the Company owns 100 percent of the outstanding member units of Augusta.
	The allocation of the purchase prices relating to the Company's other acquisitions consummated is as follows (in thousands):
	Fiscal Year
	2013				2012
Fixed assets, net	$	21			$	509
Identifiable intangible assets	3,062				9,205
Goodwill	2,871				14,695
Other assets	128				66
Total assets acquired	6,082				24,475
Accounts payable and accrued liabilities	1,444				1,955
Total liabilities assumed	1,444				1,955
Net assets acquired	$	4,638			$	22,520
The valuation of the intangible assets by component and their respective useful lives are as follows (in thousands):
	Fiscal Year								Useful life
	2013				2012
Covenants not to compete	$	—			$	203			5 years
Certificates of need	3,062				9,002				indefinite
Total	$	3,062			$	9,205
For the Company’s other acquisitions, the Company expects substantially all goodwill and identifiable intangible assets will be amortized for tax purposes.
Dispositions
Phoenix Hospice Operations
Effective November 30, 2012, the Company completed the sale of its Phoenix area hospice operations to Banner Health, an Arizona non-profit corporation, pursuant to an asset purchase agreement for cash consideration of $3.5 million. The Company recorded a gain of approximately $2.6 million which is reflected in gain on sale of businesses in the Company's consolidated statement of comprehensive income for the year ended December 31, 2012.
Gentiva Consulting, Louisiana Home Health and Hospice Operations
Effective May 31, 2012, the Company completed the sale of its Gentiva consulting business to MP Healthcare Partners, LLC, pursuant to an asset purchase agreement, for cash consideration of approximately $0.3 million.
During the second quarter of 2012, the Company sold eight home health branches and four hospice branches in Louisiana, pursuant to an asset purchase agreement, for total consideration of approximately $6.4 million. The Company received proceeds of approximately $5.9 million during 2012 and received remaining escrow funds of approximately $0.5 million in 2013.
In connection with the sales, the Company recorded a gain on sale of businesses in the Company’s consolidated statements of comprehensive income of approximately $5.4 million for the year ended December 31, 2012.
Home Health and Hospice Branch Operations
In the fourth quarter of 2011, the Company entered into asset purchase agreements to sell the assets of certain home health branches in Utah, Michigan and Nevada, as well as a hospice branch in Texas. In addition, the Company entered into an option agreement to sell the assets of the Company’s home health branch in Brooklyn, New York pending approval by the Public Health Council and New York State Agencies. The Company received all regulatory approvals and completed the Brooklyn transaction in the first quarter of 2013.
The major classes of assets sold and liabilities assumed of the Home Health and Hospice branch operations that were sold were as follows (in thousands):
	2012
	As of Date of Sale				31-Dec-11
Assets:
Accounts receivable, net	$	561			$	526
Fixed assets, net	271				338
Intangible assets	1,356				1,356
Other assets	485				640
Total assets	2,673				2,860
Liabilities:
Medicare liabilities	(86		)		(18		)
Other accrued Expenses	(405		)		(41		)
Total liabilities	(491		)		(59		)
Total	$	2,182			$	2,801
Discontinued Operations
Homemaker Services Agency and Rehab Without Walls® Operations
Effective October 14, 2011, the Company completed the sale of its homemaker services business ("IDOA") to Premier Home Health Care Services, Inc., pursuant to an asset purchase agreement, for total consideration of approximately $2.4 million, consisting of (i) cash proceeds of approximately $2.0 million and (ii) an escrow fund of approximately $0.4 million, to be received by the Company subject to certain post closing conditions. During 2012, the Company reduced the escrow fund receivable to approximately $0.3 million as a result of certain post closing conditions and received such funds during 2012.
Effective September 10, 2011, the Company completed the sale of its Rehab Without Walls® business to Southern Home Care Services, Inc., pursuant to an asset purchase agreement, for total consideration of approximately $9.8 million. The consideration consisted of (i) cash proceeds of approximately $9.2 million and (ii) an escrow fund of approximately $0.6 million which was received by the Company during 2012.
The assets of the Rehab Without Walls® and the IDOA businesses that were sold were as follows (in thousands):
	31-Dec-11
Non-current assets:
Fixed assets, net	$	183
Other assets	109
Total non-current assets	292
Total	$	292
Net revenues and operating results for the year 2011 for Rehab Without Walls® and the IDOA businesses were (in thousands):
	For the Year Ended
	31-Dec-11
Net revenues	$	22,819
Income before income taxes	$	2,430
Gain on sale of business	11,475
Income tax expense	(5,590		)
Discontinued operations, net of tax	$	8,315

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments are measured and recorded at fair value on a recurring basis, except for the notes receivable from CareCentrix and long-term debt. The fair values for the notes receivable from CareCentrix and non-financial assets, such as fixed assets, intangible assets and goodwill, are measured periodically and adjustments recorded only if an impairment charge is required. The carrying amount of the Company’s accounts receivable, accounts payable and certain other current liabilities approximates fair value due to their short maturities.
	Fair value is defined under authoritative guidance as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:
	•	Level 1—Quoted prices in active markets for identical assets or liabilities.
	•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Financial Instruments Recorded at Fair Value
	The Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis was as follows (in thousands):
		31-Dec-13										31-Dec-12
		Level 1				Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	23,695			$	—	$	—	$	23,695	$	54,085	$	—	$	—	$	54,085
	Rabbi Trust:
	Mutual funds	28,945				—		—		28,945		22,041		—		—		22,041
	Money market funds	5,737				—		—		5,737		5,698		—		—		5,698
	Total assets	$	58,377			$	—	$	—	$	58,377	$	81,824	$	—	$	—	$	81,824
	Liabilities:
	Payables to plan participants	$	34,682			$	—	$	—	$	34,682	$	27,739	$	—	$	—	$	27,739
	Acquisition contingent liability	—				—		8,110		8,110		—		—		1,100		1,100
	Total liabilities	$	34,682			$	—	$	8,110	$	42,792	$	27,739	$	—	$	1,100	$	28,839
	Assets held in the Rabbi Trust are held for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The value of assets held in the Rabbi Trust is based on quoted market prices of securities and investments, including money market accounts and mutual funds, maintained within the Rabbi Trust. The corresponding amounts payable to plan participants are equivalent to the underlying value of assets held in the Rabbi Trust. Assets held in the Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets. Money market funds held in the Company’s account represent cash equivalents and were classified in cash and cash equivalents in the Company’s consolidated balance sheets at December 31, 2013 and December 31, 2012.
	The estimated fair value of the acquisition contingent liabilities were determined using a discounted cash flow approach utilizing level 2 and level 3 inputs which included observable market discount rates, fixed payment schedules, and assumptions based on achieving certain pre-defined performance criteria. See Notes 5 and 17 for further information.
	The following table provides a summary of changes in fair value of the Company's Level 3 financial assets (in thousands):
			Estimated
			Fair Value
	Balance at December 31, 2011		$	—
	Advocate Hospice fair value of acquisition contingent liability		1,100
	Balance at December 31, 2012		1,100
	Fair value adjustment of Advocate Hospice acquisition contingent liability		900
	Fair value of Harden acquisition contingent liability		8,081
	Payment of contingent liability		(2,062		)
	Included in earnings		91			(1)
	Balance at December 31, 2013		$	8,110
	-1	Accretion of the present value of the contingent liability is recorded in interest expense and other on the Company's consolidated statements of comprehensive (loss) income. A 1 percent change in the discount rate would have an impact on the fair value of the contingent liability of approximately $0.2 million.
	Other Financial Instruments
	The carrying amount and estimated fair value of the Company’s other financial instruments were as follows (in thousands):
		31-Dec-13						31-Dec-12
		Carrying				Estimated		Carrying		Estimated
		Amount				Fair Value		Amount		Fair Value
	Assets:
	Note receivable from CareCentrix	$	25,000			$	26,403	$	25,000	$	25,220
	Seller financing note receivable from CareCentrix	3,471				3,471		3,471		3,471
	Liabilities:
	Long-term obligations	$	1,177,000			$	1,183,863	$	935,182	$	912,818
	The estimated fair values of the notes receivable from CareCentrix were determined from Level 3 inputs based on an income approach using the discounted cash flow method. The fair values represent the net present value of (i) the after tax cash flows relating to each note's annual income stream plus (ii) the return of the invested principal using a maturity date of March 19, 2017, after considering assumptions relating to risk factors and economic conditions. The estimated fair value of the seller financing note receivable from CareCentrix approximates its carrying amount due to the expected pay-off of the note as part of a proposed settlement with the owners of CareCentrix. See Note 8 for additional information.
	In determining the estimated fair value of long-term debt, Level 2 inputs based on the use of bid and ask prices were considered. Due to the infrequent number of transactions that occur related to the long-term debt, the Company does not believe an active market exists for purposes of this disclosure.
	Cash Flow Hedge
	The Company may utilize derivative financial instruments to manage interest rate risk. Derivatives are held only for the purpose of hedging such risk, not for speculative purposes. The Company’s derivative instruments consisted of (i) a one year interest rate cap with a notional value of $220.0 million and (ii) until March 9, 2011, a two year forward starting interest rate swaps with notional value of $300.0 million, each agreement designated as a cash flow hedge of the variability of cash flows associated with a portion of the Company’s variable rate term loans. During the first quarter of 2011, the Company terminated the two year forward starting interest rate swaps in connection with the refinancing of the Company’s Term Loan A and Term Loan B facilities under its senior secured credit agreement. The Company paid approximately $0.3 million to terminate the interest rate swaps, which is reflected in interest expense and other in the Company’s consolidated statement of comprehensive income in 2011. The Company’s interest rate cap expired in November 2011. The Company currently holds no derivative financial instruments.

Net_Revenues_and_Accounts_Rece

Net Revenues and Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Net Revenues and Accounts Receivable [Abstract]	'
Net Revenues and Accounts Receivable	'
	Net Revenues and Accounts Receivable
	Net revenues in the Home Health and Hospice segments were derived from all major payer classes, while Community Care segment net revenues were derived primarily from Medicaid and Insurance payer classes. Net revenue by major payer classes were as follows (in millions):
		For the Year Ended
		2013			2012			2011
	Medicare:
	Home Health	$	787.3		$	749		$	799.2
	Hospice	667.9			715.5			729.1
	Total Medicare	1,455.20			1,464.60			1,528.30
	Medicaid and Local Government	116.6			74.4			83.1
	Commercial Insurance and Other:
	Paid at episodic rates	59.6			85.2			77.7
	Other	95.2			88.6			109.7
	Total Commercial Insurance and Other	154.8			173.8			187.4
	Total net revenues	$	1,726.60		$	1,712.80		$	1,798.80
	Hospice Medicare Cap
	For 2013, the Company recorded a net hospice Medicare cap credit of $4.6 million as compared to a hospice Medicare cap expense of $4.4 million and $4.3 million for 2012 and 2011, respectively, which is reflected in net revenues in the Company’s consolidated statements of comprehensive income. For the Medicare cap year 2014, which began November 1, 2013, the Company has recorded $0.2 million in Medicare cap expense and has two hospice providers currently estimated to be in excess of Medicare cap limits. For the Medicare cap year 2013, which began November 1, 2012, the Company recorded $1.9 million in Medicare cap expense and had five hospice providers in excess of Medicare cap limits.
	The Medicare payment cap, which is calculated for each provider by the Medicare fiscal intermediary at the end of the hospice cap period, is determined under the proportional method. The proportional method allocates each beneficiary's Medicare payment cap based on the ratio of the number of days the beneficiary received hospice services from the Company over the total number of days the beneficiary received hospice services from all providers. The Medicare payment cap amount is then further allocated between the hospice cap periods based on the ratio of the number of days the Company provided hospices services during each cap period. The sum of each beneficiary's Medicare cap payment, as determined above, represents the aggregate Medicare payment cap. Medicare revenue paid to a provider during the hospice cap period cannot exceed the aggregate Medicare payment cap. As of December 31, 2013 and 2012, the Company had Medicare cap liabilities of $6.5 million and $15.9 million, respectively, which were reflected in Medicare liabilities in the Company’s consolidated balance sheets.
	Odyssey, prior to the acquisition by Gentiva, had filed appeals with CMS to change the methodology previously used to calculate the Medicare payment cap in order to utilize the proportional method of determining the payment cap, as described above. This method allocates the Medicare payment cap over the cap years that the beneficiary is on service. In connection with those appeals, the Company has received final settlement letters for many of its providers and recorded approximately $6.1 million and $1.5 million as net revenue for the year ended December 31, 2013 and 2012, respectively, in the Company's consolidated financial statements.
	Corporate Integrity Agreement
	Under Odyssey's five-year Corporate Integrity Agreement ("CIA") with the Office of Inspector General of the United States Department of Health and Human Services ("OIG"), which became effective on February 15, 2012, Odyssey must engage a third party to perform verification and unallowable cost reviews. In addition, Odyssey's eligibility review team must review the eligibility of Odyssey's Medicare beneficiaries for the hospice services those beneficiaries received and prepare an eligibility review report. Odyssey must submit to the OIG annually a report with respect to the status of, and findings regarding, Odyssey's compliance activities. Any overpayments identified by Odyssey are paid back to the various Medicare administrative contractors by April 1st of the following year. If Odyssey fails to comply with the terms of the CIA, it will be subject to penalties. In connection with the outcomes of these eligibility reviews, the Company has recorded the impact of these audits and established related reserves for ongoing audits of approximately $12.0 million and $4.9 million for the years ended December 31, 2013 and 2012, respectively, which is reflected as a reduction of net revenues in the Company's consolidated statements of comprehensive income.
	PRRB Appeal
	During 2013, the Company finalized its year 2000 cost reports, which are currently being settled by CMS. In connection with the finalized audit and the cost report settlements, the Company has recorded approximately $4.0 million as a positive adjustment to net revenues in the Company's consolidated statement of comprehensive income for the year ended December 31, 2013. See Note 16 for additional information.
	Accounts Receivable
	Accounts receivable attributable to major payer sources of reimbursement are as follows (in thousands):
		December 31, 2013			December 31, 2012
	Medicare	$	214,366		$	192,541
	Medicaid and Local Government	48,183			31,259
	Commercial Insurance and Other	38,036			36,057
	Gross Accounts Receivable	300,585			259,857
	Less: Allowance for doubtful accounts	(10,680		)	(8,777		)
	Net Accounts Receivable	$	289,905		$	251,080
	The Commercial Insurance and Other payer group included self-pay accounts receivable relating to patient co-payments of $2.4 million and $1.7 million, respectively, as of December 31, 2013 and December 31, 2012.
	The Company’s only financing receivable is the notes receivable from CareCentrix, Inc. The Company measures impairment based on the present value of expected cash flows after considering assumptions relating to risk factors and economic conditions. On an ongoing basis, the Company assesses the credit quality based on the Company’s review of CareCentrix, Inc.’s financial position and receipt of interest payments when due. Based on the Company’s analysis, as of December 31, 2013 and 2012, the Company had no allowances for credit losses.

Investment_in_and_Notes_Receiv

Investment in and Notes Receivable from CareCentrix	12 Months Ended
	Dec. 31, 2013
Note Receivable from and Investment in Entity [Abstract]	'
Note Receivable from and Investment in CareCentrix	'
	Investment in and Notes Receivable from CareCentrix
	Effective September 19, 2011, the Company sold its remaining investment in CareCentrix Holdings. The Company recorded accumulated and unpaid dividends on the preferred shares of approximately $8.6 million for 2011, which were reflected in dividend income in the Company's consolidated statements of comprehensive income. The Company also recorded a net gain of approximately $67.1 million, including an escrow of approximately $10.6 million, which was reflected in equity in net earnings of CareCentrix, in the Company's consolidated statements of comprehensive income.
	The Company holds a $25.0 million subordinated promissory note from CareCentrix, Inc. In connection with the sale of the Company’s ownership interest in CareCentrix Holdings on September 19, 2011, the maturity date of the note was extended to the earlier of March 19, 2017 or a sale of CareCentrix Holdings. The note bears interest at a fixed rate of 10 percent, which is payable quarterly. Interest on the CareCentrix promissory note, which is included in interest income in the Company’s consolidated statements of comprehensive income, amounted to $2.5 million for each of the years 2013, 2012 and 2011.
	Pursuant to the terms of the stock purchase agreement, approximately $10.6 million of the sale price due to the Company was placed into an escrow fund for future indemnification claims. During the year 2012, approximately $0.7 million of the escrow fund was paid out to cover expenses related to an indemnified claim.
	On August 24, 2012, the Company received notification from CareCentrix of its election to draw seller financing from the escrow fund pursuant to the terms of the stock purchase agreement. As such, the Company reclassified its escrow receivable of approximately $9.9 million from prepaid expenses and other current assets to a seller financing note from CareCentrix. The seller financing note receivable, which bears interest at 18 percent, matures on the earlier of March 19, 2017 or upon the sale of CareCentrix Holdings. Interest on the note is payable quarterly, in kind and will accrete as additional principal on the note. The Company expects to record interest income at the time of receipt as the note is part of the proposed settlement discussed below.
	On September 17, 2012, the Company received a formal notice of claims for indemnification from CareCentrix. In the notice, CareCentrix asserted that the total claimed amounts exceed the total amount in escrow and demanded that the entire principal amount of the seller financing note be reduced to zero. In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix. The Company established an investment in CareCentrix of $0.9 million for shares that it may receive as part of any settlement.
	The Company recognized approximately $2.3 million of equity in the net loss of CareCentrix for 2012 and $68.4 million of equity in the net earnings of CareCentrix for 2011.
	The Company’s financing receivables consist of the previously described $25.0 million subordinated promissory note from CareCentrix, Inc. dated September 19, 2011 and a $3.4 million seller financing note from CareCentrix, Inc. dated August 24, 2012. The Company measures impairment based on the present value of expected cash flows after considering assumptions relating to risk factors and economic conditions. On an ongoing basis, the Company assesses the credit quality based on the Company’s review of CareCentrix, Inc.’s financial position and receipt of interest payments when due. Based on the Company’s analysis, as of December 31, 2013 and December 31, 2012, the Company had no allowances for credit losses.

Fixed_Assets_Net

Fixed Assets, Net	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Fixed Assets, Net	'
	Fixed Assets, Net
	Fixed assets at December 31, 2013 and 2012 were as follows:
	(In thousands)	Useful Lives	31-Dec-13			31-Dec-12
	Land	Indefinite	$	768		$	1,451
	Building	30 Years	4,587			6,107
	Computer equipment and software	3-7 Years	70,131			65,718
	Home medical equipment	4 Years	5,356			5,179
	Furniture and fixtures	5 Years	35,028			24,556
	Leasehold improvements	Lease Term	18,121			18,250
	Machinery and equipment	5 Years	2,153			2,692
	Automobiles	5 Years	1,265			111
			137,409			124,064
	Less accumulated depreciation		(88,034		)	(82,650		)
	Fixed assets, net		$	49,375		$	41,414
	Depreciation expense was approximately $15.3 million for 2013, $16.6 million for 2012 and $17.2 million for 2011.
	Computer equipment and software at December 31, 2013 and December 31, 2012 included deferred software development costs of $1.5 million and $2.0 million, respectively, primarily related to enhancements of the Company’s human resources, time keeping and management reporting systems.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. As part of that analysis, the Company obtained a market assessment of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. These charges are recorded in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated statement of comprehensive income for the for the year ended December 31, 2013. See Note 10 for additional information.
	In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge related to developed software, of approximately $1.6 million, which is reflected in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated statement of comprehensive income for the for the year ended December 31, 2013.
	In connection with the Odyssey acquisition, the Company conducted a strategic evaluation of its various field operating systems, including the Company's LifeSmart clinical management system, to review alternatives towards achieving a comprehensive platform, capable of handling both its Home Health and Hospice business segments. During 2011, the Company completed its review of alternatives to replacing various field operating systems and, in connection with that review, recorded a non-cash impairment charge of approximately $40.3 million related to developed software. In addition, the Company conducted a review of real estate it owned in Dothan, Alabama which indicated that the estimated fair value of the real estate was lower than the carrying value, and recorded a non-cash impairment charge of approximately $0.9 million. These charges are recorded in goodwill, intangibles and other long-lived asset impairment in the Company’s consolidated statement of comprehensive income for the year ended December 31, 2011.

Goodwill_and_Identifiable_Inta

Goodwill and Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Identifiable Intangible Assets and Goodwill	'
	Identifiable Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various reporting units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to the carrying amount of their allocated net assets to determine if there is a potential impairment of goodwill. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than the carrying value of its goodwill. To determine the fair value of the Company's reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies and reasonableness tests, as appropriate. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. The future occurrence of a potential indicator of impairment, such as, but not limited to, a significant adverse change in legal factors or business climate, reductions of projected patient census, an adverse action or assessment by a regulator, as well as other unforeseen factors, would require an interim assessment for some or all of the reporting units.
	If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate.
	The Company has subsequently determined that a correction was needed in the Company's accounting for its licenses related to closed or consolidated locations and to correct certain assumptions used in its valuation models for testing goodwill and indefinite-lived intangible assets. Historically, the Company had incorrectly accounted for its indefinite-lived intangible assets related to closed or consolidated licenses on a pooled basis and did not write-off license costs when the Company closed or consolidated individual operating locations. The Company has determined it should amortize the full license cost over the period of closure or consolidation. As such, the Company has restated its consolidated balance sheet, consolidated statement of comprehensive loss, consolidated statement of changes in shareholders' equity and consolidated statement of cash flows as of and for the year ended December 31, 2013. See Note 2 for additional information.
	Goodwill
	The Company's operations include three reporting units: Home Health, Hospice and Community Care. To determine fair value of each of these reporting units, the Company considered the income approach, which determines fair value based on estimated future cash flows of each reporting unit, discounted by an estimated weighted-average cost of capital (“discount rate”), which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. The Company determined that discounted cash flow is the best indicator to determine fair value.
	The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care reporting units. For purposes of the annual impairment test, the Company applied certain assumptions that included, but were not limited to, patient census projections, gross margin assumptions consistent with the Company's historical trends combined with the expectations of operating efficiencies and economies of scale. The Company used discount rates of 9.9 percent to calculate the fair value of its Home Health, Hospice and Community Care reporting units. Based on this assessment, for the year ended December 31, 2013, the Company recorded a non-cash impairment charge associated with its Hospice reporting unit of approximately $399.7 million, which is reflected in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated statement of comprehensive income. The impairment primarily related to continued lower than expected average daily census in 2013 and lower expected growth in both volume and reimbursement rate assumptions in future years. The total allocated goodwill assigned to the Company's Home Health, Hospice and Community Care reporting units were $123.4 million, $143.6 million and $116.5 million, respectively, at December 31, 2013.
	At March 31, 2013, the Company determined that a triggering event had occurred due to lower than expected average daily census and higher than expected discharge rates during the quarter and performed an interim impairment test of its Hospice reporting unit. For purposes of the interim impairment test, the Company applied certain assumptions that included, but were not limited to, patient census projections, gross margin assumptions consistent with the Company's historical trends combined with the expectations of operating efficiencies and economies of scale. To determine fair value, the Company considered the income approach, which determines fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital (“discount rate”), which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. The Company used a discount rate of 9.5 percent to calculate the fair value of its Hospice reporting unit. Based on the results of the interim impairment test, the Company's Hospice reporting unit had an estimated fair value of approximately $555.0 million. As such, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million, which is reflected in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated comprehensive statement of income for the year ended December 31, 2013.
	For the year ended December 31, 2012, the Company performed an annual impairment test using discount rates of 10.6 percent and 9.5 percent, to calculate the fair value of the Company's Home Health and Hospice reporting units, respectively. There was no impairment of the Company's reporting units as of December 31, 2012. The total allocated goodwill assigned to the Company's Home Health and Hospice reporting units were $9.0 million and $647.4 million, respectively, at December 31, 2012.
	During 2011, the Company determined a triggering event had occurred and performed an interim impairment test of its goodwill in response to changes in its business climate, uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit as well as a significant decline in the price of the Company's common stock during the third quarter. The impairment assessment was completed as of August 31, 2011. The interim test concluded that the fair value of goodwill was less than their carrying value as of that date. The Company utilized a discounted cash flow approach to determine the fair values. The Company used a discount rate of 11.6 percent and 11.2 percent, respectively, to calculate the fair value of its Home Health and Hospice reporting units. Based on the results of the interim impairment test, the Company's Home Health and Hospice reporting units had estimated fair values of approximately $220.2 million and $772.8 million, respectively. As such, the Company recorded a non-cash impairment charge relating to goodwill of approximately $457.0 million, which is reflected in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated comprehensive statement of income for the year ended December 31, 2013.
	Identifiable Intangible Assets
	Licenses and Certificates of Need
	Licenses and certificates of need (“CON”) represent the largest component of the Company's identifiable intangible assets. A Medicare license, which represents a provider number issued by the federal or a state government, is a necessary requirement for any healthcare provider to be eligible to receive reimbursement for patient services under the government programs. A CON is a formal acknowledgment by a state government that a particular health care service, program or capital expenditure meets the identified needs of the state in providing health care to its population. For home health or hospice providers in certain regulated states, a CON functions as a permit or authorization to provide services in certain designated areas (i.e., counties or service areas) indefinitely. The CON process varies from state to state and is designed to prevent unnecessary duplication of services by regulating the number of providers that can engage in particular types of services within the service area. Currently, 17 states and the District of Columbia require CONs in order to operate a Medicare-certified home health agency, and 13 states and the District of Columbia require CONs in order to operate a Medicare-certified hospice agency. Without CON authority in these jurisdictions, a party is precluded from providing these services. The issuance of new CONs by most of these states has been very limited.
	The amounts set forth in the table below for “Indefinite-lived intangible assets—licenses and certificates of need” reflect the value of licenses and CONs acquired during 2006 and thereafter. The carrying values of licenses were determined using a replacement cost and an opportunity cost approach, recognizing the time and expense to obtain a license as if such license had not previously existed in the geographic areas. The carrying values of CONs were determined using an income approach, recognizing that CONs represent a right to conduct business in otherwise restricted areas as discussed above and should be recognized as an intangible asset apart from goodwill in accordance with authoritative guidance.
	The Company has also classified the Medicare licenses and CONs as indefinite-lived, and therefore determined that the value of these licenses and CONs should not be amortized, in accordance with authoritative guidance that states “if no legal, regulatory, contractual, competitive, economic, or other factors limit the useful life of an intangible asset to the reporting entity, the useful life of the asset shall be considered to be indefinite.” The holder of a license may continue to provide services indefinitely as long as the healthcare provider continues to meet eligibility requirements. The holder of a CON may provide services in CON-approved counties indefinitely as long as services continue to be provided in a manner consistent with and as authorized by the respective CON. Furthermore, CONs are not subject to obsolescence because of competition since the issuance of new CONs is subject to regulatory approval that is granted in part only if there is a “need” for services of the same type in the relevant market. That attribute is a major factor in the significant market value inherent in a CON.
	During 2013, the Company recorded approximately $4.5 million of amortization expense, which was recorded in selling, general and administrative expenses, and approximately $2.0 million of impairment expense, which is recorded in goodwill, intangibles and other long-lived asset impairment expense in the Company's consolidated statement of comprehensive income, related to license cost of operating locations which were closed or consolidated.
	During 2012, the Company initiated an effort to re-brand all of its branch operations under the single Gentiva name. In connection with this re-branding effort, the Company recorded a $19.1 million non-cash write-off of remaining trade name balances for the year 2012, which is reflected in goodwill, intangibles and other long-lived asset impairment in the Company's consolidated statements of comprehensive income.
	During 2011, the Company determined a triggering event had occurred and performed an interim impairment test of its identifiable intangible assets in response to changes in its business climate, uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit as well as a significant decline in the price of the Company's common stock during the third quarter. The impairment assessment was completed as of August 31, 2011. The interim test concluded that the fair value of certain identifiable intangible assets was less than their carrying value as of that date. The Company utilized a discounted cash flow approach to determine the fair values. As a result of this process, the Company recorded a non-cash charge of approximately $145.1 million to reduce the carrying value of certain identifiable intangible assets to their estimated fair values. The impairment charge is recorded within goodwill, intangibles and other long-lived assets impairment in the Company's consolidated statements of comprehensive income for the year 2011.
	During 2011, the Company recorded approximately $0.9 million of amortization expense related to license cost of closed or consolidated operating locations, which was recorded in selling, general and administrative expenses in the Company's consolidated statement of comprehensive income.
	During 2012, the Company recorded a charge of approximately $1.4 million to reflect the transfer of the Medicare licenses associated with the sale of the four hospice branches in Louisiana and the Phoenix area hospice operations, which is recorded in gain on sale of assets and businesses, net in the Company’s consolidated statement of comprehensive income for the year ended December 31, 2012.
	During 2011, the Company undertook a comprehensive review of its branch structure, support infrastructure and other significant expenditures in order to reduce its ongoing operating costs given the challenging rate environment that the Company was facing. As a result of this effort, the Company closed or divested 46 home health branches and 13 hospice branches in late 2011 and early 2012. In connection with these activities, during 2011, the Company recorded charges of $1.1 million related to the disposition of intangible assets for certain of the closed or divested branches. Approximately $0.7 million of these charges are recorded in gain on sale of assets and businesses, net and the remaining $0.4 million are recorded as selling, general and administrative expenses in the Company's consolidated statement of comprehensive income for the year ended December 31, 2011.
	The gross carrying amount and accumulated amortization of each category of identifiable intangible assets as of December 31, 2013 and December 31, 2012 were as follows (in thousands):
		December 31, 2013 (Restated)												December 31, 2012 (Revised)												Useful
																										Life
		Home			Hospice			Community Care			Total			Home			Hospice			Community Care			Total
		Health												Health
	Amortized intangible assets:
	Covenants not to compete	$	2,157		$	16,183		$	1,029		$	19,369		$	1,667		$	15,685		$	—		$	17,352		2-5 Yrs
	Less: accumulated amortization	(1,553		)	(15,720		)	(91		)	(17,364		)	(1,449		)	(14,113		)	—			(15,562		)
	Net covenants not to compete	604			463			938			2,005			218			1,572			—			1,790
	Customer relationships	27,196			910			—			28,106			27,196			910			—			28,106			5-10 Yrs
	Less: accumulated amortization	(19,997		)	(481		)	—			(20,478		)	(17,651		)	(390		)	—			(18,041		)
	accumulated impairment losses	(27		)	—			—			(27		)	(27		)	—			—			(27		)
	Net customer relationships	7,172			429			—			7,601			9,518			520			—			10,038
	Tradenames	19,267			17,528			11,922			48,717			18,215			16,730			—			34,945			5-10 Yrs
	Less: accumulated amortization	(11,992		)	(3,763		)	(227		)	(15,982		)	(11,794		)	(3,608		)	—			(15,402		)
	accumulated impairment losses	(6,421		)	(13,122		)	—			(19,543		)	(6,421		)	(13,122		)	—			(19,543		)
	Net tradenames	854			643			11,695			13,192			—			—			—			—
	Licenses	714			8,021			—			8,735			—			2,888			—			2,888
	Less: accumulated amortization	(588		)	(6,812		)	—			(7,400		)	—			(2,888		)	—			(2,888		)
	Net licenses	126			1,209			—			1,335			—			—			—			—
	Amortized intangible assets	8,756			2,744			12,633			24,133			9,736			2,092			—			11,828
	Indefinite-lived intangible assets:
	Licenses and certificates of need	245,086			105,632			26,011			376,729			225,227			98,861			—			324,088
	Less: accumulated impairment	(144,672		)	(2,463		)	—			(147,135		)	(144,672		)	(519		)	—			(145,191		)
	losses
	Net licenses and certificates of need	100,414			103,169			26,011			229,594			80,555			98,342			—			178,897
	Total identifiable intangible assets	$	109,170		$	105,913		$	38,644		$	253,727		$	90,291		$	100,434		$	—		$	190,725
	For 2013, 2012 and 2011, the Company recorded amortization expense of approximately $9.3 million, $10.0 million, and $13.9 million, respectively. The estimated amortization expense for each of the next five succeeding years approximates $7.1 million for 2014, $4.1 million for 2015, $3.1 million for 2016, $2.4 million for 2017, and $1.6 million for 2018.
	The gross carrying amount of goodwill as of December 31, 2013 and December 31, 2012 and activity during the years 2013 and 2012 were as follows (in thousands):
		Goodwill, Gross												Accumulated Impairment Losses
		Home Health			Hospice			Community Care			Total			Home Health			Hospice			Total			Net
	Balance at December 31, 2011	$	267,058		$	831,648		$	—		$	1,098,706		$	(263,370	)	$	(193,667	)	$	(457,037	)	$	641,669
	Goodwill acquired during 2012	5,331			9,364			—			14,695			—			—			—			14,695
	Balance at December 31, 2012	272,389			841,012			—			1,113,401			(263,370		)	(193,667		)	(457,037		)	656,364
	Goodwill acquired during 2013 (Restated)	114,330			103,175			116,534			334,039			—			—			—			334,039
	Impairment losses during 2013 (Restated)	—			—			—			—			—			(606,916		)	(606,916		)	(606,916		)
	Balance at December 31, 2013 (Restated)	$	386,719		$	944,187		$	116,534		$	1,447,440		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	383,487
	The Company expects that substantially all of the goodwill acquired will be deductible for tax purposes with the exception of the Harden transaction which the Company expects approximately 20 percent of the goodwill to be tax deductible.

Cost_Savings_Initiatives_Acqui

Cost Savings Initiatives, Acquisition and Integration Activities and Legal Settlements	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Cost Savings Initiatives and Other Restructuring Costs, Acquisition and Integration Activities and Legal Settlements	'
	Cost Savings Initiatives, Acquisition and Integration Activities and Legal Settlements
	During 2013, 2012 and 2011, the Company recorded net charges of $27.5 million, $5.7 million and $49.1 million, respectively, relating to cost savings initiatives and other restructuring, acquisition and integration activities and legal settlements. These charges were recorded in selling, general and administrative expenses in the Company’s consolidated statements of comprehensive income.
	Cost Savings Initiatives
	2013 Initiatives
	During 2013, the Company undertook a corporate restructuring initiative, referred to as "One Gentiva", to better align its home health, hospice and community care businesses under a common regional management structure. In addition, the Company undertook a branch rationalization initiative to review under performing branches. As a result of this review, the Company has closed or consolidated 77 branches through early 2014. As such, the Company recorded charges of $8.7 million in 2013, primarily related to severance and facility lease costs.
	2011 / 2012 Initiatives
	During 2011 and early 2012, the Company undertook a comprehensive review of its branch structure, support infrastructure and other significant expenditures in order to reduce its ongoing operating costs given the challenging rate environment facing the Company. As a result of this effort, the Company (i) closed or divested 46 home health branches and 13 hospice branches and (ii) significantly reduced staffing levels in regional, area and corporate support functions. In connection with these activities, during 2013, 2012 and 2011, the Company recorded charges of $0.1 million, $1.7 million and $15.3 million.
	Acquisition and Integration Activities
	During 2013, the Company recorded charges of $18.8 million, primarily related to the Company's acquisition of Harden. These costs consisted of (i) severance and lease costs associated with consolidation of branches in overlapping markets and consolidation of back office functions, (ii) legal, accounting and other professional fees and expenses associated with the transaction, (iii) write-off of prepaid debt issuance costs associated with the termination of the Company's former credit agreement.
	During 2012, the Company recorded positive adjustments to the acquisition and integration reserves of $1.0 million, primarily relating to favorable lease settlements associated with the acquisition of Odyssey.
	During 2011, the Company recorded charges of $7.9 million in connection with costs of acquisition and integration activities, primarily related to the Odyssey transaction. These costs consisted of legal, accounting and other professional fees and expenses, costs of obtaining required regulatory approvals, write-off of prepaid fees in connection with the termination of the Company’s 2006 credit agreement and severance costs.
	Legal Settlements
	For the year ended December 31, 2012, the Company recorded legal settlements of $5.0 million related to the settlement of the Wilkie wage and hour lawsuit.
	For the year ended December 31, 2011, the Company recorded legal settlements of $26.0 million related to a settlement with the United States regarding Odyssey's provision of continuous care services prior to the Company's acquisition of Odyssey in August 2010.
	The costs incurred and cash expenditures associated with these activities during 2013, 2012 and 2011 were as follows (in thousands):
		Cost Savings Initiatives			Acquisition &			Legal			Total
					Integration			Settlements
	Balance at December 31, 2010	$	2,893		$	3,984		$	12,500		$	19,377
	Charge in 2011	15,259			7,879			26,000			49,138
	Cash expenditures	(7,680		)	(8,155		)	(12,500		)	(28,335		)
	Non-cash expenditures	(1,801		)	—			—			(1,801		)
	Balance at December 31, 2011	8,671			3,708			26,000			38,379
	Charge in 2012	1,701			(989		)	4,958			5,670
	Cash expenditures	(8,544		)	(1,492		)	(30,958		)	(40,994		)
	Non-cash expenditures	(143		)	(216		)	—			(359		)
	Balance at December 31, 2012	1,685			1,011			—			2,696
	Charge in 2013	8,742			18,797			—			27,539
	Cash expenditures	(3,525		)	(9,550		)	—			(13,075		)
	Non-cash expenditures	(656		)	(79		)	—			(735		)
	Non-cash reclassification	476			(476		)	—			—
	Balance at December 31, 2013	$	6,722		$	9,703		$	—		$	16,425
	The balance of unpaid charges relating to cost savings initiatives, and acquisition and integration activities aggregated $16.4 million and $2.7 million at December 31, 2013 and December 31, 2012, respectively. These items were included in other accrued expenses in the Company's consolidated balance sheets.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Basic and diluted earnings per share for each period presented have been computed by dividing (loss) income from continuing operations attributable to Gentiva shareholders, discontinued operations, net of tax and net (loss) income attributable to Gentiva shareholders, by the weighted average number of shares outstanding for each respective period. The computations of the basic and diluted per share amounts were as follows (in thousands, except per share amounts):
		For the Year Ended
		December 31, 2013 (Restated)			December 31, 2012		December 31, 2011 (Revised)
	Net (loss) income attributable to Gentiva shareholders	$	(605,061	)	$	26,796	$	(451,062	)
	Basic weighted average common shares outstanding	31,954			30,509		30,336
	Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	—			178		—
	Diluted weighted average common shares outstanding	31,954			30,687		30,336
	Basic earnings per common share
	Net (loss) income attributable to Gentiva shareholders	$	(18.94	)	$	0.88	$	(14.86	)
	Diluted earnings per common share:
	Net (loss) income attributable to Gentiva shareholders	$	(18.94	)	$	0.87	$	(14.86	)
	Anti-dilutive shares by type:
	Stock options	595			2,813		2,388
	Performance share units	—			89		129
	Restricted stock	231			330		348
	Total anti-dilutive shares	826			3,232		2,865
	For 2013, 2012 and 2011 approximately 0.8 million, 3.2 million and 2.9 million shares, respectively, were excluded from the computation of diluted earnings per common share as their inclusion would be anti-dilutive under the treasury stock

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2013
Long-term Debt, Unclassified [Abstract]	'
Long-Term Debt	'
	Credit Arrangements
	On October 18, 2013, Gentiva entered into a new senior secured credit agreement providing for (i) a six year $670 million term Loan B facility, (ii) a five-year $155 million Term Loan C facility and (iii) a five-year $100 million revolving credit facility (collectively, the “New Credit Agreement”), which replaced the Company's existing Credit Agreement. The New Credit Agreement’s revolving credit facility also includes borrowing capacity of $80 million available for letters of credit and $15 million for borrowings on same-day notice, referred to as swing line loans.
	The Company used cash on hand and proceeds from the New Credit Agreement to (i) pay the cash purchase price in connection with the Harden transaction, (ii) repay all amounts outstanding under Harden's then existing credit facility, which was then terminated, (iii) repay all amounts outstanding under Gentiva's then existing credit facility as further described below and (iv) pay various fees and expenses incurred in connection with the Harden transaction and related financing.
	Prior to October 18, 2013, Gentiva maintained a credit agreement which initially consisted of (i) a $200 million Term Loan A facility, (ii) a $550 million Term Loan B facility and (iii) a $110 million revolving credit facility. On October 18, 2013, remaining outstanding borrowings under the former Credit Agreement, which consisted of term loan borrowings of $585.2 million, were repaid and that Credit Agreement was terminated. In connection with that termination and entering into the Company's New Credit Agreement, the Company performed a debt modification analysis and based on that analysis wrote-off a portion of its existing prepaid debt issuance costs of approximately $16.1 million, which is reflected in interest expense and other in the Company’s consolidated statement of comprehensive income for the year ended 2013, and capitalized debt issuance costs of approximately $24.2 million.
	As of December 31, 2013 and December 31, 2012, the Company’s long-term debt consisted of the following (in thousands):
		December 31, 2013				December 31, 2012
	Credit Agreement:
	Term Loan A, matured October 18, 2013	$	—			$	143,750
	Term Loan B, matured October 18, 2013	—				466,432
	Term Loan B, maturing October 18, 2019, net of unamortized discount of $6.508 million as of December 31, 2013	663,492				—
	Term Loan C, maturing October 18, 2018, net of unamortized discount of $0.735 million as of December 31, 2013	154,265				—
	11.5% Senior Notes due 2018	325,000				325,000
	Revolving Credit Facility	27,000				—
	Total debt	1,169,757				935,182
	Less: current portion of long-term debt	(45,325		)		(25,000		)
	Total long-term debt	$	1,124,432			$	910,182
	As of December 31, 2013, advances under the revolving credit facility may be made, and letters of credit may be issued, up to the $100 million borrowing capacity of the facility at any time prior to the facility expiration date of October 18, 2018. Outstanding letters of credit were $52.0 million and $45.4 million at December 31, 2013 and December 31, 2012, respectively. The letters of credit were issued to guarantee payments under the Company’s workers’ compensation program and for certain other commitments. As of December 31, 2013, the Company’s unused and available borrowing capacity under the New Credit Agreement was $21.0 million. As governed by the indenture covering the unsecured senior notes, the Company has a maximum permitted borrowing capacity, as defined, under its New Credit Agreement which may limit the Company's ability to borrow up to the full capacity of the revolving credit facility.
	The Term Loan B facility is subject to mandatory principal payments of $6.7 million per year, payable in equal quarterly installments, with the remaining balance of the original $670 million loan payable on October 18, 2019. The Term Loan C facility is subject to annual mandatory principal payments, payable in equal quarterly installments. The mandatory principal payments for 2014 are $11.6 million and increase each year through the maturity date of the loan, October 18, 2018.
	As of December 31, 2013, the mandatory aggregate principal payments of long-term debt were $18.3 million for 2014, $26.1 million in 2015, $29.9 million in 2016, $37.7 million in 2017, $76.5 million in 2018 and $636.5 million thereafter under the New Credit Agreement, and $325.0 million due in 2018 under the Senior Notes. The weighted average cash interest rate on outstanding borrowings was 7.7 percent per annum at December 31, 2013 and 8.2 percent per annum at December 31, 2012.
	The Company may voluntarily repay outstanding loans under the revolving credit facility or the term loans at any time without premium or penalty, other than customary “breakage” costs with respect to LIBOR loans. Prepayment and commitment reductions will be required in connection with (i) certain asset sales, (ii) certain extraordinary receipts such as certain insurance proceeds, (iii) cash proceeds from the issuance of debt, and (iv) 75 percent of “Excess Cash Flow” (as defined in the New Credit Agreement) with two step-downs based on the Company’s leverage ratio.
	The interest rate per annum on borrowings under the New Credit Agreement is based on, at the option of the Company, (i) the Eurodollar Rate, adjusted for certain costs plus an Applicable Margin or (ii) the Base Rate, plus an Applicable Rate. The Base Rate represents the highest of (x) the Barclays Bank prime rate, (y) the federal funds rate plus 0.50 percent or (z) the Eurodollar Rate adjusted for certain costs plus 1.00 percent. In connection with determining the interest rates on the Term Loan B and Term Loan C facilities, in no event shall the Eurodollar Rate be less than 1.25 percent and the Base Rate be less than 2.25 percent. The Company may select interest periods of one, two, three or six months for Eurodollar Rate loans. Interest is payable at the end of the selected interest period. The Company must also pay a fee of 0.50 percent per annum on unused commitments under the revolving credit facility.
	From January 1, 2013 through October 17, 2013, the interest rate on borrowings under the former Credit Agreement for term Loan A was 6.25 percent and Term Loan B was 6.50 percent per annum. For the period subsequent to October 17, 2013, under the New Credit Agreement the interest rate on Term Loan B borrowings is 6.50 percent, Term Loan C borrowings is 5.75 percent and revolving credit borrowings is 4.69 percent.
	Under the Company's New Credit Agreement, the Applicable Rate component of the interest rate is based on the Company's consolidated leverage ratio as follows:
			Applicable Rates
	Consolidated		Eurodollar Rate for Revolving Credit Facility and Letter of Credit Fees		Base Rate for Revolving Credit Facility		Term Loan B			Term Loan C
	Leverage Ratio						Eurodollar Rate		Base Rate	Eurodollar Rate	Base Rate
	> 4.0:1		4.50%		3.50%		5.25%		4.25%	4.50%	3.50%
	< 4.0:1		4.25%		3.25%		5.25%		4.25%	4.50%	3.50%
	Debt Covenants
	The New Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s and its subsidiaries’ ability to incur additional indebtedness or issue certain preferred stock, create liens on assets, enter into sale and leaseback transactions, engage in mergers or consolidations with other companies, sell assets, pay dividends, repurchase capital stock, make investments, loans and advances, make certain acquisitions, engage in certain transactions with affiliates, amend material agreements, repay certain indebtedness, change the nature of the Company’s business, change accounting policies and practices, grant negative pledges and incur capital expenditures. In addition, the New Credit Agreement requires the Company to maintain a maximum consolidated leverage ratio and contains certain customary affirmative covenants and events of default.
	The Company's maximum consolidated leverage ratio is as follows:
	Four Fiscal Quarters Ending	Maximum Consolidated
		Leverage Ratio
	March 31, 2014 to March 31, 2015	≤ 6.75:1
	June 30, 2015 to March 31, 2016	≤ 6.50:1
	June 30, 2016 to March 31, 2017	≤ 6.25:1
	June 30, 2017 to December 31, 2017	≤ 6.00:1
	March 31, 2018 and each fiscal quarter thereafter	≤ 5.75:1
	As of December 31, 2013, the Company’s consolidated leverage ratio was 5.5x. As of December 31, 2013, the Company was in compliance with all covenants in the New Credit Agreement.
	Guaranty Agreement and Security Agreement
	Gentiva and substantially all of its subsidiaries (the “Guarantor Subsidiaries”) entered into a guaranty agreement pursuant to which the Guarantor Subsidiaries have agreed, jointly and severally, fully and unconditionally to guarantee all of the Company’s obligations under the New Credit Agreement. Additionally, Gentiva and its Guarantor Subsidiaries entered into a security agreement pursuant to which a first-priority security interest was granted in substantially all of the Company’s and its Guarantor Subsidiaries’ present and future real, personal and intangible assets, including the pledge of 100 percent of all outstanding capital stock of substantially all of the Company’s domestic subsidiaries to secure full payment of all of the Company’s obligations for the ratable benefit of the lenders.
	Senior Notes
	The Senior Notes are unsecured, senior subordinated obligations of the Company. The Senior Notes are guaranteed by all of Gentiva’s subsidiaries that are guarantors under the New Credit Agreement. Interest on the Senior Notes accrues at a rate of 11.5 percent per annum and is payable semi-annually in arrears on March 1 and September 1. Gentiva will make each interest payment to the holders of record on the immediately preceding February 15 and August 15.
	The Senior Notes mature on September 1, 2018 and are generally free to be transferred. Gentiva may redeem the Senior Notes, in whole or in part, at any time prior to the first interest payment of 2014, at a price equal to 100 percent of the principal amount of the Senior Notes redeemed plus an applicable make-whole premium based on the present value of the remaining payments discounted at the treasury rate plus 50 basis points plus accrued and unpaid interest, if any, to the date of redemption.
	On or after September 1, 2014, Gentiva may redeem all or part of the Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest, if any, as defined in the indenture relating to the Senior Notes during the twelve month period beginning on September 1 of the years indicated below:
	Year	Percentage
	2014	105.75%
	2015	102.88%
	2016 and thereafter	100.00%

Shareholders_Equity

Shareholdersb Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Shareholdersb Equity	'
	Shareholders’ Equity
	The Company’s authorized capital stock includes 25,000,000 shares of preferred stock, $.01 par value, of which 1,000 shares have been designated Series A Cumulative Non-voting Redeemable Preferred Stock (“cumulative preferred stock”).
	On October 18, 2013, the Company issued 4,812,414 shares of its common stock in connection with the acquisition of certain net assets relating to the home health, hospice and community care businesses of Harden.
	On March 13, 2012, the Company announced that its Board of Directors had authorized the repurchase of up to $5,000,000 of shares of the Company’s outstanding common stock (the “2012 Repurchase Program”). The repurchases can occur periodically in the open market or through privately negotiated transactions based on market conditions and other factors. During 2013, the Company did not repurchase any shares of its outstanding common stock. As of December 31, 2013, the Company had remaining authorization under the 2012 Repurchase Program to repurchase common stock with an aggregate purchase price of up to $1.5 million, subject to the additional limitations set forth below.
	The Company’s New Credit Agreement provides for repurchases of the Company’s common stock not to exceed $7.5 million per year, and not to exceed $25.0 million per year if the consolidated leverage ratio is less than or equal to 3.5:1.0 immediately after giving effect on a pro forma basis to the repurchase. The indenture governing the Company’s Senior Notes also contains limitations on the Company’s repurchases of its common stock.

EquityBased_Compensation_Plans

Equity-Based Compensation Plans	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Equity-Based Compensation Plans	'
	The Company provides several equity-based compensation plans under which the Company’s officers, employees and non-employee directors may participate, including (i) the 2004 Equity Incentive Plan (amended and restated as of March 16, 2011, as further amended by Amendment Nos. 1 and 2 thereto) (“2004 Plan”), (ii) the Stock & Deferred Compensation Plan for Non-Employee Directors (“DSU Plan”) and (iii) the Employee Stock Purchase Plan (“ESPP”). Collectively, these equity-based compensation plans permit the grants of (i) incentive stock options, (ii) non-qualified stock options, (iii) stock appreciation rights, (iv) restricted stock, (v) performance units, (vi) stock units and (vii) cash, as well as allow employees to purchase shares of the Company’s common stock under the ESPP at a pre-determined discount.
	Under the 2004 Plan, 7.8 million shares of common stock are available for grant, which includes the additional 1.6 million shares of common stock last authorized on May 9, 2013 by the shareholders of the Company for issuance under the 2004 Plan. The maximum number of shares of common stock for which grants may be made in any calendar year to any 2004 Plan participant is 500,000. Under the 2004 Plan, stock options granted on and after February 25, 2009 will have a maximum term of seven years. Options granted prior to February 25, 2009 retain their ten year term. As of December 31, 2013, the Company had 1,850,597 shares available for issuance under the 2004 Plan.
	For the year ended December 31, 2013, the Company recorded equity-based compensation expense, as calculated on a straight-line basis over the vesting periods of the related equity instruments, of $8.2 million as compared to $7.6 million and $7.5 million for the corresponding periods of 2012 and 2011, which were reflected as selling, general and administrative expense in the consolidated statements of comprehensive income. During 2011, the Company recorded non-cash compensation expense of approximately $0.4 million associated with modifications of stock options for a former executive officer, which is reflected as selling, general and administrative expense in the consolidated statements of comprehensive income.
	Stock Options
	The weighted average fair values of the Company’s stock options granted during 2013, 2012 and 2011 calculated using the Black-Scholes option pricing model and other assumptions used in the option pricing model, were as follows:
		For the Year Ended
		December 31, 2013				December 31, 2012				31-Dec-11
	Weighted average fair value of options granted	$	6.02			$	4.32			$	3.46
	Risk-free interest rate	0.29% - 0.54%				0.77% - 0.95%				0.91		%
	Expected volatility	76% - 79%				64% - 65%				60		%
	Contractual life	7 years				7 years				7 years
	Expected life	3.4 - 5.4 years				3.4 - 5.4 years				4.5 - 6.5 years
	Expected dividend yield	—		%		—		%		—		%
	For the year ended December 31, 2013, the Company issued 375,000 stock options that are both time-vesting (one-third each year) and carry a market vesting feature based on the average 30-day closing stock price of the Company's common stock based on stock price thresholds of $14, $16, and $18 (each covering one-third of the options granted). The fair value of the stock options granted ranged from $5.22 to $5.87 and was determined using the Monte Carlo stock option valuation model. Assumptions used in the model included volatility of 67 percent, risk-free interest rate of 0.60 percent, zero percent dividend yield, a forfeiture rate based on the Company's historical experience and a contractual life of seven years.
	Stock option grants in 2011 through 2013 vest over a three-year period based on a vesting schedule that provides for one-third vesting after each year. Stock option grants in 2010 fully vest over a four-year period based on a vesting schedule that provides for one-half vesting after year two and an additional one-fourth vesting after each of years three and four. The Company’s expected volatility assumptions are based on the historical volatility of the Company’s stock price over a period corresponding to the expected term of the stock option. Forfeitures are estimated utilizing the Company’s historical forfeiture experience. The expected life of the Company’s stock options is based on the Company’s historical experience of the exercise patterns associated with its stock options.
	A summary of Gentiva stock option activity as of December 31, 2013 and changes during the year then ended is presented below:
		Number of			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic
					Exercise				Remaining		Value
					Price				Contractual
									Life (Years)
	Balance as of December 31, 2012	3,752,418			$	15.99
	Granted	642,700			10.74
	Exercised	(97,455	)		5.6
	Cancelled	(292,074	)		15.98
	Balance as of December 31, 2013	4,005,589			$	15.4			4.4		$	8,651,115
	Exercisable options	2,829,292			$	17.58			3.9		$	4,771,998
	Shares expected to vest as of December 31, 2013	1,139,228			$	10.19			5.5		$	3,785,503
	During 2013, the Company granted 642,700 stock options to employees under its 2004 Plan at an average exercise price of $10.74 and a weighted-average, grant-date fair value of $6.02. The total intrinsic value of options exercised during 2013, 2012 and 2011 was $0.6 million, $0.3 million and $1.9 million, respectively.
	As of December 31, 2013 and December 31, 2012, the Company had $3.4 million and $2.5 million, respectively, of total unrecognized compensation cost related to nonvested stock options. This compensation expense is expected to be recognized over a weighted-average period of 1.4 years and 1.3 years, respectively. The total fair value of options that vested during 2013 and 2012 was $4.0 million and $4.7 million, respectively.
	Performance Based Awards
	The Company may grant performance based awards under its 2004 Plan that are either settled in shares of the Company's common stock or settled in cash depending on the individual award type. Performance based awards may result in the issuance of a range of shares of common stock or cash based on the achievement of defined levels of performance criteria. Performance based awards also carry a three-year service period requirement from the date of grant to vest. Forfeitures are estimated utilizing the Company’s historical forfeiture experience.
	A summary of Gentiva's performance based share award activity by grant year as of December 31, 2013 is presented below:
		2010			2011			Number of			Weighted-
								Performance			Average
								Share Units			Exercise
											Price
	Service period to vest:	3 years			3 years
	Performance range of target:	0% - 150%			0% - 200%
	Performance measured on:	EPS			EPS
	Performance measurement period:	1/3 based on 2010 results			90% based on 2011 results
		1/3 based on 2011 results			10% based on 2013 results
		1/3 based on 2012 results
	Performance target achieved:	2010 - 150%			2011 - 200%
		2011 - 150%			2013 - 0%
		2012 - 0%
	Performance share units:
	Balance as of December 31, 2012	33,700			166,750			200,450			$	26.31
	Forfeited	—			(1,800	)		(1,800	)		26.67
	Change in performance achievement expectations	—			(6,650	)		(6,650	)		26.58
	Issued	(33,700	)		(158,300	)		(192,000	)		26.29
	Balance as of December 31, 2013	—			—			—			$	—
	These performance share units carry performance criteria measured on annual diluted earnings per share targets and fully vest at the end of a three-year service period provided the performance criteria are met. There were no grants of performance share units for 2012 or 2013.
	As of December 31, 2013, all performance share units were fully vested and the Company had no unrecognized compensation cost related to performance based share awards. As of December 31, 2012, the Company had $1.5 million of total unrecognized compensation cost related to performance based share awards, which is expected to be recognized over a weighted-average period of 1.0 year.
	A summary of Gentiva's performance based cash award activity by grant year as of December 31, 2013 is presented below:
		2012				2013
	Service period to vest:	3 years				3 years
	Performance range of target:	0% - 200%				0% - 240%
	Performance measured on:	EPS				EPS
	Performance measurement period:	1/2 based on 2012 results				60% based on 2013 results
		1/2 based on 2014 results				40% based on 2015 results
	Performance target achieved:	2012 - 85%				2013 - 0%
	Performance cash:
Balance as of December 31, 2012	$	1,293,687			$	—
Earned	1,225,589				1,005,832
Issued	—				—
Balance as of December 31, 2013	$	2,519,276			$	1,005,832
For the year ended December 31, 2013, the Company recorded $2.2 million of compensation expense associated with its performance based cash awards as compared to $1.3 million for the corresponding period of 2012. As of December 31, 2013, the Company had unrecognized compensation cost at target of $3.3 million to be recognized over a weighted-average period of 1.6 years. As of December 31, 2012, the Company had unrecognized compensation cost at target of $2.6 million to be recognized over a weighted-average period of 2.0 years. During the third quarter of 2013, the Company's Compensation Committee and Board of Directors approved an amendment to the 2013 performance cash awards for the Company's named executive officers to measure performance based entirely on year 2015 results and not on any year 2013 results. Also, under the amendment, the performance range of target could extend to 240 percent under certain circumstances.
Restricted Stock
A summary of Gentiva restricted stock activity as of December 31, 2013 is presented below:
	Number of			Weighted-				Aggregate
	Restricted			Average				Intrinsic
	Shares			Exercise				Value
				Price
Balance as of December 31, 2012	364,650			$	25.25
Granted	338,300			11.37
Exercised	(39,750	)		26.06
Cancelled	(27,800	)		14.7
Balance as of December 31, 2013	635,400			$	18.27			$	7,885,314
Nonvested shares expected to vest as of December 31, 2013	602,343			$	18.53			$	7,475,074
The restricted stock fully vests at the end of a three-year or five-year period, depending on the individual grants. Forfeitures are estimated utilizing the Company’s historical forfeiture experience.
As of December 31, 2013, 2012 and 2011 the aggregate intrinsic value of the restricted stock awards was $7.9 million, $3.7 million and $2.5 million, respectively. The Company had $4.9 million and $4.3 million of total unrecognized compensation cost related to restricted stock as of December 31, 2013 and 2012, respectively. This compensation expense is expected to be recognized over a weighted-average period of 2.0 and 2.5 years, respectively.
Directors Deferred Share Units
Under the Company’s DSU Plan, each non-employee director receives an annual deferred stock unit award credited quarterly and paid in shares of the Company’s common stock following termination of the director’s service on the Board of Directors. In May of 2012, the Company’s shareholders approved increasing the aggregate number of shares of common stock available for issuance under the plan by 350,000 shares; therefore, the total number of shares of common stock reserved for issuance under this plan is 650,000, of which 206,837 shares were available for future grants as of December 31, 2013. During 2013, the Company granted 67,696 stock units under the DSU Plan at a grant date weighted-average fair value of $11.29 per stock unit. Prior to the increase in the aggregate shares available for issuance in May of 2012, there were insufficient deferred stock units available under the DSU Plan for the full quarterly equity grant to each non-employee director in the first quarter of 2012. Therefore, the Company also made a cash payment of approximately $28,100 to each non-employee director during 2012. Under the DSU Plan, 332,776 stock units were outstanding as of December 31, 2013.
Employee Stock Purchase Plan
The Company’s ESPP, as amended on May 10, 2012, provides an aggregate of 1,800,000 shares of common stock available for issuance under the ESPP. The Compensation Committee of the Company’s Board of Directors administers the plan and has the power to determine the terms and conditions of each offering of common stock. All employees of the Company are immediately eligible to purchase stock under the plan regardless of their actual or scheduled hours of service. Employees may purchase shares having a fair market value of up to $25,000 per calendar year based on the value of the shares on the date of purchase. The maximum number of shares of common stock that may be sold to any employee in any offering, however, will generally be 10 percent of that employee’s compensation during the period of the offering. The offering period is three months and the purchase price of shares is equal to 85 percent of the fair market value of the Company’s common stock on the last day of the three-month offering period. As of December 31, 2013, 2,067,483 shares of common stock were available for future issuance under the ESPP. During 2013, 2012 and 2011, the Company issued 269,156 shares, 403,292 shares and 407,091 shares shares, respectively, of common stock under its ESPP. The Company records compensation expense equal to the 15 percent discount from the fair market value of the Company’s common stock on the date of purchase.

Legal_Matters

Legal Matters	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Legal Matters	'
	ompany in which five former employees ("Plaintiffs") alleged wage and hour law violations. The former employees claimed they were paid pursuant to “an unlawful hybrid” compensation plan that paid them on both a per visit and an hourly basis, thereby voiding their exempt status and entitling them to overtime pay. Plaintiffs alleged continuing violations of federal and state law and sought damages under the Fair Labor Standards Act (“FLSA”), as well as under the New York Labor Law and North Carolina Wage and Hour Act (“NCWHA”). On October 8, 2010, the Court granted the Company’s motion to transfer the venue of the lawsuit to the United States District Court for the Northern District of Georgia. On April 13, 2011, the Court granted Plaintiffs’ motion for conditional certification of the FLSA claims as a collective action. On May 26, 2011, the Court bifurcated the FLSA portion of the suit into a liability phase, in which discovery closed on January 15, 2013, and a potential damages phase, to be scheduled pending outcome of the liability phase. Following a motion for partial summary judgment by the Company regarding the New York state law claims, Plaintiffs agreed voluntarily to dismiss those claims in a filing on December 12, 2011. Plaintiffs filed a motion for certification of a North Carolina state law class for NCWHA claims on January 20, 2012. On August 29, 2012, the Court denied Plaintiffs' motion for certification of a North Carolina state law class. The Company filed a motion for partial summary judgment on Plaintiffs’ claims under the NCWHA on March 22, 2012, which the Court granted on January 16, 2013. On February 14, 2013, the Company filed two motions for partial summary judgment with regard to the Company's liability for Plaintiffs' FLSA claims. On the same day, Plaintiffs filed a motion for partial summary judgment in their favor with regard to the Company's liability. On July 26, 2013, the Court denied the Company's motion for summary judgment with regard to the Company's liability for Plaintiffs' FLSA claims and granted Plaintiffs' motion for summary judgment. On November 4, 2013, the Court denied the Company's motion to amend the District Court's July 26 Order to certify two legal issues for immediate interlocutory appeal to the Eleventh Circuit Court of Appeals. In its Order, the Court established a 30-day deadline for the Company to file its motion for decertification of the FLSA collective action class, which the Company then filed on December 4, 2013. If the District Court denies the Company's motion for decertification, the case will move into the damages phase of the litigation. If the District Court grants the Company's motion for decertification, the case will move into the damages phase of the litigation for the five named Plaintiffs only. While the parties continue to prepare to litigate the damages phase of the lawsuit and potential decertification of the collective action, the case remains conditionally certified with a class of approximately 1,000 allegedly similar employees seeking attorneys’ fees, back wages and liquidated damages going back three years under the FLSA.
	Based on the information the Company has at this time in the Rindfleisch lawsuit, the Company is unable to assess the probable outcome or potential liability, if any, arising from this proceeding on the business, financial condition, results of operations, liquidity or capital resources of the Company. The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made for this lawsuit at this time. The Company intends to defend itself vigorously in this lawsuit.
	On June 11, 2010, a collective and class action complaint entitled Catherine Wilkie, individually and on behalf of all others similarly situated v. Gentiva Health Services, Inc. was filed in the United States District Court for the Eastern District of California against the Company in which a former employee alleged wage and hour violations under the FLSA and California law. The complaint alleged that the Company paid some of its employees on both a per visit and hourly basis, thereby voiding their exempt status and entitling them to overtime pay. The complaint further alleged that California employees were subject to violations of state laws requiring meal and rest breaks, overtime pay, accurate wage statements and timely payment of wages. The plaintiff sought class certification, attorneys’ fees, back wages, penalties and damages going back three years on the FLSA claim and four years on the state wage and hour claims. The Company denies the plaintiff's allegations but, following a March 2012 mediation, agreed to pay a total settlement amount of $5 million to settle the collective and class action claims. The federal district court granted final approval of the settlement on March 26, 2013, and funds were disbursed to the participating class members, 99 percent of whom timely negotiated their settlement checks. The unclaimed wages will escheat to the State of California, and any balance remaining will be distributed to a cy pres beneficiary at the conclusion of the escheat process. A status conference is scheduled for June 22, 2015, at which time the parties will present a final accounting of the settlement fund, and the court is expected to approve distribution of the residual to the cy pres beneficiary and dismiss the case.
	On December 29, 2011, Odyssey HealthCare, Inc. was served with a complaint captioned United States of America and the State of Illinois ex rel. Laurie Geschrey and Laurie Janus v. Generations Healthcare, LLC, Odyssey HealthCare, Inc., Narayan Ponakala and Catherine Ponakala , which was filed on April 19, 2010 as a qui tam action in the United States District Court for the Northern District of Illinois, Eastern Division, Case No. 10 C 2413, under the provisions of the federal False Claims Act, the Illinois Whistleblower Reward and Protection Act and the Illinois Whistleblower Act. The plaintiffs, two former employees of Generations Healthcare, LLC, a hospice company whose assets were acquired by Odyssey on December 31, 2009, were the relators and alleged that defendants committed fraud against the United States and the State of Illinois by, among other things, recruiting and certifying patients as being eligible for hospice care when they were known not to be eligible and falsifying patients’ medical records in support of the claims for reimbursement. Relators further alleged that Odyssey was aware of Generations Healthcare’s alleged fraudulent business practices. Both the United States and the State of Illinois declined to intervene in the action, and the complaint was unsealed on December 1, 2011. Relators sought statutory damages, which are three times the amount of any actual damages suffered by the United States and the State of Illinois, the maximum statutory civil penalty due under the statutes plus all costs and attorneys fees. Additionally, relators sought back pay plus interest and other damages because of defendants’ alleged retaliation against relators. Odyssey sought indemnification from Generations Healthcare and its owners, who were defendants in this action. The action has been settled and all parties have signed a confidential settlement agreement. A stipulation of dismissal was filed on February 11, 2014, dismissing the case in its entirety, with prejudice.
	On July 10, 2013, the Company was served with a complaint captioned United States ex rel. Vicky White v. Gentiva Health Services, Inc., which had been filed on September 8, 2010 as a qui tam action in United States District Court for the Eastern District of Tennessee by a former employee, Vicky White, as relator. The United States had declined to intervene in this action on April 5, 2013. Relator seeks treble damages and civil penalties under the federal False Claims Act for alleged violations by the Company in presenting false claims for payment and receiving Medicare reimbursement for certain home health services it had provided and also seeks damages relating to her alleged retaliatory discharge by the Company. On September 6, 2013, the Company filed a motion to dismiss the action in its entirety, which remains pending. Given the preliminary stage of this action and the limited information that the Company has regarding this matter, the Company is unable to assess the probable outcome or potential liability, if any, arising from this action. The Company intends to defend itself vigorously in this lawsuit.
	Federal Securities Class Action Litigation
	Between November 2, 2010 and October 25, 2011, five shareholder class actions were filed against Gentiva and certain of its current and former officers and directors in the United States District Court for the Eastern District of New York. Each of these actions asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "1934 Act") in connection with the Company’s participation in the Medicare Home Health Prospective Payment System (“HH PPS”). Following consolidation of the actions and the appointment of Los Angeles City Employees’ Retirement System as lead plaintiff, on April 16, 2012, a consolidated shareholder class action complaint, captioned In re Gentiva Securities Litigation, Civil Action No. 10-CV-5064, was filed in the United States District Court for the Eastern District of New York. The complaint, which named Gentiva and certain current and former officers and directors as defendants, asserted claims under Sections 10(b) and 20(a) of the 1934 Act, as well as Sections 11 and 15 of the Securities Act of 1933 (the "1933 Act"), in connection with the Company’s participation in the HH PPS. The complaint alleged, among other things, that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purposes of triggering higher reimbursement rates under the HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock during the period between July 31, 2008 and October 4, 2011. On June 15, 2012, defendants filed a motion to dismiss the complaint. On March 25, 2013, the court granted defendants' motion to dismiss with leave to amend the complaint in accordance with the court's rulings as set forth in its March 25 order. On May 10, 2013, lead plaintiff filed a consolidated amended class action complaint, and, on June 24, 2013, defendants filed a motion to dismiss. On September 19, 2013, the court granted in part and denied in part defendants’ motion to dismiss. As a result of the court’s decision, the named current officers and directors were dismissed from the action, and certain claims against Gentiva and a former officer and a former officer/director remained. On October 3, 2013, the remaining defendants moved for partial reconsideration of the court’s September 19 order. On December 10, 2013, the court granted in part and denied in part the remaining defendants' motion for partial reconsideration. As a result of the court's decision, Gentiva and the former officer were dismissed from the action, and only a Section 10(b) claim against the former officer/director remains. On January 9, 2014, the former officer/director filed an answer to the consolidated amended class action complaint. On January 28, 2014, lead plaintiff filed a motion for the entry of final judgment under Rule 54(b) of the Federal Rules of Civil Procedure. On March 3, 2014, the court granted in part and denied in part lead plaintiff's motion under Rule 54(b), granting the motion to the extent lead plaintiff sought final judgment for the claims brought pursuant to the 1933 Act as to all defendants, and denying the motion to the extent lead plaintiff sought final judgment for the claims brought pursuant to the 1934 Act as to all defendants other than the former officer/director. As a result of the court's decision, on March 6, 2014, the court entered final judgment in favor of all defendants on lead plaintiff's claims under Sections 11 and 15 of the 1933 Act.
	Given the preliminary stage of the action, the Company is unable to assess the probable outcome or potential liability, if any, arising from the action on the business, financial condition, results of operations, liquidity or capital resources of the Company. The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made for the action at this time. The defendants intend to defend themselves vigorously in the action.
	Shareholder Derivative Litigation
	On January 4, 2011 and October 31, 2011, two actions were filed against certain of Gentiva’s current and former directors in Superior Court of DeKalb County in the State of Georgia, alleging, among other things, that Gentiva’s board of directors breached its fiduciary duties to the Company. The actions were consolidated and, on February 9, 2012, plaintiffs filed a consolidated complaint (the “Georgia State Court Action”). The Georgia State Court Action, which named certain of Gentiva’s current and former directors as defendants, alleged, among other things, that Gentiva’s board of directors had actual or constructive knowledge that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purpose of triggering higher reimbursement rates under HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock. On March 26, 2012, defendants filed a motion to dismiss the Georgia State Court Action and further requested a transfer to the Superior Court of Cobb County. On October 12, 2012, the Cobb County court granted defendants' motion to dismiss the consolidated complaint with prejudice. On November 30, 2012, one of the plaintiffs in the Georgia State Court Action made a demand on Gentiva's board of directors to take action to remedy the breaches of fiduciary duty alleged in the Georgia State Court Action. The board of directors formed a committee (the “Committee”) to consider the demand.
	On October 7 and October 13, 2011, two actions were filed against certain of Gentiva’s current and former directors and officers in the United States District Court for the Northern District of Georgia, alleging, among other things, that Gentiva’s board of directors breached its fiduciary duties to the Company. The actions also asserted a claim under Section 14(a) of the Securities Exchange Act of 1934. The actions were consolidated and, on March 5, 2012, plaintiffs filed a consolidated complaint (the “Georgia Federal Court Action”). The Georgia Federal Court Action, which named certain of Gentiva’s current and former directors and officers as defendants, alleged, among other things, that Gentiva’s board of directors had actual or constructive knowledge that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purpose of triggering higher reimbursement rates under the HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock. The complaint further alleged that the Company’s Proxy Statement for its 2010 Annual Meeting of Shareholders was materially false and misleading. On April 16, 2012, defendants filed a motion to dismiss the Georgia Federal Court Action and, on February 11, 2013, the court granted defendants' motion to dismiss with prejudice.  On March 11, 2013, one of the plaintiffs in the Georgia Federal Court Action filed a notice of appeal to the United States Court of Appeals for the Eleventh Circuit. On April 10, 2013, that plaintiff and defendants filed a joint motion to dismiss the appeal with prejudice in the Eleventh Circuit. On April 30, 2013, that motion was granted.  On August 2, 2013 and September 24, 2013, respectively, each of the plaintiffs in the Georgia Federal Court Action made a demand on Gentiva’s board of directors to take action to remedy the breaches of fiduciary duty alleged in the Georgia Federal Court Action.  The demands were considered by the Committee along with the November 30, 2012 demand, and, after conducting an investigation of the allegations contained in each of the three demands, the Committee and the Board determined that taking any or all of the demanded actions would not serve the best interests of Gentiva and its shareholders. Accordingly, the Board voted unanimously to rejects the demands.
	Government Matters
	PRRB Appeal
	In connection with the audit of the Company’s 1997 cost reports, the Medicare fiscal intermediary made certain audit adjustments related to the methodology used by the Company to allocate a portion of its residual overhead costs. The Company filed cost reports for years subsequent to 1997 using the fiscal intermediary’s methodology. The Company believed the methodology it used to allocate such overhead costs was accurate and consistent with past practice accepted by the fiscal intermediary; as such, the Company filed appeals with the Provider Reimbursement Review Board (“PRRB”) concerning this issue with respect to cost reports for the years 1997, 1998 and 1999. The Company’s consolidated financial statements for the years 1997, 1998 and 1999 had reflected use of the methodology mandated by the fiscal intermediary. In June 2003, the Company and its Medicare fiscal intermediary signed an Administrative Resolution relating to the issues covered by the appeals pending before the PRRB. Under the terms of the Administrative Resolution, the fiscal intermediary agreed to reopen and adjust the Company’s cost reports for the years 1997, 1998 and 1999 using a modified version of the methodology used by the Company prior to 1997. This modified methodology will also be applied to cost reports for the year 2000, which are finalized and being settled. The Administrative Resolution required that the process to (i) reopen all 1997 cost reports, (ii) determine the adjustments to allowable costs through the issuance of Notices of Program Reimbursement and (iii) make appropriate payments to the Company, be completed in early 2004. Cost reports relating to years subsequent to 1997 were to be reopened after the process for the 1997 cost reports was completed.
	The fiscal intermediary completed the reopening of all 1997, 1998 and 1999 cost reports and determined that the adjustment to allowable costs aggregated $15.9 million which the Company has received and recorded as adjustments to net revenues in the fiscal years 2004 through 2006. The 2000 cost reports are now finalized and being settled by the Centers for Medicare & Medicaid Services. In connection with the settlements, the Company has recorded approximately $4.0 million as a positive adjustment to net revenues in 2013.
	Investigations Involving Odyssey
	On May 5, 2008, Odyssey HealthCare, Inc. (“Odyssey”) received a letter from the U.S. Department of Justice (“DOJ”) notifying Odyssey that the DOJ was conducting an investigation of VistaCare, Inc. (“VistaCare”) and requesting that Odyssey provide certain information and documents related to the DOJ’s investigation of claims submitted by VistaCare to Medicare, Medicaid and the U.S. government health insurance plan for active military members, their families and retirees, formerly the Civilian Health and Medical Program of the Uniformed Services (“TRICARE”), from January 1, 2003 through March 6, 2008, the date Odyssey completed the acquisition of VistaCare. Odyssey has been informed by the DOJ and the Medicaid Fraud Control Unit of the Texas Attorney General’s Office that they are reviewing allegations that VistaCare may have billed the federal Medicare, Medicaid and TRICARE programs for hospice services that were not reasonably or medically necessary or performed as claimed. The basis of the investigation is a qui tam lawsuit filed in the United States District Court for the Northern District of Texas by a former employee of VistaCare. The lawsuit alleges, among other things, that VistaCare submitted false claims to Medicare and Medicaid for hospice services that were not medically necessary and for hospice services that were referred in violation of the anti-kickback statute. The court unsealed the lawsuit on October 5, 2009 and Odyssey was served on January 28, 2010. In connection with the unsealing of the complaint, the DOJ filed a notice with the court declining to intervene in the qui tam action at such time. The Texas Attorney General also filed a notice of non-intervention with the court. These actions should not be viewed as a final assessment by the DOJ or the Texas Attorney General of the merits of this qui tam action. Odyssey continues to cooperate with the DOJ and the Texas Attorney General in their investigation. The relator has continued to pursue the qui tam lawsuit. Odyssey and VistaCare filed motions to dismiss the relator’s complaint on March 30, 2010 and April 2, 2012. The court issued orders on the motions to dismiss on March 9, 2011 and July 23, 2012. Consistent with the court’s orders, relator’s false claims act claims based on alleged medically unnecessary hospice services and for hospice services referred in violation of the anti-kickback statute are permitted to proceed to discovery. On or about September 6, 2013, relator filed her fourth amended complaint. This pleading only alleged wrongdoing against VistaCare from January 1, 2003 through December 31, 2012 and did not allege any wrongdoing against Odyssey or the Company and only asserted claims against them as purported successors in interest. On or about September 27, 2013, VistaCare answered the fourth amended complaint, and the Company and Odyssey moved to dismiss the allegations made against them. That motion is pending before the court, and discovery is continuing. The case has been set for trial on September 21, 2015. VistaCare, Odyssey, and the Company deny the allegations made in this qui tam action and will vigorously defend against them. Based on the information available at this time, the Company cannot predict the outcome of the qui tam lawsuit, the governments’ continuing investigation, the DOJ’s or Texas Attorney General’s views of the issues being investigated, other than the DOJ’s and Texas Attorney General’s notice declining to intervene in the qui tam action, or any actions that the DOJ or Texas Attorney General may take.
	On February 23, 2010, Odyssey received a subpoena from the Department of Health and Human Services, Office of Inspector General (“OIG”), requesting various documents and certain patient records of one of Odyssey’s hospice programs relating to services performed from January 1, 2006 through December 31, 2009. Odyssey is cooperating with the OIG and has completed its subpoena production. Based on the limited information that Odyssey has at this time, the Company cannot predict the outcome of the investigation, the OIG’s views of the issues being investigated or any actions that the OIG may take.
	The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made at this time with regard to the above investigations involving Odyssey. Based on the limited information that Odyssey has at this time regarding such investigations, the Company is unable to predict the impact, if any, that such investigations may have on Odyssey’s and the Company’s business, financial condition, results of operations, liquidity or capital resources.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
		Related Party Transactions
	On October 18, 2013, the Company completed the acquisition of Harden Healthcare Holdings, Inc., a provider of home health, hospice and community care services primarily in the southwestern United States, for approximately $365.0 million in cash, $53.8 million in shares of Gentiva's common stock and additional contingent consideration of $9.5 million, recorded at estimated fair value of approximately $8.1 million. Under the terms of the related Agreement and Plan of Merger dated as of September 18, 2013 (“Merger Agreement”), R. Steven Hicks, one of the Harden selling stockholders and one of the Company's directors, received 481,288 shares of Gentiva's common stock. In addition, five trusts, of which Mr. Hicks was trustee, received an aggregate of 484,715 shares of Gentiva's common stock, and two entities, of which one Mr. Hicks was the managing member and of which the other Mr. Hicks was managing partner of its general partner, received an aggregate of 1,955,905 shares of Gentiva's common stock. Mr. Hicks, the five trusts (in the aggregate) and the two entities (in the aggregate) also received approximately $0.89 million, $0.89 million and $3.6 million, respectively, in cash consideration pursuant to the terms of the Merger Agreement.
	Pursuant to the Merger Agreement, Mr. Hicks serves as “Stockholder Representative” of the former Harden securityholders who are signatory to the Merger Agreement. In that capacity, Mr. Hicks is responsible for representing the interests of the former securityholders under the Merger Agreement, including in respect of any indemnity claims that may arise.
	In connection with the Company's acquisition of Harden Healthcare Holdings, effective October 18, 2013, the Company entered into a Stockholders’ Agreement among the Harden sellers and R. Steven Hicks, one of the Company's directors, pursuant to which the Company's Board of Directors agreed to appoint Mr. Hicks to serve on the Board of Directors as its Vice Chairman and to nominate Mr. Hicks for election at the Annual Meeting. Pursuant to the Stockholders’ Agreement, the Company also (i) agreed to file, not later than 30 days following the closing date, a shelf registration statement on Form S-3 registering the resale of shares of Gentiva's common stock issued to the Harden sellers in connection with the acquisition and (ii) granted the Harden sellers certain piggyback registration rights, subject to customary cutback provisions. In November 2013, the Company filed the shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission in December 2013.
	On October 18, 2013, the Company also entered into a five-year Consulting Agreement with Capstar Partners, LLC (“Capstar”), a Texas limited partnership of which Mr. Hicks has been Chairman since 2000, pursuant to which Capstar will provide the Company with certain transitional, strategic or commercial matters, including assistance with the development and maintenance of relationships with key customers and third party payors. Pursuant to the Consulting Agreement, the Company has agreed to pay Capstar, for each of five calendar years commencing January 1, 2014, an amount equal to $1.0 million per year if the reimbursement rate for certain healthcare services in the State of Texas exceeds a specified base reimbursement rate. If for any reason such reimbursement rate fails to exceed the specified base reimbursement rate, Capstar will not be entitled to any payment under the Consulting Agreement for such year. In addition, on October 18, 2013, the Company entered into an agreement pursuant to which Capstar Investment Partners, L.P., a Texas limited partnership in which Mr. Hicks has an indirect material interest (“Capstar L.P.”), agreed to terminate a certain sublease agreement in connection with the Company's acquisition of Harden. Under the agreement, the Company agreed to pay Capstar L.P., for each of five calendar years commencing January 1, 2014, an amount equal to either (i) $750,000 if the reimbursement rate for certain healthcare services in the State of Texas exceeds the specified base reimbursement rate for such year and (ii) $0 if such reimbursement rate fails to exceed the specified base reimbursement rate for such year. Effective December 31, 2013, Capstar L.P. assigned its right under the sublease termination agreement to Capstar. Although the Company's policies did not require that the Company's Audit Committee pre-approve the transactions as Mr. Hicks was not a director prior to the acquisition of Harden, the transactions were reviewed by the Company's Board of Directors prior to closing.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments	'
	Commitments
	The Company rents certain properties under non-cancelable, long-term operating leases, which expire at various dates. Certain of these leases require additional payments for taxes, insurance and maintenance and, in many cases, provide for renewal options. Rent expense under all leases associated with the Company’s continuing operations was $45.9 million in 2013, $45.3 million in 2012 and $47.9 million in 2011. Rent expense associated with the Company’s discontinued operations amounted to $0.6 million for 2011.
	Future minimum rental commitments and sublease rentals for all non-cancelable leases at December 31, 2013 are as follows (in thousands):
	Fiscal Year	Total		Sublease		Net
		Commitment		Rentals
	2014	$	50,738	$	525	$	50,213
	2015	38,205		237		37,968
	2016	27,387		69		27,318
	2017	19,259		37		19,222
	2018	13,398		28		13,370
	Thereafter	13,785		—		13,785

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	A comparative analysis of the provision for income taxes follows (in thousands):
		For the Year Ended
		December 31, 2013 (Restated)				31-Dec-12				December 31, 2011 (Revised)
	Current:
	Federal	$	(3,968	)		$	(7,784	)		$	7,784
	State and local	1,063				1,522				2,460
	Current income tax expense (benefit)	(2,905		)		(6,262		)		10,244
	Deferred:
	Federal	(30,655		)		20,211				(71,267		)
	State and local	(6,393		)		3,302				(15,100		)
	Deferred income tax (benefit) expense	(37,048		)		23,513				(86,367		)
	Income tax (benefit) expense	$	(39,953	)		$	17,251			$	(76,123	)
	A reconciliation of the differences between federal statutory tax rate and the Company’s effective tax rate for 2013, 2012 and 2011 is as follows:
		For the Year Ended
		31-Dec-13			31-Dec-12			31-Dec-11
	Federal statutory tax rate	35	%		35	%		35	%
	Impairment	(29.2	)		—			(23.6	)
	State income taxes, net of Federal benefit	0.6			4.6			1.7
	Change in tax reserve	(0.1	)		(3.4	)		(0.5	)
	Net change in state valuation allowance	—			(0.6	)		(0.1	)
	Other	(0.1	)		0.9			0.1
	Effective tax rate	6.2	%		36.5	%		12.6	%
	Deferred income tax assets and deferred tax liabilities are as follows (in thousands):
		December 31, 2013 (Restated)				December 31, 2012 (Revised)
	Deferred tax assets
	Current:
	Reserves and allowances	$	18,840			$	8,833
	Payroll and related accruals	5,343				5,953
	Net operating loss carryforwards, state	6,216				—
	Other	409				446
	Less: valuation allowance	(777		)		(511		)
	Total current deferred tax assets	30,031				14,721
	Noncurrent:
	Equity compensation	17,376				16,940
	Deferred rent	2,241				2,935
	Net operating loss carryforwards, federal	12,141				—
	Capital loss carryforward	232				—
	Federal tax credit carryforwards	4,408				4,809
	Other	5,920				3,669
	Less: valuation allowance	(2,864		)		(2,367		)
	Total noncurrent deferred tax assets	39,454				25,986
	Total deferred tax assets	69,485				40,707
	Deferred tax liabilities:
	Current:
	Prepaid assets	(1,873		)		(2,458		)
	Other	(5		)		—
	Total current deferred tax liabilities	(1,878		)		(2,458		)
	Noncurrent:
	Fixed assets	(2,684		)		(1,409		)
	Intangible assets	(39,202		)		(50,398		)
	Developed software	(3,568		)		(4,559		)
	Financing fees	(1,940		)		(10,637		)
	Other	(543		)		—
	Total non-current deferred tax liabilities	(47,937		)		(67,003		)
	Total deferred tax liabilities	(49,815		)		(69,461		)
	Net deferred tax assets (liabilities)	$	19,670			$	(28,754	)
	At December 31, 2013 and 2012, current net deferred tax assets were $28.2 million and $12.3 million, respectively and non-current net deferred tax liabilities were $8.5 million and $41.0 million, respectively.
	At December 31, 2013, the Company had a federal tax credit carryforwards of $4.4 million, a federal net operating loss of $34.7 million, and a federal capital loss carryforward of $0.7 million. The Company had a deferred tax asset of $4.4 million for the federal tax credit carryforwards, $12.1 million for the federal net operating loss, and $0.2 million for the federal capital loss carryforwards. A valuation allowance of $0.2 million has been recorded to reduce the deferred tax asset for the capital loss carryforward to its estimated realizable value. The Company had state net operating loss carryforwards of approximately $133.0 million that expire beginning in 2014. Deferred tax assets relating to the state net operating loss carryforward approximate $6.2 million. A valuation allowance of $3.4 million has been recorded to reduce this deferred tax asset to its estimated realizable value since certain state net operating loss carryforwards may expire before realization. The majority of the federal carryforwards and approximately $15.6 million of the state net operating losses are from the Harden Healthcare Holdings, Inc. acquisition and are subject to Internal Revenue Code §382 limitations.
	Authoritative guidance requires that the realization of an uncertain income tax position must be more likely than not (i.e., greater than 50 percent likelihood of receiving a benefit) before it can be recognized in the financial statements. At December 31, 2013 and 2012, the Company had $7.7 million and $8.4 million, respectively, of unrecognized tax benefits, all of which would affect the Company’s effective tax rate if recognized.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
	Balance at December 31, 2010	$	3,651
	Additions for tax positions of the current year	9,039
Additions for tax positions of prior year	2,316
Changes in judgment	(584		)
Reductions for tax positions of prior years for:
Settlements during the period	(3,184		)
Lapses of applicable statute of limitations	(211		)
Balance at December 31, 2011	11,027
Additions for tax positions of the current year	126
Additions for tax positions of prior year	245
Changes in judgment	(2,312		)
Reductions for tax positions of prior years for:
Settlements during the period	(274		)
Lapses of applicable statute of limitations	(456		)
Balance at December 31, 2012	8,356
Additions for tax positions of the current year	456
Additions for tax positions of acquired companies	910
Reductions for tax positions of prior years for:
Settlements during the period	(1,898		)
Lapses of applicable statute of limitations	(148		)
Balance at December 31, 2013	$	7,676
The Company recognizes interest and penalties on uncertain tax positions in income tax expense. The Company had approximately $1.4 million and $0.6 million of accrued interest related to uncertain tax positions as of December 31, 2013 and 2012, respectively.
The Company continues to participate in the IRS’ Compliance Assurance Process (“CAP”). As a result of the Company’s participation in CAP, management has closed federal tax years prior to 2012 and anticipates closing 2012 in early 2014. The Company is still open under statute of limitations for examination of income and non-income tax filings in various state and local jurisdictions from 2009 through current filings.

Benefit_Plans_for_Employee

Benefit Plans for Employee	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Benefit Plans for Employee	'
	Benefit Plans for Employees
	The Company maintains qualified and non-qualified defined contribution plans for its salaried employees, which provide for a partial match of employee savings under the plans and for discretionary contributions based on employee compensation. With respect to the Company’s non-qualified defined contribution plan for salaried employees, all pre-tax contributions, matching contributions and discretionary contributions (and the earnings therein) are held in a Rabbi Trust and are subject to the claims of the general, unsecured creditors of the Company. All post-tax contributions are held in a secular trust and are not subject to the claims of the creditors of the Company. The fair value of the assets held in the Rabbi Trust and the liability to plan participants as of December 31, 2013 and 2012, totaling approximately $34.7 million and $27.7 million, respectively, were included in other assets and other liabilities in the Company’s consolidated balance sheets. Company contributions under the defined contribution plans were approximately $8.0 million in 2013, $7.6 million in 2012 and $9.1 million in 2011.

Business_Segment_Information

Business Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Business Segment Information	'
	Business Segment Information
	The Company’s operations involve servicing its patients and customers through its Home Health, Hospice, and Community Care segments.
	Home Health
	The Home Health segment is comprised of direct home nursing and therapy services operations, including specialty programs. The Company conducts direct home nursing and therapy services operations through licensed and Medicare-certified agencies, located in 38 states, from which the Company provides various combinations of skilled nursing and therapy services and paraprofessional nursing services to adult and elder patients. The Company’s direct home nursing and therapy services operations also deliver services to its customers through focused specialty programs that include:
	•	Gentiva Orthopedics, which provides individualized home orthopedic rehabilitation services to patients recovering from joint replacement or other major orthopedic surgery;
	•	Gentiva Safe Strides®, which provides therapies for patients with balance issues who are prone to injury or immobility as a result of falling;
	•	Gentiva Cardiopulmonary, which helps patients and their physicians manage heart and lung health in a home-based environment;
	•	Gentiva Neurorehabilitation, which helps patients who have experienced a neurological injury or condition by removing the obstacles to healing in the patient’s home; and
	•	Gentiva Senior Health, which addresses the needs of patients with age-related diseases and issues to effectively and safely stay in their homes.
	In addition, through May 31, 2012, the Company provided consulting services to home health agencies, which included operational support, billing and collection activities, and on-site agency support and consulting. For 2011, the Company’s Rehab Without Walls® and IDOA businesses are reflected as discontinued operations in accordance with applicable accounting guidance. See Note 5 for additional information.
	Hospice
	The Hospice segment serves terminally ill patients and their families through Medicare-certified providers operating in 30 states. Comprehensive management of the healthcare services and products needed by hospice patients and their families are provided through the use of an interdisciplinary team. Depending on a patient’s needs, each hospice patient is assigned an interdisciplinary team comprised of a physician, nurse(s), home health aide(s), medical social worker(s), chaplain, dietary counselor and bereavement coordinator, as well as other care professionals.
	The Hospice segment also delivers services through focused specialty programs that include:
	•	Memory Care Specialty Program, which provides an individualized disease management program addressing the physical needs specific to Alzheimer’s and dementia patients and support mechanisms for their caregivers; and
	•	Cardiac Specialty Program, which helps patients and their physicians aggressively manage symptoms associated with heart disease, focusing on quality of life and pain control.
	Community Care
	The Community Care segment serves patients who have chronic or long-term disabilities who need help with routine personal care operating in 5 states: Texas, Missouri, Oklahoma, North Carolina and Kansas. These services include help with personal needs, such as bathing and dressing, and household activities, such as laundry and shopping, all of which help enable the patient to remain at home. Community Care services are funded primarily through state Medicaid programs which vary state to state.
	Corporate Expenses
	Corporate expenses consist of costs relating to executive management and corporate and administrative support functions that are not directly attributable to a specific segment, including equity-based compensation expense. Corporate and administrative support functions represent primarily information services, accounting and finance, tax compliance, risk management, procurement, marketing, clinical administration, training, legal and human resource benefits and administration.
	Other Information
	The Company’s senior management evaluates performance and allocates resources based on operating contributions of the reportable segments, which exclude corporate expenses, depreciation, amortization and net interest costs, but include revenues and all other costs (including special items) directly attributable to the specific segment. Segment assets represent net accounts receivable, identifiable intangible assets, goodwill, and certain other assets associated with segment activities. All other assets are assigned to corporate assets for the benefit of all segments for the purposes of segment disclosure.
	Segment net revenues by major payer source were as follows (in millions):
		Home Health		Hospice				Community Care			Total
	For the year ended December 31, 2013
	Medicare	$	787.3	$	667.9			$	—		$	1,455.20
	Medicaid and Local Government	43.8		28.3				44.5			116.6
	Commercial Insurance and Other:
	Paid at episodic rates	59.6		—				—			59.6
	Other	75.1		19				1.1			95.2
	Total net revenues	$	965.8	$	715.2			$	45.6		$	1,726.60
	For the year ended December 31, 2012
	Medicare	$	749	$	715.5			$	—		$	1,464.60
	Medicaid and Local Government	46.8		27.7				—			74.4
	Commercial Insurance and Other:
	Paid at episodic rates	85.2		—				—			85.2
	Other	67		21.6				—			88.6
	Total net revenues	$	948	$	764.8			$	—		$	1,712.80
	For the year ended December 31, 2011
	Medicare	$	799.2	$	729.1			$	—		$	1,528.30
	Medicaid and Local Government	52.3		30.8				—			83.1
	Commercial Insurance and Other:
	Paid at episodic rates	77.7		—				—			77.7
	Other	83.4		26.3				—			109.7
	Total net revenues	$	1,012.60	$	786.2			$	—		$	1,798.80
	Segment information about the Company's operations is as follows (in thousands):
		Home Health				Hospice					Community Care		Total
	For the year ended December 31, 2013 (Restated)
	Net revenue	$	965,848			$	715,190				$	45,606	$	1,726,644
	Operating contribution	$	113,809	-1		$	78,810			-1	$	6,385	$	199,004
	Corporate expenses												(96,146		)	-1
	Goodwill, intangibles and other long-lived asset impairment												(612,380		)	-3
	Depreciation and amortization												(24,621		)
	Interest expense and other, net												(110,384		)	-2
	(Loss) from continuing operations before income taxes and equity in earnings of affiliate												$	(644,527	)
	Segment assets	$	406,367			$	348,445			-3	172,308		$	927,120
	Corporate assets												326,348			-3
	Total assets												$	1,253,468
	For the year ended December 31, 2012 (Revised)
	Net revenue	$	948,019			$	764,785				$	—	$	1,712,804
	Operating contribution	$	125,445	-1		$	133,133			-1	$	—	$	258,578
	Corporate expenses												(83,700		)	-1
	Goodwill, intangibles and other long-lived asset impairment												(19,132		)	-3
	Depreciation and amortization												(26,581		)
Gain on sale of businesses												8,014
Interest expense and other, net												(89,947		)	-2
Income from continuing operations before income taxes and equity in loss of affiliate												$	47,232
Segment assets	$	242,603	-3		$	855,614			-3	$	—	$	1,098,217
Corporate assets												409,829
Total assets												$	1,508,046
For the year ended December 31, 2011 (Revised)
Net revenue	$	1,012,566			$	786,212				$	—	$	1,798,778
Operating contribution	$	126,194	-1		$	139,723			-1	$	—	$	265,917
Corporate expenses												(115,861		)	-1
Goodwill, intangibles and other long-lived asset impairment												(643,305		)	-3
Dividend income												8,590			-4
Depreciation and amortization												(31,032		)
Gain on sale of assets and businesses, net												1,061
Interest expense and other, net												(88,610		)	-2
(Loss) from continuing operations before income taxes and equity in earnings of affiliate												$	(603,240	)
Segment assets	$	239,751	-3		$	902,397			-3	$	—	$	1,142,148
Corporate assets												385,292			-3
Total assets												$	1,527,440
-1	For the years ended December 31, 2013, 2012 and 2011, the Company recorded charges relating to cost savings initiatives and other restructuring costs, acquisition and integration costs and legal settlements of $27.5 million, $5.7 million and $49.1 million, respectively. See Note 11 for additional information.
The charges were reflected as follows for segment reporting purposes (in millions):
	2013		2012				2011
Home Health	$	3.3	$	5.6			$	7.7
Hospice	8.2		0.4				3.7
Corporate expenses	16		(0.3		)		37.7
Total	$	27.5	$	5.7			$	49.1
-2	For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Company’s interest rate swaps in connection with the refinancing of the Company’s Term Loan A and Term Loan B under the Company’s former credit agreement. See Note 13 for additional information.
-3	The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.
At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.
For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.
For the year ended December 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of December 31, 2011, as a result of the impairment.
-4	For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Company’s combined common and preferred ownership of CareCentrix.

Supplemental_Guarantor_and_Non

Supplemental Guarantor and Non-Guarantor Financial Information	12 Months Ended
	Dec. 31, 2013
Supplemental Guarantor and Non-Guarantor Financial Information [Abstract]	'
Supplemental Guarantor and Non-Guarantor Financial Information	'
	Supplemental Guarantor and Non-Guarantor Financial Information
	Gentiva’s guarantor subsidiaries are guarantors to the Company’s debt securities which are registered under the Securities Act of 1933, as amended. The condensed consolidating financial statements presented below are provided pursuant to Rule 3-10 of Regulation S-X. Separate financial statements of each subsidiary guaranteeing Gentiva’s debt securities are not presented because the guarantor subsidiaries are jointly and severally, fully and unconditionally liable under the guarantees, subject to certain customary release provisions and 100 percent owned by the Company. There are no restrictions on the ability to obtain funds from these subsidiaries by dividends or other means.
	The following condensed consolidating financial statements include the balance sheets as of December 31, 2013 and December 31, 2012, statements of comprehensive income for the years ended December 31, 2013, December 31, 2012 and December 31, 2011 and statements of cash flows for the years ended December 31, 2013, December 31, 2012 and December 31, 2011 of (i) Gentiva Health Services, Inc., (ii) its guarantor subsidiaries, and (iii) its non-guarantor subsidiaries, (in each case, reflecting investments in its consolidated subsidiaries under the equity method of accounting) along with eliminations necessary to arrive at the information for the Company on a consolidated basis. The condensed consolidating financial statements should be read in conjunction with the accompanying consolidated financial statements.
	In connection with the restatement of the Company's audited consolidated financial statements, the Company has restated its condensed consolidated balance sheet, condensed consolidated statement of comprehensive income and condensed consolidated statement of cash flows as of and for the year ended December 31, 2013, due to a correction in the Company's accounting for its licenses related to closed or consolidated locations and to correct certain assumptions used in its valuation models for testing of goodwill and indefinite-lived intangible assets. The Company has also revised the presentation of its condensed consolidated statement of comprehensive income and the condensed consolidated statement of cash flows for the year ended December 31, 2011, as well as its condensed consolidated balance sheet and condensed consolidated statement of changes in shareholders' equity for the year ended December 31, 2012, although the impact was determined to be immaterial to the condensed consolidated financial statements for 2011 and 2012. See Note 2 for additional information.
	The Company also restated its condensed consolidated balance sheet, condensed consolidated statement of comprehensive income and condensed consolidated statement of cash flows as of and for the year ended December 31, 2013 to appropriately recognize the change in status of one of its non-controlling interests from a non-guarantor subsidiary to a guarantor subsidiary, effective October 18, 2013.
	In addition, the Company made a previously disclosed revisions to the 2012 condensed consolidating balance sheet to conform to the current year presentation, which reflects the Company's debt issuance costs and the unamortized discount on the Company's term loans under Gentiva Health Services, Inc., with the accompanying debt, and not as assets and liabilities of the guarantor subsidiaries.
	The Company assessed the materiality of the revisions noted above and concluded that they were not material to any of the Company's previously issued financial statements.
	Condensed Consolidating Balance Sheet
	31-Dec-13
	(In thousands)
	As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	55,076			$	—		$	31,881		$	—		$	86,957
	Receivables, net	—				284,379			34,136			(28,610		)	289,905
	Deferred tax assets, net	—				25,845			2,308			—			28,153
	Prepaid expenses and other current assets	—				50,890			13,856			—			64,746
	Total current assets	55,076				361,114			82,181			(28,610		)	469,761
	Notes receivable from CareCentrix	—				28,471			—			—			28,471
	Fixed assets, net	—				48,824			551			—			49,375
	Intangible assets, net	—				253,682			2,600			—			256,282
	Goodwill	—				384,017			6,064			—			390,081
	Investment in subsidiaries	790,589				28,382			—			(818,971		)	—
	Other assets	28,266				40,370			11			—			68,647
	Total assets	$	873,931			$	1,144,860		$	91,407		$	(847,581	)	$	1,262,617
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	45,325			$	—		$	—		$	—		$	45,325
	Accounts payable	—				15,377			282			—			15,659
	Other current liabilities	—				283,228			59,868			(28,610		)	314,486
	Total current liabilities	45,325				298,605			60,150			(28,610		)	375,470
	Long-term debt	1,124,432				—			—			—			1,124,432
	Deferred tax liabilities, net	—				9,825			—			—			9,825
	Other liabilities	7,243				45,841			—			—			53,084
	Total Gentiva shareholders’ equity	(303,069		)		790,589			28,382			(818,971		)	(303,069		)
	Noncontrolling interests	—				—			2,875			—			2,875
	Total equity	(303,069		)		790,589			31,257			(818,971		)	(300,194		)
	Total liabilities and equity	$	873,931			$	1,144,860		$	91,407		$	(847,581	)	$	1,262,617
	Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Intangible assets, net	$	—			$	(2,555	)	$	—		$	—		$	(2,555	)
	Goodwill	—				(6,594		)	—			—			(6,594		)
	Investment in subsidiaries	(7,807		)		—			—			7,807			—
	Total assets	(7,807		)		(9,149		)	—			7,807			(9,149		)
	Deferred tax liabilities, net	—				(1,342		)	—			—			(1,342		)
	Total Gentiva shareholders’ equity	(7,807		)		(7,807		)	—			7,807			(7,807		)
	Total equity	(7,807		)		(7,807		)	—			7,807			(7,807		)
	Total liabilities and equity	(7,807		)		(9,149		)	—			7,807			(9,149		)
	Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Cash and cash equivalents	$	312			$	—		$	(312	)	$	—		$	—
	Receivables, net	—				258			(258		)	—			—
	Prepaid expenses and other current assets	—				2,081			(2,081		)	—			—
	Total current assets	312				2,339			(2,651		)	—			—
	Fixed assets, net	—				31			(31		)	—			—
	Goodwill	—				2,457			(2,457		)	—			—
	Investment in subsidiaries	(312		)		(4,889		)	—			5,201			—
	Other assets	—				5			(5		)	—			—
	Total assets	—				(57		)	(5,144		)	5,201			—
	Other current liabilities	—				255			(255		)	—			—
	Total current liabilities	—				255			(255		)	—			—
	Total Gentiva shareholders’ equity					(312		)	(4,889		)	5,201			—
Total equity	—				(312		)	(4,889		)	5,201			—
Total liabilities and equity	—				(57		)	(5,144		)	5,201			—
As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
ASSETS
Current assets:
Cash and cash equivalents	$	55,388			$	—		$	31,569		$	—		$	86,957
Receivables, net	—				284,637			33,878			(28,610		)	289,905
Deferred tax assets, net	—				25,845			2,308			—			28,153
Prepaid expenses and other current assets	—				52,971			11,775			—			64,746
Total current assets	55,388				363,453			79,530			(28,610		)	469,761
Notes receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				48,855			520			—			49,375
Intangible assets, net	—				251,127			2,600			—			253,727
Goodwill	—				379,880			3,607			—			383,487
Investment in subsidiaries	782,470				23,493			—			(805,963		)	—
Other assets	28,266				40,375			6			—			68,647
Total assets	866,124				1,135,654			86,263			(834,573		)	1,253,468
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,325			$	—		$	—		$	—		$	45,325
Accounts payable	—				15,377			282			—			15,659
Other current liabilities	—				283,483			59,613			(28,610		)	314,486
Total current liabilities	45,325				298,860			59,895			(28,610		)	375,470
Long-term debt	1,124,432				—			—			—			1,124,432
Deferred tax liabilities, net	—				8,483			—			—			8,483
Other liabilities	7,243				45,841			—			—			53,084
Total Gentiva shareholders’ equity	(310,876		)		782,470			23,493			(805,963		)	(310,876		)
Noncontrolling interests	—				—			2,875			—			2,875
Total equity	(310,876		)		782,470			26,368			(805,963		)	(308,001		)
Total liabilities and equity	$	866,124			$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
Condensed Consolidating Balance Sheet
31-Dec-12
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
ASSETS
Current assets:
Cash and cash equivalents	$	166,140			$	—		$	40,912		$	—		$	207,052
Receivables, net	—				245,191			19,744			(13,855		)	251,080
Deferred tax assets, net	—				10,280			1,983			—			12,263
Prepaid expenses and other current assets	—				36,899			8,733			—			45,632
Total current assets	166,140				292,370			71,372			(13,855		)	516,027
Note receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				41,066			348			—			41,414
Intangible assets, net	—				193,513			100			—			193,613
Goodwill	—				650,300			6,064			—			656,364
Investment in subsidiaries	1,002,204				27,210			—			(1,029,414		)	—
Other assets	44,219				30,820			6			—			75,045
Total assets	$	1,212,563			$	1,263,750		$	77,890		$	(1,043,269	)	$	1,510,934
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	25,000			$	—		$	—		$	—		$	25,000
Accounts payable	—				27,300			—			(13,855		)	13,445
Other current liabilities	—				202,321			49,133			—			251,454
Total current liabilities	25,000				229,621			49,133			(13,855		)	289,899
Long-term debt	910,182				—			—			—			910,182
Deferred tax liabilities, net	—				42,165			—			—			42,165
Other liabilities	—				33,979			9			—			33,988
Total Gentiva shareholders’ equity	277,381				957,985			27,210			(1,029,414		)	233,162
Noncontrolling interests	—				—			1,538			—			1,538
Total equity	277,381				957,985			28,748			(1,029,414		)	234,700
Total liabilities and equity	$	1,212,563			$	1,263,750		$	77,890		$	(1,043,269	)	$	1,510,934
Revision Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Intangible assets, net	$	—			$	(2,888	)	$	—		$	—		$	(2,888	)
Total assets	—				(2,888		)	—			—			(2,888		)
Deferred tax liabilities, net	—				(1,148		)	—			—			(1,148		)
Total Gentiva shareholders’ equity	—				(1,740		)	—			—			(1,740		)
Total equity	—				(1,740		)	—			—			(1,740		)
Total liabilities and equity	—				(2,888		)	—			—			(2,888		)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations (Revised)			Consolidated
	Services, Inc. (Revised				Subsidiaries (Revised)			Subsidiaries						Total (Revised)
ASSETS
Current assets:
Cash and cash equivalents	$	166,140			$	—		$	40,912		$	—		$	207,052
Receivables, net	—				245,191			19,744			(13,855		)	251,080
Deferred tax assets, net	—				10,280			1,983			—			12,263
Prepaid expenses and other current assets	—				36,899			8,733			—			45,632
Total current assets	166,140				292,370			71,372			(13,855		)	516,027
Note receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				41,066			348			—			41,414
Intangible assets, net	—				190,625			100			—			190,725
Goodwill	—				650,300			6,064			—			656,364
Investment in subsidiaries	1,002,204				27,210			—			(1,029,414		)	—
Other assets	44,219				30,820			6			—			75,045
Total assets	$	1,212,563			$	1,260,862		$	77,890		$	(1,043,269	)	$	1,508,046
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	25,000			$	—		$	—		$	—		$	25,000
Accounts payable	—				27,300			—			(13,855		)	13,445
Other current liabilities	—				202,321			49,133			—			251,454
Total current liabilities	25,000				229,621			49,133			(13,855		)	289,899
Long-term debt	910,182				—			—			—			910,182
Deferred tax liabilities, net	—				41,017			—			—			41,017
Other liabilities	—				33,979			9			—			33,988
Total Gentiva shareholders’ equity	277,381				956,245			27,210			(1,029,414		)	231,422
Noncontrolling interests	—				—			1,538			—			1,538
Total equity	277,381				956,245			28,748			(1,029,414		)	232,960
Total liabilities and equity	$	1,212,563			$	1,260,862		$	77,890		$	(1,043,269	)	$	1,508,046
Condensed Consolidating Statement of Comprehensive Income
For the Year Ended December 31, 2013
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,676,888		$	64,989		$	(15,233	)	$	1,726,644
Cost of services sold	—				905,261			52,152			(15,233		)	942,180
Gross profit	—				771,627			12,837			—			784,464
Selling, general and administrative expenses	—				(682,262		)	(19,454		)	—			(701,716		)
Goodwill, intangibles and other long-lived asset impairment	—				(610,436		)	—			—			(610,436		)
Interest (expense) and other, net	(110,477		)		—			93			—			(110,384		)
Equity in earnings of subsidiaries	(530,697		)		(4,561		)	—			535,258			—
(Loss) income before income taxes	(641,174		)		(525,632		)	(6,524		)	535,258			(638,072		)
Income tax benefit (expense)	42,180				(5,065		)	2,450			—			39,565
Net (loss) income	(598,994		)		(530,697		)	(4,074		)	535,258			(598,507		)
Noncontrolling interests	—				—			(487		)	—			(487		)
Net (loss) income attributable to Gentiva shareholders	(598,994		)		(530,697		)	(4,561		)	535,258			(598,994		)
Comprehensive (loss) income	(598,994		)		(530,697		)	(4,074		)	535,258			(598,507		)
Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Selling, general and administrative expenses	$	—			$	(4,511	)	$	—		$	—		$	(4,511	)
Goodwill, intangibles and other long-lived asset impairment	—				(1,944		)	—			—			(1,944		)
Equity in earnings of subsidiaries	(6,067		)		—			—			6,067			—
(Loss) income before income taxes	(6,067		)		(6,455		)	—			6,067			(6,455		)
Income tax benefit (expense)	—				388			—			—			388
Net (loss) income	(6,067		)		(6,067		)	—			6,067			(6,067		)
Net (loss) income attributable to Gentiva shareholders	(6,067		)		(6,067		)	—			6,067			(6,067		)
Comprehensive (loss) income	(6,067		)		(6,067		)	—			6,067			(6,067		)
Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,004		$	(1,004	)	$	—		$	—
Cost of services sold	—				538			(538		)	—			—
Gross profit	—				466			(466		)	—			—
Selling, general and administrative expenses	—				(224		)	224			—			—
(Loss) income before income taxes	—				242			(242		)	—			—
Income tax benefit (expense)	—				(93		)	93			—			—
Net (loss) income	—				149			(149		)	—			—
Net (loss) income attributable to Gentiva shareholders	—				149			(149		)	—			—
Comprehensive (loss) income	—				145			(145		)	—			—
As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,677,892		$	63,985		$	(15,233	)	$	1,726,644
Cost of services sold	—				905,799			51,614			(15,233		)	942,180
Gross profit	—				772,093			12,371			—			784,464
Selling, general and administrative expenses	—				(686,997		)	(19,230		)	—			(706,227		)
Goodwill, intangibles and other long-lived asset impairment	—				(612,380		)	—			—			(612,380		)
Interest (expense) and other, net	(110,477		)		—			93			—			(110,384		)
Equity in earnings of subsidiaries	(536,764		)		(4,710		)	—			541,474			—
(Loss) income before income taxes	(647,241		)		(531,994		)	(6,766		)	541,474			(644,527		)
Income tax benefit (expense)	42,180				(4,770		)	2,543			—			39,953
Net (loss) income	(605,061		)		(536,764		)	(4,223		)	541,474			(604,574		)
Noncontrolling interests	—				—			(487		)	—			(487		)
Net (loss) income attributable to Gentiva shareholders	(605,061		)		(536,764		)	(4,710		)	541,474			(605,061		)
Comprehensive (loss) income	(605,061		)		(536,764		)	(4,223		)	541,474			(604,574		)
Condensed Consolidating Statement of Comprehensive Income
For the Year Ended December 31, 2012
(In thousands)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,666,368		$	61,656		$	(15,220	)	$	1,712,804
Cost of services sold	—				884,903			39,058			(15,220		)	908,741
Gross profit	—				781,465			22,598			—			804,063
Selling, general and administrative expenses	—				(638,975		)	(16,791		)	—			(655,766		)
Goodwill, intangibles and other long-lived asset impairment	—				(19,132		)	—			—			(19,132		)
Gain on sale of assets and businesses, net	—				8,014			—			—			8,014
Interest (expense) and other, net	(90,054		)		—			107			—			(89,947		)
Equity in earnings of subsidiaries	79,622				3,038			—			(82,660		)	—
(Loss) income before income taxes and equity in net (loss) earnings of CareCentrix	(10,432		)		134,410			5,914			(82,660		)	47,232
Income tax benefit (expense)	37,228				(52,487		)	(1,992		)	—			(17,251		)
Equity in net (loss) earnings of CareCentrix	—				(2,301		)	—			—			(2,301		)
Net income	26,796				79,622			3,922			(82,660		)	27,680
Noncontrolling interests	—				—			(884		)	—			(884		)
Net income attributable to Gentiva shareholders	$	26,796			$	79,622		$	3,038		$	(82,660	)	$	26,796
Comprehensive income	$	26,796			$	79,622		$	3,922		$	(82,660	)	$	27,680
Condensed Consolidating Statement of Comprehensive Income
For the Year Ended December 31, 2011
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,757,459		$	52,404		$	(11,085	)	$	1,798,778
Cost of services sold	—				921,826			37,714			(11,085		)	948,455
Gross profit	—				835,633			14,690			—			850,323
Selling, general and administrative expenses	—				(715,343		)	(15,064		)	—			(730,407		)
Goodwill, intangibles and other long-lived asset impairment	—				(643,305		)	—			—			(643,305		)
Gain on sale of assets and businesses, net	—				1,061			—			—			1,061
Dividend income	—				8,590			—			—			8,590
Interest (expense) and other, net	(88,665		)		—			55			—			(88,610		)
Equity in earnings of subsidiaries	(380,176		)		221			—			379,955			—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(468,841		)		(513,143		)	(319		)	379,955			(602,348		)
Income tax benefit (expense)	18,316				56,637			815			—			75,768
Equity in net earnings of CareCentrix	—				68,381			—			—			68,381
(Loss) income from continuing operations	(450,525		)		(388,125		)	496			379,955			(458,199		)
Discontinued operations, net of tax	—				7,949			366			—			8,315
Net (loss) income	(450,525		)		(380,176		)	862			379,955			(449,884		)
Noncontrolling interests	—				—			(641		)	—			(641		)
Net (loss) income attributable to Gentiva shareholders	$	(450,525	)		$	(380,176	)	$	221		$	379,955		$	(450,525	)
Comprehensive (loss) income	$	(451,003	)		$	(380,176	)	$	862		$	379,955		$	(450,362	)
Other Restatement Adjustments	Gentiva Health			Guarantor			Non-Guarantor		Eliminations		Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries				Total
Selling, general and administrative expenses	—			(892	)		—		—		(892	)
Equity in earnings of subsidiaries	(537	)		—			—		537		—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(537	)		(892	)		—		537		(892	)
Income tax benefit (expense)	—			355			—		—		355
(Loss) income from continuing operations	(537	)		(537	)		—		537		(537	)
Net (loss) income	(537	)		(537	)		—		537		(537	)
Net (loss) income attributable to Gentiva shareholders	(537	)		(537	)		—		537		(537	)
Comprehensive (loss) income	(537	)		(537	)		—		537		(537	)
As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations (Revised)			Consolidated
	Services, Inc. (Revised)				Subsidiaries (Revised)			Subsidiaries						Total (Revised)
Net revenues	$	—			$	1,757,459		$	52,404		$	(11,085	)	$	1,798,778
Cost of services sold	—				921,826			37,714			(11,085		)	948,455
Gross profit	—				835,633			14,690			—			850,323
Selling, general and administrative expenses	—				(716,235		)	(15,064		)	—			(731,299		)
Goodwill, intangibles and other long-lived asset impairment	—				(643,305		)	—			—			(643,305		)
Gain on sale of assets and businesses, net	—				1,061			—			—			1,061
Dividend income	—				8,590			—			—			8,590
Interest (expense) and other, net	(88,665		)		—			55			—			(88,610		)
Equity in earnings of subsidiaries	(380,713		)		221			—			380,492			—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(469,378		)		(514,035		)	(319		)	380,492			(603,240		)
Income tax benefit (expense)	18,316				56,992			815			—			76,123
Equity in net earnings of CareCentrix	—				68,381			—			—			68,381
(Loss) income from continuing operations	(451,062		)		(388,662		)	496			380,492			(458,736		)
Discontinued operations, net of tax	—				7,949			366			—			8,315
Net (loss) income	(451,062		)		(380,713		)	862			380,492			(450,421		)
Noncontrolling interests	—				—			(641		)	—			(641		)
Net (loss) income attributable to Gentiva shareholders	$	(451,062	)		$	(380,713	)	$	221		$	380,492		$	(451,062	)
Comprehensive (loss) income	$	(451,540	)		$	(380,713	)	$	862		$	380,492		$	(450,899	)
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2013
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(29,406	)		$	80,742		$	(10,194	)	$	(4,037	)	$	37,105
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(18,690		)	(385		)	—			(19,075		)
Proceeds from sale of businesses	—				508			—			—			508
Proceeds from the sale of assets	—				203			—			—			203
(Payments to) proceeds from affiliates	—				(7,400		)	—			7,400			—
Acquisition of businesses	—				(356,935		)	(2,500		)	—			(359,435		)
Net cash (used in) provided by investing activities	—				(382,314		)	(2,885		)	7,400			(377,799		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,231				—			—			—			3,231
Windfall tax benefits associated with equity-based compensation	119				—			—			—			119
Payment of contingent consideration accrued at acquisition date	—				(1,675		)	—			—			(1,675		)
Proceeds from issuance of debt	817,525				—			—			—			817,525
Borrowings under revolving credit facility	27,000				—			—			—			27,000
Intercompany dividend	—				—			(2,300		)	2,300			—
Repayment of long-term debt	(610,182		)		—			—			—			(610,182		)
Debt issuance costs	(15,187		)		—			—			—			(15,187		)
Investment in affiliate	—				—			5,000			(5,000		)	—
Minority interest capital contribution	—				—			1,600			—			1,600
Majority interest capital contribution	—				—			2,400			(2,400		)	—
Distribution to minority interests	—				—			(750		)	—			(750		)
Distribution to majority interests	—				—			(1,737		)	1,737			—
Other	(889		)		(28		)	(165		)	—			(1,082		)
Net payments related to intercompany financing	(303,275		)		303,275			—			—			—
Net cash provided by (used in) financing activities	(81,658		)		301,572			4,048			(3,363		)	220,599
Net change in cash and cash equivalents	(111,064		)		—			(9,031		)	—			(120,095		)
Cash and cash equivalents at beginning of period	166,140				—			40,912			—			207,052
Cash and cash equivalents at end of period	$	55,076			$	—		$	31,881		$	—		$	86,957
Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net cash (used in) provided by operating activities	$	—			$	235		$	(235	)	$	—		$	—
Purchase of fixed assets	—				(16		)	16			—			—
Net cash (used in) provided by investing activities	—				(16		)	16			—			—
Net payments related to intercompany financing	312				(219		)	(93		)	—			—
Net cash provided by (used in) financing activities	312				(219		)	(93		)	—			—
Net change in cash and cash equivalents	312				—			(312		)	—			—
Cash and cash equivalents at end of period	312				—			(312		)	—			—
As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(29,406	)		$	80,977		$	(10,429	)	$	(4,037	)	$	37,105
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(18,706		)	(369		)	—			(19,075		)
Proceeds from sale of businesses	—				508			—			—			508
Proceeds from the sale of assets	—				203			—			—			203
(Payments to) proceeds from affiliates	—				(7,400		)	—			7,400			—
Acquisition of businesses	—				(356,935		)	(2,500		)	—			(359,435		)
Net cash (used in) provided by investing activities	—				(382,330		)	(2,869		)	7,400			(377,799		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,231				—			—			—			3,231
Windfall tax benefits associated with equity-based compensation	119				—			—			—			119
Payment of contingent consideration accrued at acquisition date	—				(1,675		)	—			—			(1,675		)
Proceeds from issuance of debt	817,525				—			—			—			817,525
Borrowings under revolving credit facility	27,000				—			—			—			27,000
Intercompany dividend	—				—			(2,300		)	2,300			—
Repayment of long-term debt	(610,182		)		—			—			—			(610,182		)
Debt issuance costs	(15,187		)		—			—			—			(15,187		)
Investment in affiliate	—				—			5,000			(5,000		)	—
Minority interest capital contribution	—				—			1,600			—			1,600
Majority interest capital contribution	—				—			2,400			(2,400		)	—
Distribution to minority interests	—				—			(750		)	—			(750		)
Distribution to majority interests	—				—			(1,737		)	1,737			—
Other	(889		)		(28		)	(165		)	—			(1,082		)
Net payments related to intercompany financing	(302,963		)		303,056			(93		)	—			—
Net cash provided by (used in) financing activities	(81,346		)		301,353			3,955			(3,363		)	220,599
Net change in cash and cash equivalents	(110,752		)		—			(9,343		)	—			(120,095		)
Cash and cash equivalents at beginning of period	166,140				—			40,912			—			207,052
Cash and cash equivalents at end of period	$	55,388			$	—		$	31,569		$	—		$	86,957
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2012
(In thousands)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(18,089	)		$	138,316		$	5,741		$	—		$	125,968
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(11,609		)	(170		)	—			(11,779		)
Proceeds from sale of businesses	—				9,220			—			—			9,220
Acquisition of businesses	—				(22,335		)	—			—			(22,335		)
Net cash used in investing activities	—				(24,724		)	(170		)	—			(24,894		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,980				—			—			—			3,980
Windfall tax benefits associated with equity-based compensation	88				—			—			—			88
Repayment of long-term debt	(52,943		)		—			—			—			(52,943		)
Debt issuance costs	(4,125		)		—			—			—			(4,125		)
Repurchase of common stock	(4,974		)		—			—			—			(4,974		)
Repayment of capital lease obligations	(135		)		—			—			—			(135		)
Other	4,673				(28		)	(5,470		)	—			(825		)
Net payments related to intercompany financing	113,564				(113,564		)	—			—			—
Net cash provided by (used in) financing activities	60,128				(113,592		)	(5,470		)	—			(58,934		)
Net change in cash and cash equivalents	42,039				—			101			—			42,140
Cash and cash equivalents at beginning of period	124,101				—			40,811			—			164,912
Cash and cash equivalents at end of period	$	166,140			$	—		$	40,912		$	—		$	207,052
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2011
(In thousands)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(46,730	)		$	51,221		$	650		$	—		$	5,141
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(19,053		)	(178		)	—			(19,231		)
Proceeds from sale of businesses	—				146,261			54			—			146,315
Acquisition of businesses	—				(320		)	—			—			(320		)
Net cash provided by (used in) investing activities	—				126,888			(124		)	—			126,764
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	7,901				—			—			—			7,901
Windfall tax benefits associated with equity-based compensation	192				—			—			—			192
Repayment of long-term debt	(63,438		)		—			—			—			(63,438		)
Debt issuance costs	(15,460		)		—			—			—			(15,460		)
Repayment of capital lease obligations	(267		)		—			—			—			(267		)
Other	—				(22		)	(651		)	—			(673		)
Net payments related to intercompany financing	178,087				(178,087		)	—			—			—
Net cash provided by (used in) financing activities	107,015				(178,109		)	(651		)	—			(71,745		)
Net change in cash and cash equivalents	60,285				—			(125		)	—			60,160
Cash and cash equivalents at beginning of period	63,816				—			40,936			—			104,752
Cash and cash equivalents at end of period	$	124,101			$	—		$	40,811		$	—		$	164,912

Quarterly_Financial_Informatio

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information (Unaudited)	'
	Quarterly Financial Information (Unaudited)
	The unaudited quarterly financial data presented below have been revised and restated for each quarter for the year ended December 31, 2013, due to a correction in the Company's accounting for its licenses related to closed or consolidated locations and to correct certain assumptions used in its valuation models for testing of goodwill and indefinite-lived intangible assets. See Note 2 for further information.
	(in thousands, except per share amounts)
	Year ended December 31, 2013 (As Reported)	First					Second				Third					Fourth
		Quarter					Quarter				Quarter					Quarter
	Net revenues	$	415,591				$	414,424			$	410,492				$	486,137
	Gross profit	194,018					195,477				190,014					204,955
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	(212,472		)	(2	)	11,392				6,852					(443,844		)	-2
	(Loss) net income attributable to Gentiva shareholders (1)	(207,177		)	(2	)	6,347				3,720					(401,884		)	-2
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	(6.73	)			$	0.21			$	0.12				$	(11.46	)
	Diluted	$	(6.73	)			$	0.2			$	0.12				$	(11.46	)
	Weighted average shares outstanding:
	Basic	30,785					30,941				31,037					35,054
	Diluted	30,785					31,239				31,532					35,054
	Year ended December 31, 2013 (Restatement and Revision Adjustments)	First					Second				Third					Fourth
		Quarter (Revised)					Quarter (Revised)				Quarter (Revised)					Quarter (Restated)
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	13,648					(351		)		(258		)			(19,494		)
	(Loss) net income attributable to Gentiva shareholders (1)	13,039					(213		)		(157		)			(18,736		)
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	0.42				$	(0.01	)		$	—				$	(0.54	)
	Diluted	$	0.42				$	—			$	(0.01	)			$	(0.54	)
	Year ended December 31, 2013 (As Restated and Revised)	First					Second				Third					Fourth
		Quarter (Revised)					Quarter (Revised)				Quarter (Revised)					Quarter (Restated)
	Net revenues	$	415,591				$	414,424			$	410,492				$	486,137
	Gross profit	194,018					195,477				190,014					204,955
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	(198,824		)	(2	)	11,041				6,594					(463,338		)	-2
	(Loss) net income attributable to Gentiva shareholders (1)	(194,138		)	(2	)	6,134				3,563					(420,620		)	-2
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	(6.31	)			$	0.2			$	0.12				$	(12.00	)
	Diluted	$	(6.31	)			$	0.2			$	0.11				$	(12.00	)
	Weighted average shares outstanding:
	Basic	30,785					30,941				31,037					35,054
	Diluted	30,785					31,239				31,532					35,054
	Year ended December 31, 2012	First					Second				Third					Fourth
		Quarter					Quarter				Quarter					Quarter
	Net revenues	$	435,652				$	427,691			$	424,444				$	425,017
	Gross profit	202,791					204,954				200,555					195,763
	Income (loss) before income taxes and equity in net earnings (loss) of CareCentrix	7,582					23,818			-3	(2,678		)	(2	)	18,510			-3
	Net income (loss) attributable to Gentiva shareholders (1)	4,840					13,909			-3	(523		)	(2	)	8,570			(3),(4)
	Earnings Per Share:
	Net income (loss) attributable to Gentiva shareholders:
	Basic	$	0.16				$	0.46			$	(0.02	)			$	0.28
	Diluted	$	0.16				$	0.46			$	(0.02	)			$	0.28
	Weighted average shares outstanding:
	Basic	30,724					30,338				30,423					30,548
	Diluted	30,959					30,446				30,423					30,891
	-1	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):
		First				Second				Third				Fourth
		Quarter				Quarter				Quarter				Quarter
	Year ended December 31, 2013	$	141			$	744			$	1,699			$	24,955
	Year ended December 31, 2012	$	5,391			$	25			$	53			$	201
	-2	For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.
	For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.
	For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.
	-3	For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations.
	For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.
	-4	In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

SCHEDULE_IIVALUATION_AND_QUALI

SCHEDULE IIbVALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
SCHEDULE IIbVALUATION AND QUALIFYING ACCOUNTS	'
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
	(in thousands)
		Balance at		Additions		Deductions			Balance at
		beginning of		charged to					end of
		period		costs and					period
				expenses
	Allowance for Doubtful Accounts:
	For the year ended December 31, 2013	$	8,777	$	6,730	$	(4,827	)	$	10,680
	For the year ended December 31, 2012	11,562		4,066		(6,851		)	8,777
	For the year ended December 31, 2011	7,654		8,541		(4,633		)	11,562
	Valuation allowance on deferred tax assets:
	For the year ended December 31, 2013	$	2,878	$	763	$	—		$	3,641
	For the year ended December 31, 2012	4,667		—		(1,789		)	2,878
	For the year ended December 31, 2011	13,376		258		(8,967		)	4,667

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation	'
	Consolidation
	The Company's consolidated financial statements include the accounts and operations of the Company and its subsidiaries in which the Company owns more than a 50 percent interest. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of the Company's hospice programs, are reported below net income under the heading “Net income attributable to noncontrolling interests” in the Company's consolidated statements of comprehensive income for the years ended December 31, 2013, 2012 and 2011 and presented as a component of equity in the Company's consolidated balance sheets at December 31, 2013 and 2012. All material balances and transactions between the consolidated entities have been eliminated.
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The most critical estimates relate to revenue recognition, which incorporates the impact of various revenue adjustments including payment caps under the Medicare program for hospice, the collectibility of accounts receivable and related reserves, impairment tests for goodwill and other indefinite-lived intangible assets, obligations under insurance programs, including workers’ compensation, professional liability, property and general liability and employee health and welfare insurance programs.
	A description of the critical accounting policies and a discussion of the significant estimates and judgments associated with such policies are described below.
Revenue Recognition	'
	Revenue Recognition
	Revenues recognized by the Company are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. In each category described below, the impact of the estimate, if applicable, undertaken by the Company with respect to these elements is reflected in net revenues in the consolidated statements of comprehensive income. See further discussion of the elements below under the heading “Causes and Impact of Change on Revenue.”
	Home Health Episodic Net Revenues
	Under the home health Prospective Payment System (“PPS”) of reimbursement, for Medicare and Medicare Advantage programs paid at episodic rates, the Company estimates net revenues to be recorded based on a reimbursement rate which is determined using relevant data, relating to each patient’s health status including clinical condition, functional abilities and service needs, as well as applicable wage indices to give effect to geographic differences in wage levels of employees providing services to the patient. Billings under PPS are initially recognized as deferred revenue and are subsequently amortized into revenue over an average patient treatment period. The process for recognizing revenue to be recorded is based on certain assumptions and judgments, including (i) the average length of time of each treatment as compared to a standard 60 day episode (ii) any differences between the clinical assessment of and the therapy service needs for each patient at the time of certification as compared to actual experience, as well as (iii) the level of adjustments to the fixed reimbursement rate relating to patients who receive a limited number of visits, are discharged but readmitted to another agency within the same 60 day episodic period or are subject to certain other factors during the episode. Deferred revenue of approximately $43.9 million and $37.4 million, primarily relating to the PPS program, is included under current liabilities in the consolidated balance sheets as of December 31, 2013 and 2012, respectively.
	Hospice Medicare Net Revenues
	Medicare revenues for Hospice are recorded on an accrual basis based on the number of days a patient has been on service at amounts equal to an estimated payment rate. The payment rate is dependent on whether a patient is receiving routine home care, general inpatient care, continuous home care or respite care. Adjustments to Medicare revenues are recorded based on an inability to obtain appropriate billing documentation or authorizations acceptable to the payer or other reasons unrelated to credit risk.
	In addition, each hospice provider is subject to certain Medicare payment limitations, including an overall payment cap. The Medicare payment cap, which is calculated for each provider by the Medicare fiscal intermediary at the end of the hospice cap period, is determined under the proportional method. The proportional method allocates each beneficiary's Medicare payment cap based on the ratio of the number of days the beneficiary received hospice services from the Company over the total number of days the beneficiary received hospice services from all providers. The Medicare payment cap amount is then further allocated between the hospice cap periods based on the ratio of the number of days the Company provided hospices services during each cap period. The sum of each beneficiary's Medicare cap payment, as determined above, represents the aggregate Medicare payment cap. Medicare revenue paid to a provider during the hospice cap period cannot exceed the aggregate Medicare payment cap. As of December 31, 2013, the Company currently has 2 programs estimated to exceed the Medicare cap limits for the 2014 cap year. The Company has recorded a net hospice Medicare cap credit of approximately $4.6 million in the Company’s consolidated statements of comprehensive income for 2013 and $4.4 million and $4.3 million for estimated cap exposure as a reduction in Medicare revenues in the Company’s consolidated statements of comprehensive income for 2012 and 2011, respectively. As of December 31, 2013 and 2012, approximately $6.5 million and $15.9 million, respectively, is reflected as Medicare liabilities in the Company’s consolidated balance sheets associated with Medicare cap exposures.
	Fee-for-Service Agreements
	Under fee-for-service agreements with commercial payers, certain state and local government payers and patients, net revenues are recorded based on net realizable amounts to be received in the period in which the services are provided. Fee-for-service contracts with commercial payers are traditionally one year in term and renew automatically on an annual basis, unless terminated by either party.
	Medicare Settlement Issues under Interim Payment System
	Prior to October 1, 2000, reimbursement of Medicare home healthcare services was based on reasonable allowable costs incurred in providing services to eligible beneficiaries subject to both per visit and per beneficiary limits in accordance with the Interim Payment System established through the Balanced Budget Act of 1997. These costs were reported in annual cost reports which were filed with CMS and were subject to audit by the fiscal intermediary engaged by CMS. During the third quarter of 2013, the fiscal intermediary finalized its audit of the fiscal 2000 cost reports, which are now being settled by CMS. In connection with the finalized audit and expected settlements, the Company recorded approximately $4.0 million as a positive adjustment to net revenues in the Company's consolidated statement of comprehensive income for the year ended December 31, 2013.
	Settlement liabilities are recorded at the time of any probable and reasonably estimable event and any positive settlements are recorded as revenue in the Company’s consolidated statements of comprehensive income in the period in which such gain contingencies are realized.
	Causes and Impact of Change on Revenue
	For each of the sources of revenue, the principal elements in addition to those described above, which can cause change in the amount of revenue to be realized, are (i) an inability to obtain appropriate billing documentation, (ii) an inability to obtain authorizations acceptable to the payer, (iii) utilization of services at levels other than authorized and (iv) other reasons unrelated to credit risk.
	Revenue adjustments resulting from differences between estimated and actual reimbursement amounts are recorded as adjustments to net revenues or recorded against allowance for doubtful accounts, depending on the nature of the adjustment. These are determined by Company management and reviewed from time to time, but no less often than quarterly. Each of the elements described here and under each of the various sources of revenue can effect change in the estimates. Although it is not possible to predict the degree of change that might be effected by a variation in one or more of the elements described, the Company believes that changes in these elements could cause a change in estimate which could have a material impact on the consolidated financial statements. There have not been any material revisions in these estimates for the periods presented in this report.
	Billing and Receivables Processing
	The Company’s billing systems record revenues at net expected reimbursement based on established or contracted fee schedules. The systems provide for an initial contractual allowance adjustment from “usual and customary” charges, which is typical for the payers in the healthcare field. The Company records an initial contractual allowance at the time of billing and reduces the Company’s revenue to expected reimbursement levels. Changes in contractual allowances, if any, are recorded each month. Changes in the nature of contractual allowances have not been material for the periods presented in this filing.
	“Accounts Receivable” section below further outlines matters considered with respect to estimating the allowance for doubtful accounts.
Accounts Receivable	'
	Accounts Receivable
	Collection Policy
	The process for estimating the ultimate collection of receivables involves significant assumptions and judgments. The Company believes that its collection and reserve processes, along with the monitoring of its billing processes, help to reduce the risk associated with material revisions to reserve estimates resulting from adverse changes in reimbursement experience, revenue adjustments and billing functions. Collection processes are performed in accordance with the Fair Debt Collections Practices Act and include reviewing aging and cash posting reports, contacting payers to determine why payment has not been made, resubmission of claims when appropriate and filing appeals with payers for claims that have been denied. Collection procedures generally include follow up contact with the payer at least every 30 days from invoice date, and a review of collection activity at 90 days to determine continuation of internal collection activities or potential referral to collection agencies. The Company’s bad debt policy includes escalation procedures and guidelines for write-off of an account, as well as the authorization required, once it is determined that the open account has been worked by the Company’s internal collectors and/or collection agencies in accordance with the Company’s standard procedures and resolution of the open account through receipt of payment is determined to be remote. The Company reviews each account individually and does not have either a threshold dollar amount or aging period that it uses to trigger a balance write-off, although the Company does have a small balance write-off policy for non-governmental accounts with debit balances under $10.
	The Company’s policy is to bill for patient co-payments and make good faith efforts to collect such amounts. At the end of each reporting period, the Company estimates the amount of outstanding patient co-payments that will not be collected and the amount of outstanding co-payments that may be waived due to financial hardship based on a review of historical trends. This estimate is made as part of the Company’s evaluation of the adequacy of its allowance for doubtful accounts. There have not been any material revisions in this estimate for the periods presented in this report.
	Accounts Receivable Reserve Methodology
	The Company has implemented a standardized approach to estimate and review the collectibility of its receivables based on accounts receivable aging trends. The Company analyzes historical collection trends, reimbursement experience and revenue adjustment trends by major payers, including Medicare and other payers, as well as by business lines as an integral part of the estimation process related to determining the valuation allowance for accounts receivable. In addition, the Company assesses the current state of its billing functions on a quarterly basis in order to identify any known collection or reimbursement issues to determine the impact, if any, on its reserve estimates, which involve judgment. Revisions in reserve estimates are recorded as an adjustment to the provision for doubtful accounts, which is reflected in selling, general and administrative expenses for continuing operations and in discontinued operations, net of tax in the consolidated statements of comprehensive income. The provision for doubtful accounts relating to continuing operations amounted to $6.7 million and $4.1 million in 2013 and 2012, respectively. The provision for doubtful accounts relating to continuing operations and discontinued operations amounted to $8.4 million and $0.1 million, respectively, in 2011. The allowance for doubtful accounts at December 31, 2013 and 2012 was $10.7 million and $8.8 million, respectively. Additional information regarding the allowance for doubtful accounts can be found in Schedule II—Valuation and Qualifying Accounts in Item 8. Financial Statements and Supplementary Data of this report.
Goodwill and Other Indefinite-Lived Intangible Assets	'
	Goodwill and Other Indefinite-Lived Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various operating units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to its carrying amount to determine if there is potential impairment of goodwill and other indefinite-lived intangible assets. If the fair value of an reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than the carrying value of its goodwill. To determine the fair value of the Company’s reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies and reasonableness tests, as appropriate.
	The Company is required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. The future occurrence of a potential indicator of impairment, such as, but not limited to, a significant adverse change in legal factors or business climate, reductions of projected patient census, an adverse action or assessment by a regulator, as well as other unforeseen factors, would require an interim assessment for some or all of the Company's reporting units and could have a material impact of the Company's consolidated financial statements. See Note 10 for information on the Company's impairment testing.
Obligations Under Self Insurance Programs	'
	Obligations Under Insurance Programs
	The Company is obligated for certain costs under various insurance programs, including workers’ compensation, professional liability, property and general liability, and employee health and welfare.
	The Company may be subject to workers’ compensation claims and lawsuits alleging negligence or other similar legal claims. The Company maintains various insurance programs to cover this risk with insurance policies subject to substantial deductibles and retention amounts. The Company recognizes its obligations associated with these programs in the period the claim is incurred. The cost of both reported claims and claims incurred but not reported, up to specified deductible limits, have generally been estimated based on historical data, industry statistics, the Company’s specific historical claims experience, current enrollment statistics and other information. The Company’s estimates of its obligations and the resulting reserves are reviewed and updated from time to time, but at least quarterly. The elements which impact this critical estimate include the number, type and severity of claims and the policy deductible limits; therefore, the estimate is sensitive and changes in the estimate could have a material impact on the Company’s consolidated financial statements.
	Workers’ compensation and professional and general liability costs associated with continuing operations were $33.9 million, $21.0 million and $15.1 million for the years ended December 31, 2013, 2012 and 2011, respectively. The Company’s workers’ compensation and professional and general liability costs relating to discontinued operations were approximately $0.5 million for the year ended December 31, 2011. The increase in expense for 2013 relates to overall recent trends of rising healthcare costs and the results from a review, conducted by the Company's third-party claims administrators, of established case loss reserves on all open claims in excess of $10,000 and settlements in excess of established reserves. Other drivers of differences in costs between years relate primarily to the number and severity of claims incurred in each reported period as well as changes in the cost of insurance coverage. Workers’ compensation and professional liability claims, including any changes in estimate relating thereto, are recorded primarily in cost of services sold in the Company’s consolidated statements of comprehensive income. There have not been any material revisions in estimates of prior year costs for the periods presented in this report.
	The Company maintains insurance coverage on individual claims. The Company is responsible for the cost of individual workers’ compensation claims and individual professional liability claims up to $500 thousand per incident that occurred prior to March 15, 2002, and $1 million per incident thereafter. The Company also maintains excess liability coverage relating to professional liability and casualty claims which provides insurance coverage for individual claims of up to $25 million in excess of the underlying coverage limits. Payments under the Company’s workers’ compensation program are guaranteed by letters of credit. The Company believes that its present insurance coverage and reserves are sufficient to cover currently estimated exposures, but there can be no assurance that the Company will not incur liabilities in excess of recorded reserves or in excess of its insurance limits.
	The Company provides employee health and welfare benefits under a self insured program and maintains stop loss coverage for individual claims in excess of $400 thousand for 2013. For the years ended December 31, 2013, 2012 and 2011, employee health and welfare benefit costs associated with continuing operations were $86.6 million, $87.5 million and $93.0 million, respectively. Employee health and welfare benefit costs associated with discontinued operations were $0.7 million for December 31, 2011. Differences in costs between years relate primarily to increased enrollment and the number and severity of individual claims incurred in each reported period. Changes in estimates of the Company’s employee health and welfare claims are recorded in cost of services sold for clinical associates and in selling, general and administrative costs for administrative associates in the Company’s consolidated statements of comprehensive income. There have not been any material revisions in estimates of prior year costs for the periods presented in this report.
	The Company also maintains Directors and Officers liability insurance coverage with an aggregate limit of $60 million.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date three months or less from their date of acquisition to be cash equivalents, including money market funds invested in U.S. Treasury securities, short-term treasury bills and commercial paper. Cash and cash equivalents also included amounts on deposit with several major financial institutions in excess of the maximum amount insured by the Federal Deposit Insurance Corporation. Management believes that these major financial institutions are viable entities.
	The Company had operating funds of approximately $5.5 million and $5.4 million at December 31, 2013 and 2012, respectively, which relate exclusively to a non-profit hospice operation managed in Florida.
Investments	'
	Investments
	During 2011, the Company sold its investment in CareCentrix Holdings Inc. The Company recorded accumulated and unpaid dividends on the preferred shares it held of approximately $8.6 million in 2011, which is reflected in dividend income in the Company's consolidated statements of comprehensive income. The Company also recorded a net gain of approximately $67.1 million, which is reflected in equity in net earnings of CareCentrix, including gain on sale in the Company's consolidated statements of comprehensive income.
	As of December 31, 2013 and 2012, the Company held an investment, at cost, in CareCentrix Holdings Inc. of $0.9 million for shares that it expects to receive in settlement of certain tax amounts owed to the Company as set forth in the stock purchase agreement.
	At December 31, 2013 and December 31, 2012, the Company had assets of $34.7 million and $27.7 million, respectively, held in a Rabbi Trust for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The corresponding amounts payable to the plan participants are equivalent to the underlying value of the assets held in the Rabbi Trust. Assets held in a Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets.
Debt Issuance Costs	'
	Debt Issuance Costs
	The Company amortizes deferred debt issuance costs over the term of its credit agreement and senior notes. As of December 31, 2013 and 2012, the Company had unamortized debt issuance costs of $28.3 million and $44.2 million, respectively, recorded in other assets in the Company’s consolidated balance sheets.
	On October 18, 2013, the Company entered into a new senior secured credit agreement and terminated the Company's existing credit agreement. In accordance with applicable guidance, due to changes in certain of the Company's participating lenders under the new credit agreement, the Company performed a debt modification analysis. That analysis resulted in the Company recording a write-off of a portion of its prepaid debt issuance costs of approximately $16.1 million, for the year ended December 31, 2013, which is reflected in interest expense in the Company's consolidated statement of income and capitalized debt issuance costs of approximately $24.2 million, which are being amortized over the life of the New Credit Agreement utilizing an effective interest rate methodology. See Note 11.
	During 2012 and 2011, the Company recorded additional write-offs of prepaid debt issuance costs of approximately $0.5 million and $3.5 million, respectively, in conjunction with various amendments of its former credit facility which are reflected in interest expense in the Company’s consolidated statements of comprehensive income.
Fixed Assets	'
	Fixed Assets
	Fixed assets, including costs of Company developed software, are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Leasehold improvements are amortized over the shorter of the life of the lease or the life of the improvement. Repairs and maintenance costs are expensed as incurred. See Note 9 for additional information.
Accounting for Impairment and Disposal of Long-Lived Assets	'
	Accounting for Impairment and Disposal of Long-Lived Assets
	The Company evaluates the possible impairment of its long-lived assets, including intangible assets, which are amortized pursuant to authoritative guidance. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. Evaluation of possible impairment is based on the Company's ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset. See Note 9 and Note 10 for additional information.
Nursing Home Costs	'
	Nursing Home Costs
	For patients receiving nursing home care under a state Medicaid program who elect hospice care under Medicare or Medicaid, the Company contracts with nursing homes for the nursing homes to provide patients’ room and board services. The state must pay the Company, in addition to the applicable Medicare or Medicaid hospice daily or hourly rate, an amount equal to at least 95 percent of the Medicaid daily nursing home rate for room and board furnished to the patient by the nursing home. Under the Company’s standard nursing home contracts, the Company pays the nursing home for these room and board services at the Medicaid daily nursing home rate. Nursing home costs are partially offset by nursing home net revenue, and the net amount is included in cost of services sold in the Company’s consolidated statements of comprehensive income.
Equity-Based Compensation Plans	'
	Equity-Based Compensation Plans
	The Company has several stock ownership and compensation plans, which are described more fully in Note 15. The Company accounts for its equity-based compensation plans in accordance with authoritative guidance under which the estimated fair value of share-based awards granted under the Company's equity-based compensation plans is recognized as compensation expense over the vesting period of the award.
Income Taxes	'
	Income Taxes
	The Company uses the liability method to account for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the carrying amounts of assets and liabilities and their respective tax bases using tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted. Deferred income tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Uncertain tax positions must be more likely than not before a tax benefit is recognized in the financial statements. The benefit to be recorded is the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. See Note 19 for additional information.

Background_and_Basis_of_Presen1

Background and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2013
Significant Acquisitions and Disposals [Line Items]	'
Schedule of business acquisitions	'
	A summary of the transactions for 2013, 2012 and 2011 and the consideration paid are as follows (in millions):
	Acquisitions:	Geographic Service Area		Date		Consideration
	Harden Healthcare Holdings, Inc	Nationwide		October 18, 2013		$	426.8
	Appalachian Regional Health Systems	North Carolina		September 30, 2013		2.7
	Wake Forest Baptist Health Care at Home, LLC	North Carolina		August 23, 2013		2.4
	Hope Hospice, Inc.	Indiana		April 30, 2013		1
	Family Home Care Corporation	Washington and Idaho		August 31, 2012		12.3
	North Mississippi Hospice	Mississippi		August 31, 2012		4.7
	Advocate Hospice	Indiana		July 22, 2012		5.5
	Odyssey HealthCare of Augusta, LLC	Georgia		April 29, 2011		0.3
Home Health and Hospice [Member]	'
Significant Acquisitions and Disposals [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	A summary of the Company's operations which were sold during 2012 and 2011 are as follows (in millions):
	Dispositions:	Date		Consideration
	Phoenix area hospice operations	November 30, 2012		$	3.5
	Gentiva Consulting	May 31, 2012		0.3
	Louisiana home health and hospice operations	Second Quarter 2012		6.4
	Certain home health branches-Utah, Michigan, Nevada and Brooklyn, New York	Fourth Quarter 2011		1.6
	The major classes of assets sold and liabilities assumed of the Home Health and Hospice branch operations that were sold were as follows (in thousands):
		2012
		As of Date of Sale				31-Dec-11
	Assets:
	Accounts receivable, net	$	561			$	526
	Fixed assets, net	271				338
	Intangible assets	1,356				1,356
	Other assets	485				640
	Total assets	2,673				2,860
	Liabilities:
	Medicare liabilities	(86		)		(18		)
	Other accrued Expenses	(405		)		(41		)
	Total liabilities	(491		)		(59		)
	Total	$	2,182			$	2,801
Home Maker Services Agency Rehab Without Wallsand HME and IV [Member]	'
Significant Acquisitions and Disposals [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	Furthermore, during 2011 the Company sold its IDOA business based in Illinois and its Rehab Without Walls® business. A summary of these transactions follows (in millions):
	Discontinued operations:	Date		Consideration
	IDOA	October 14, 2011		$	2.4
	Rehab Without Walls®	September 10, 2011		9.8

Restatement_and_Revision_of_Pr1

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments	'
	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding restated or revised amounts:
		As of December 31, 2013
	Restated Consolidated Balance Sheet (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Intangible assets, net	$	256,282		$	(2,555	)	$	253,727
	Goodwill	390,081			(6,594		)	383,487
	Total Assets	1,262,617			(9,149		)	1,253,468
	Deferred tax liabilities, net	9,825			(1,342		)	8,483
	Accumulated deficit	(750,329		)	(7,807		)	(758,136		)
	Total Gentiva shareholders’ equity	(303,069		)	(7,807		)	(310,876		)
	Total equity	(300,194		)	(7,807		)	(308,001		)
	Total liabilities and equity	1,262,617			(9,149		)	1,253,468
		As of December 31, 2012
	Revised Consolidated Balance Sheet (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Intangible assets, net	$	193,613		$	(2,888	)	$	190,725
	Total Assets	1,510,934			(2,888		)	1,508,046
	Deferred tax liabilities, net	42,165			(1,148		)	41,017
	Accumulated deficit	(151,335		)	(1,740		)	(153,075		)
	Total Gentiva shareholders’ equity	233,162			(1,740		)	231,422
	Total equity	234,700			(1,740		)	232,960
	Total liabilities and equity	1,510,934			(2,888		)	1,508,046
		For the Year Ended December 31, 2013
	Restated Consolidated Statement of Comprehensive Loss (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Selling, general and administrative expenses	$	(701,716	)	$	(4,511	)	$	(706,227	)
	Goodwill, intangibles and other long-lived asset impairment	(610,436		)	(1,944		)	(612,380		)
	Loss from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	(638,072		)	(6,455		)	(644,527		)
	Income tax benefit	39,565			388			39,953
	Loss from continuing operations	(598,507		)	(6,067		)	(604,574		)
	Net loss	(598,507		)	(6,067		)	(604,574		)
	Net loss attributable to Gentiva shareholders	(598,994		)	(6,067		)	(605,061		)
	Total comprehensive loss	(598,507		)	(6,067		)	(604,574		)
	Basic Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Diluted Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(18.75	)	$	(0.19	)	$	(18.94	)
		For the Year Ended December 31, 2011
	Revised Consolidated Statement of Comprehensive Loss (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Selling, general and administrative expenses	$	(730,407	)	$	(892	)	$	(731,299	)
	Loss from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	(602,348		)	(892		)	(603,240		)
	Income tax benefit	75,768			355			76,123
	Loss from continuing operations	(458,199		)	(537		)	(458,736		)
	Net loss	(449,884		)	(537		)	(450,421		)
	Net loss attributable to Gentiva shareholders	(450,525		)	(537		)	(451,062		)
	Total comprehensive loss	(450,362		)	(537		)	(450,899		)
	Basic Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(15.13	)	$	(0.01	)	$	(15.14	)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(14.85	)	$	(0.01	)	$	(14.86	)
	Diluted Earnings Per Share: Loss from continuing operations attributable to Gentiva shareholders	$	(15.13	)	$	(0.01	)	$	(15.14	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(14.85	)	$	(0.01	)	$	(14.86	)
	Revised Consolidated Statement of Changes in Shareholders' Equity (In thousands)	As Previously Reported			Revision Adjustments			As Revised
	Retained Earnings (Deficit), Balance at December 31, 2010	$	272,394		$	(1,203	)	$	271,191
	Net loss	(450,525		)	(537		)	(451,062		)
	Total comprehensive loss	(450,525		)	(537		)	(451,062		)
	Retained Earnings (Deficit), Balance at December 31, 2011	(178,131		)	(1,740		)	(179,871		)
	Total Shareholders' Equity, Balance at December 31, 2010	$	638,232		$	(1,203	)	$	637,029
	Net loss	(449,884		)	(537		)	(450,421		)
	Total comprehensive loss	(450,362		)	(537		)	(450,899		)
	Total Shareholders' Equity, Balance at December 31, 2011	202,531			(1,740		)	200,791
	Restated Consolidated Statement of Changes in Shareholders' Equity (In thousands)	As Previously Reported			Restatement Adjustments			As Restated
	Retained Earnings (Deficit), Balance at December 31, 2012	$	(151,335	)	$	(1,740	)	$	(153,075	)
	Net loss	(598,994		)	(6,067		)	(605,061		)
	Total comprehensive loss	(598,994		)	(6,067		)	(605,061		)
	Retained Earnings (Deficit), Balance at December 31, 2013	(750,329		)	(7,807		)	(758,136		)
	Total Shareholders' Equity, Balance at December 31, 2012	$	234,700		$	(1,740	)	$	232,960
	Net loss	(598,507		)	(6,067		)	(604,574		)
Total comprehensive loss	(598,507		)	(6,067		)	(604,574		)
Total Shareholders' Equity, Balance at December 31, 2013	(300,194		)	(7,807		)	(308,001		)
	For the Year Ended December 31, 2013
Restated Consolidated Statement of Cash Flows	As Previously Reported			Restatement Adjustments			As Restated
(In thousands)
Net loss	$	(598,507	)	$	(6,067	)	$	(604,574	)
Depreciation and amortization	20,110			4,511			24,621
Goodwill, intangibles and other long-lived asset impairment	610,436			1,944			612,380
Deferred income tax benefit	(36,660		)	(388		)	(37,048		)
	For the Year Ended December 31, 2011
Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			As Revised
(In thousands)
Net loss	$	(449,884	)	$	(537	)	$	(450,421	)
Depreciation and amortization	30,140			892			31,032
Deferred income tax benefit	(86,012		)	(355		)	(86,367		)

Acquisitions_and_Dispositions_

Acquisitions and Dispositions (Tables)	12 Months Ended
	Dec. 31, 2013
Harden Healthcare Holdings Inc. [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of recognized identified assets acquired and liabilities assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed as of the acquisition date (in thousands):
		October 18, 2013 (Restated)
	Cash and cash equivalents	$	10,203
	Accounts receivable, net	46,195
	Deferred tax asset	13,589
	Prepaids and other current assets	1,890
	Fixed assets, net	9,476
	Identifiable intangible assets, net	71,215
	Goodwill	331,167
	Other assets	2,889
	Total assets acquired	486,624
	Accounts payable and accrued liabilities	58,563
	Other current liabilities	8,720
	Deferred tax liabilities, noncurrent	590
	Total liabilities, assumed	67,873
	Net assets acquired	$	418,751
Schedule of acquired finite-lived intangible assets	'
	The valuation of the intangible assets by component and their respective useful life are as follows (in thousands):
		(Restated)
	Restated	Home Health			Hospice			Community Care			Total		Useful
													Life
	Intangible assets:
	Tradenames	$	1,052		$	798		$	11,922		$	13,772	5-10 Years
	Covenants not to compete	490			499			1,029			2,018		2-3 Years
	Medicare licenses and certificates of need	18,001			11,413			26,011			55,425		Indefinite
	Total	$	19,543		$	12,710		$	38,962		$	71,215
Business acquisition, pro forma information	'
	The pro forma results for the year ended December 31, 2013 combine the results of the Company for such period and the historical results of Harden from January 1 through October 17, 2013. The pro forma results presented below for the year ended December 31, 2012 combine the results of the Company and the historical results of Harden (in thousands, except per share amounts):
		For the Year Ended			For the Year Ended
		December 31, 2013			December 31, 2012
	Net revenues	$	2,105,562		$	2,188,915
	Net (loss) income attributable to Gentiva shareholders	$	(618,592	)	$	40,748
	Earnings per common share:
	Basic	$	(17.29	)	$	1.15
	Diluted	$	(17.29	)	$	1.15
	Weighted average shares outstanding:
	Basic	35,786			35,321
	Diluted	35,786			35,499
Series of Individually Immaterial Business Acquisitions [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of recognized identified assets acquired and liabilities assumed	'
	The allocation of the purchase prices relating to the Company's other acquisitions consummated is as follows (in thousands):
		Fiscal Year
		2013				2012
	Fixed assets, net	$	21			$	509
	Identifiable intangible assets	3,062				9,205
	Goodwill	2,871				14,695
	Other assets	128				66
	Total assets acquired	6,082				24,475
	Accounts payable and accrued liabilities	1,444				1,955
	Total liabilities assumed	1,444				1,955
	Net assets acquired	$	4,638			$	22,520
Schedule of acquired finite-lived intangible assets	'
	The valuation of the intangible assets by component and their respective useful lives are as follows (in thousands):
		Fiscal Year								Useful life
		2013				2012
	Covenants not to compete	$	—			$	203			5 years
	Certificates of need	3,062				9,002				indefinite
	Total	$	3,062			$	9,205
Home Health and Hospice [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	A summary of the Company's operations which were sold during 2012 and 2011 are as follows (in millions):
	Dispositions:	Date		Consideration
	Phoenix area hospice operations	November 30, 2012		$	3.5
	Gentiva Consulting	May 31, 2012		0.3
	Louisiana home health and hospice operations	Second Quarter 2012		6.4
	Certain home health branches-Utah, Michigan, Nevada and Brooklyn, New York	Fourth Quarter 2011		1.6
	The major classes of assets sold and liabilities assumed of the Home Health and Hospice branch operations that were sold were as follows (in thousands):
		2012
		As of Date of Sale				31-Dec-11
	Assets:
	Accounts receivable, net	$	561			$	526
	Fixed assets, net	271				338
	Intangible assets	1,356				1,356
	Other assets	485				640
	Total assets	2,673				2,860
	Liabilities:
	Medicare liabilities	(86		)		(18		)
	Other accrued Expenses	(405		)		(41		)
	Total liabilities	(491		)		(59		)
	Total	$	2,182			$	2,801
Discontinued Operations [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	Net revenues and operating results for the year 2011 for Rehab Without Walls® and the IDOA businesses were (in thousands):
		For the Year Ended
		31-Dec-11
	Net revenues	$	22,819
	Income before income taxes	$	2,430
	Gain on sale of business	11,475
	Income tax expense	(5,590		)
	Discontinued operations, net of tax	$	8,315
Discontinued Operations [Member] | Rehab Without Walls and Homemaker Services Agency [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		31-Dec-11
	Non-current assets:
	Fixed assets, net	$	183
	Other assets	109
	Total non-current assets	292
	Total	$	292

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]	'
Financial assets measured at fair value on a recurring basis	'
	any’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis was as follows (in thousands):
		31-Dec-13										31-Dec-12
		Level 1				Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	23,695			$	—	$	—	$	23,695	$	54,085	$	—	$	—	$	54,085
	Rabbi Trust:
	Mutual funds	28,945				—		—		28,945		22,041		—		—		22,041
	Money market funds	5,737				—		—		5,737		5,698		—		—		5,698
	Total assets	$	58,377			$	—	$	—	$	58,377	$	81,824	$	—	$	—	$	81,824
	Liabilities:
	Payables to plan participants	$	34,682			$	—	$	—	$	34,682	$	27,739	$	—	$	—	$	27,739
	Acquisition contingent liability	—				—		8,110		8,110		—		—		1,100		1,100
	Total liabilities	$	34,682			$	—	$	8,110	$	42,792	$	27,739	$	—	$	1,100	$	28,839
	Assets
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	owing table provides a summary of changes in fair value of the Company's Level 3 financial assets (in thousands):
			Estimated
			Fair Value
	Balance at December 31, 2011		$	—
	Advocate Hospice fair value of acquisition contingent liability		1,100
	Balance at December 31, 2012		1,100
	Fair value adjustment of Advocate Hospice acquisition contingent liability		900
	Fair value of Harden acquisition contingent liability		8,081
	Payment of contingent liability		(2,062		)
	Included in earnings		91			(1)
	Balance at December 31, 2013		$	8,110
	-1	Ac
Carrying amount and estimated fair value of financial instruments	'
	rying amount and estimated fair value of the Company’s other financial instruments were as follows (in thousands):
		31-Dec-13						31-Dec-12
		Carrying				Estimated		Carrying		Estimated
		Amount				Fair Value		Amount		Fair Value
	Assets:
	Note receivable from CareCentrix	$	25,000			$	26,403	$	25,000	$	25,220
	Seller financing note receivable from CareCentrix	3,471				3,471		3,471		3,471
	Liabilities:
	Long-term obligations	$	1,177,000			$	1,183,863	$	935,182	$	912,818
	The est

Net_Revenues_and_Accounts_Rece1

Net Revenues and Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Net Revenues and Accounts Receivable [Abstract]	'
Net revenues by major payer classification	'
	Net revenues in the Home Health and Hospice segments were derived from all major payer classes, while Community Care segment net revenues were derived primarily from Medicaid and Insurance payer classes. Net revenue by major payer classes were as follows (in millions):
		For the Year Ended
		2013			2012			2011
	Medicare:
	Home Health	$	787.3		$	749		$	799.2
	Hospice	667.9			715.5			729.1
	Total Medicare	1,455.20			1,464.60			1,528.30
	Medicaid and Local Government	116.6			74.4			83.1
	Commercial Insurance and Other:
	Paid at episodic rates	59.6			85.2			77.7
	Other	95.2			88.6			109.7
	Total Commercial Insurance and Other	154.8			173.8			187.4
	Total net revenues	$	1,726.60		$	1,712.80		$	1,798.80
Accounts receivable attributable to major payer sources of reimbursement	'
	Accounts receivable attributable to major payer sources of reimbursement are as follows (in thousands):
		December 31, 2013			December 31, 2012
	Medicare	$	214,366		$	192,541
	Medicaid and Local Government	48,183			31,259
	Commercial Insurance and Other	38,036			36,057
	Gross Accounts Receivable	300,585			259,857
	Less: Allowance for doubtful accounts	(10,680		)	(8,777		)
	Net Accounts Receivable	$	289,905		$	251,080

Fixed_Assets_Net_Tables

Fixed Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of fixed assets	'
	Fixed assets at December 31, 2013 and 2012 were as follows:
	(In thousands)	Useful Lives	31-Dec-13			31-Dec-12
	Land	Indefinite	$	768		$	1,451
	Building	30 Years	4,587			6,107
	Computer equipment and software	3-7 Years	70,131			65,718
	Home medical equipment	4 Years	5,356			5,179
	Furniture and fixtures	5 Years	35,028			24,556
	Leasehold improvements	Lease Term	18,121			18,250
	Machinery and equipment	5 Years	2,153			2,692
	Automobiles	5 Years	1,265			111
			137,409			124,064
	Less accumulated depreciation		(88,034		)	(82,650		)
	Fixed assets, net		$	49,375		$	41,414

Goodwill_and_Identifiable_Inta1

Goodwill and Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Gross carrying amount and accumulated amortization of identifiable intangible assets	'
	The gross carrying amount and accumulated amortization of each category of identifiable intangible assets as of December 31, 2013 and December 31, 2012 were as follows (in thousands):
		December 31, 2013 (Restated)												December 31, 2012 (Revised)												Useful
																										Life
		Home			Hospice			Community Care			Total			Home			Hospice			Community Care			Total
		Health												Health
	Amortized intangible assets:
	Covenants not to compete	$	2,157		$	16,183		$	1,029		$	19,369		$	1,667		$	15,685		$	—		$	17,352		2-5 Yrs
	Less: accumulated amortization	(1,553		)	(15,720		)	(91		)	(17,364		)	(1,449		)	(14,113		)	—			(15,562		)
	Net covenants not to compete	604			463			938			2,005			218			1,572			—			1,790
	Customer relationships	27,196			910			—			28,106			27,196			910			—			28,106			5-10 Yrs
	Less: accumulated amortization	(19,997		)	(481		)	—			(20,478		)	(17,651		)	(390		)	—			(18,041		)
	accumulated impairment losses	(27		)	—			—			(27		)	(27		)	—			—			(27		)
	Net customer relationships	7,172			429			—			7,601			9,518			520			—			10,038
	Tradenames	19,267			17,528			11,922			48,717			18,215			16,730			—			34,945			5-10 Yrs
	Less: accumulated amortization	(11,992		)	(3,763		)	(227		)	(15,982		)	(11,794		)	(3,608		)	—			(15,402		)
	accumulated impairment losses	(6,421		)	(13,122		)	—			(19,543		)	(6,421		)	(13,122		)	—			(19,543		)
	Net tradenames	854			643			11,695			13,192			—			—			—			—
	Licenses	714			8,021			—			8,735			—			2,888			—			2,888
	Less: accumulated amortization	(588		)	(6,812		)	—			(7,400		)	—			(2,888		)	—			(2,888		)
	Net licenses	126			1,209			—			1,335			—			—			—			—
	Amortized intangible assets	8,756			2,744			12,633			24,133			9,736			2,092			—			11,828
	Indefinite-lived intangible assets:
	Licenses and certificates of need	245,086			105,632			26,011			376,729			225,227			98,861			—			324,088
	Less: accumulated impairment	(144,672		)	(2,463		)	—			(147,135		)	(144,672		)	(519		)	—			(145,191		)
	losses
	Net licenses and certificates of need	100,414			103,169			26,011			229,594			80,555			98,342			—			178,897
	Total identifiable intangible assets	$	109,170		$	105,913		$	38,644		$	253,727		$	90,291		$	100,434		$	—		$	190,725
Gross carrying amount of goodwill	'
	The gross carrying amount of goodwill as of December 31, 2013 and December 31, 2012 and activity during the years 2013 and 2012 were as follows (in thousands):
		Goodwill, Gross												Accumulated Impairment Losses
		Home Health			Hospice			Community Care			Total			Home Health			Hospice			Total			Net
	Balance at December 31, 2011	$	267,058		$	831,648		$	—		$	1,098,706		$	(263,370	)	$	(193,667	)	$	(457,037	)	$	641,669
	Goodwill acquired during 2012	5,331			9,364			—			14,695			—			—			—			14,695
	Balance at December 31, 2012	272,389			841,012			—			1,113,401			(263,370		)	(193,667		)	(457,037		)	656,364
	Goodwill acquired during 2013 (Restated)	114,330			103,175			116,534			334,039			—			—			—			334,039
	Impairment losses during 2013 (Restated)	—			—			—			—			—			(606,916		)	(606,916		)	(606,916		)
	Balance at December 31, 2013 (Restated)	$	386,719		$	944,187		$	116,534		$	1,447,440		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	383,487
	The Company expects that substantially all of the goodwill acquired will be deductible for tax purposes with the exception of the Harden transaction which the Company expects approximately 20 percent of the goodwill to be tax deductible.

Cost_Savings_Initiatives_Acqui1

Cost Savings Initiatives, Acquisition and Integration Activities and Legal Settlements (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Costs incurred and cash expenditures	'
	The costs incurred and cash expenditures associated with these activities during 2013, 2012 and 2011 were as follows (in thousands):
		Cost Savings Initiatives			Acquisition &			Legal			Total
					Integration			Settlements
	Balance at December 31, 2010	$	2,893		$	3,984		$	12,500		$	19,377
	Charge in 2011	15,259			7,879			26,000			49,138
	Cash expenditures	(7,680		)	(8,155		)	(12,500		)	(28,335		)
	Non-cash expenditures	(1,801		)	—			—			(1,801		)
	Balance at December 31, 2011	8,671			3,708			26,000			38,379
	Charge in 2012	1,701			(989		)	4,958			5,670
	Cash expenditures	(8,544		)	(1,492		)	(30,958		)	(40,994		)
	Non-cash expenditures	(143		)	(216		)	—			(359		)
	Balance at December 31, 2012	1,685			1,011			—			2,696
	Charge in 2013	8,742			18,797			—			27,539
	Cash expenditures	(3,525		)	(9,550		)	—			(13,075		)
	Non-cash expenditures	(656		)	(79		)	—			(735		)
	Non-cash reclassification	476			(476		)	—			—
	Balance at December 31, 2013	$	6,722		$	9,703		$	—		$	16,425

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Computations of the basic and diluted per share amounts	'
	The computations of the basic and diluted per share amounts were as follows (in thousands, except per share amounts):
		For the Year Ended
		December 31, 2013 (Restated)			December 31, 2012		December 31, 2011 (Revised)
	Net (loss) income attributable to Gentiva shareholders	$	(605,061	)	$	26,796	$	(451,062	)
	Basic weighted average common shares outstanding	31,954			30,509		30,336
	Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	—			178		—
	Diluted weighted average common shares outstanding	31,954			30,687		30,336
	Basic earnings per common share
	Net (loss) income attributable to Gentiva shareholders	$	(18.94	)	$	0.88	$	(14.86	)
	Diluted earnings per common share:
	Net (loss) income attributable to Gentiva shareholders	$	(18.94	)	$	0.87	$	(14.86	)
	Anti-dilutive shares by type:
	Stock options	595			2,813		2,388
	Performance share units	—			89		129
	Restricted stock	231			330		348
	Total anti-dilutive shares	826			3,232		2,865

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Long-term Debt, Unclassified [Abstract]	'
Long-term debt	'
	As of December 31, 2013 and December 31, 2012, the Company’s long-term debt consisted of the following (in thousands):
		December 31, 2013				December 31, 2012
	Credit Agreement:
	Term Loan A, matured October 18, 2013	$	—			$	143,750
	Term Loan B, matured October 18, 2013	—				466,432
	Term Loan B, maturing October 18, 2019, net of unamortized discount of $6.508 million as of December 31, 2013	663,492				—
	Term Loan C, maturing October 18, 2018, net of unamortized discount of $0.735 million as of December 31, 2013	154,265				—
	11.5% Senior Notes due 2018	325,000				325,000
	Revolving Credit Facility	27,000				—
	Total debt	1,169,757				935,182
	Less: current portion of long-term debt	(45,325		)		(25,000		)
	Total long-term debt	$	1,124,432			$	910,182
Applicable Rate for Term Loans	'
	Under the Company's New Credit Agreement, the Applicable Rate component of the interest rate is based on the Company's consolidated leverage ratio as follows:
			Applicable Rates
	Consolidated		Eurodollar Rate for Revolving Credit Facility and Letter of Credit Fees		Base Rate for Revolving Credit Facility		Term Loan B			Term Loan C
	Leverage Ratio						Eurodollar Rate		Base Rate	Eurodollar Rate	Base Rate
	> 4.0:1		4.50%		3.50%		5.25%		4.25%	4.50%	3.50%
	< 4.0:1		4.25%		3.25%		5.25%		4.25%	4.50%	3.50%
Gentiva's permitted maximum consolidated leverage ratio	'
	Four Fiscal Quarters Ending	Maximum Consolidated
		Leverage Ratio
	March 31, 2014 to March 31, 2015	≤ 6.75:1
	June 30, 2015 to March 31, 2016	≤ 6.50:1
	June 30, 2016 to March 31, 2017	≤ 6.25:1
	June 30, 2017 to December 31, 2017	≤ 6.00:1
	March 31, 2018 and each fiscal quarter thereafter	≤ 5.75:1
Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest	'
	On or after September 1, 2014, Gentiva may redeem all or part of the Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest, if any, as defined in the indenture relating to the Senior Notes during the twelve month period beginning on September 1 of the years indicated below:
	Year	Percentage
	2014	105.75%
	2015	102.88%
	2016 and thereafter	100.00%

EquityBased_Compensation_Plans1

Equity-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted-average fair values of the Company's stock options granted	'
	The weighted average fair values of the Company’s stock options granted during 2013, 2012 and 2011 calculated using the Black-Scholes option pricing model and other assumptions used in the option pricing model, were as follows:
		For the Year Ended
		December 31, 2013				December 31, 2012				31-Dec-11
	Weighted average fair value of options granted	$	6.02			$	4.32			$	3.46
	Risk-free interest rate	0.29% - 0.54%				0.77% - 0.95%				0.91		%
	Expected volatility	76% - 79%				64% - 65%				60		%
	Contractual life	7 years				7 years				7 years
	Expected life	3.4 - 5.4 years				3.4 - 5.4 years				4.5 - 6.5 years
	Expected dividend yield	—		%		—		%		—		%
Summary of stock option activity	'
	A summary of Gentiva stock option activity as of December 31, 2013 and changes during the year then ended is presented below:
		Number of			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic
					Exercise				Remaining		Value
					Price				Contractual
									Life (Years)
	Balance as of December 31, 2012	3,752,418			$	15.99
	Granted	642,700			10.74
	Exercised	(97,455	)		5.6
	Cancelled	(292,074	)		15.98
	Balance as of December 31, 2013	4,005,589			$	15.4			4.4		$	8,651,115
	Exercisable options	2,829,292			$	17.58			3.9		$	4,771,998
	Shares expected to vest as of December 31, 2013	1,139,228			$	10.19			5.5		$	3,785,503
Summary of restricted stock activity	'
	A summary of Gentiva restricted stock activity as of December 31, 2013 is presented below:
		Number of			Weighted-				Aggregate
		Restricted			Average				Intrinsic
		Shares			Exercise				Value
					Price
	Balance as of December 31, 2012	364,650			$	25.25
	Granted	338,300			11.37
	Exercised	(39,750	)		26.06
	Cancelled	(27,800	)		14.7
	Balance as of December 31, 2013	635,400			$	18.27			$	7,885,314
	Nonvested shares expected to vest as of December 31, 2013	602,343			$	18.53			$	7,475,074
Performance Cash Award [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Summary of performance share unit	'
	A summary of Gentiva's performance based cash award activity by grant year as of December 31, 2013 is presented below:
		2012				2013
	Service period to vest:	3 years				3 years
	Performance range of target:	0% - 200%				0% - 240%
	Performance measured on:	EPS				EPS
	Performance measurement period:	1/2 based on 2012 results				60% based on 2013 results
		1/2 based on 2014 results				40% based on 2015 results
	Performance target achieved:	2012 - 85%				2013 - 0%
	Performance cash:
	Balance as of December 31, 2012	$	1,293,687			$	—
	Earned	1,225,589				1,005,832
	Issued	—				—
	Balance as of December 31, 2013	$	2,519,276			$	1,005,832
Performance Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Summary of performance share unit	'
	A summary of Gentiva's performance based share award activity by grant year as of December 31, 2013 is presented below:
		2010			2011			Number of			Weighted-
								Performance			Average
								Share Units			Exercise
											Price
	Service period to vest:	3 years			3 years
	Performance range of target:	0% - 150%			0% - 200%
	Performance measured on:	EPS			EPS
	Performance measurement period:	1/3 based on 2010 results			90% based on 2011 results
		1/3 based on 2011 results			10% based on 2013 results
		1/3 based on 2012 results
	Performance target achieved:	2010 - 150%			2011 - 200%
		2011 - 150%			2013 - 0%
		2012 - 0%
	Performance share units:
	Balance as of December 31, 2012	33,700			166,750			200,450			$	26.31
	Forfeited	—			(1,800	)		(1,800	)		26.67
	Change in performance achievement expectations	—			(6,650	)		(6,650	)		26.58
	Issued	(33,700	)		(158,300	)		(192,000	)		26.29
	Balance as of December 31, 2013	—			—			—			$	—

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum rental payments for operating leases	'
	Future minimum rental commitments and sublease rentals for all non-cancelable leases at December 31, 2013 are as follows (in thousands):
	Fiscal Year	Total		Sublease		Net
		Commitment		Rentals
	2014	$	50,738	$	525	$	50,213
	2015	38,205		237		37,968
	2016	27,387		69		27,318
	2017	19,259		37		19,222
	2018	13,398		28		13,370
	Thereafter	13,785		—		13,785

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense (benefit)	'
	A comparative analysis of the provision for income taxes follows (in thousands):
		For the Year Ended
		December 31, 2013 (Restated)				31-Dec-12				December 31, 2011 (Revised)
	Current:
	Federal	$	(3,968	)		$	(7,784	)		$	7,784
	State and local	1,063				1,522				2,460
	Current income tax expense (benefit)	(2,905		)		(6,262		)		10,244
	Deferred:
	Federal	(30,655		)		20,211				(71,267		)
	State and local	(6,393		)		3,302				(15,100		)
	Deferred income tax (benefit) expense	(37,048		)		23,513				(86,367		)
	Income tax (benefit) expense	$	(39,953	)		$	17,251			$	(76,123	)
Schedule of effective income tax rate reconciliation	'
	A reconciliation of the differences between federal statutory tax rate and the Company’s effective tax rate for 2013, 2012 and 2011 is as follows:
		For the Year Ended
		31-Dec-13			31-Dec-12			31-Dec-11
	Federal statutory tax rate	35	%		35	%		35	%
	Impairment	(29.2	)		—			(23.6	)
	State income taxes, net of Federal benefit	0.6			4.6			1.7
	Change in tax reserve	(0.1	)		(3.4	)		(0.5	)
	Net change in state valuation allowance	—			(0.6	)		(0.1	)
	Other	(0.1	)		0.9			0.1
	Effective tax rate	6.2	%		36.5	%		12.6	%
Schedule of deferred tax assets and liabilities	'
	Deferred income tax assets and deferred tax liabilities are as follows (in thousands):
		December 31, 2013 (Restated)				December 31, 2012 (Revised)
	Deferred tax assets
	Current:
	Reserves and allowances	$	18,840			$	8,833
	Payroll and related accruals	5,343				5,953
	Net operating loss carryforwards, state	6,216				—
	Other	409				446
	Less: valuation allowance	(777		)		(511		)
	Total current deferred tax assets	30,031				14,721
	Noncurrent:
	Equity compensation	17,376				16,940
	Deferred rent	2,241				2,935
	Net operating loss carryforwards, federal	12,141				—
	Capital loss carryforward	232				—
	Federal tax credit carryforwards	4,408				4,809
	Other	5,920				3,669
	Less: valuation allowance	(2,864		)		(2,367		)
	Total noncurrent deferred tax assets	39,454				25,986
	Total deferred tax assets	69,485				40,707
	Deferred tax liabilities:
	Current:
	Prepaid assets	(1,873		)		(2,458		)
	Other	(5		)		—
	Total current deferred tax liabilities	(1,878		)		(2,458		)
	Noncurrent:
	Fixed assets	(2,684		)		(1,409		)
	Intangible assets	(39,202		)		(50,398		)
	Developed software	(3,568		)		(4,559		)
	Financing fees	(1,940		)		(10,637		)
	Other	(543		)		—
	Total non-current deferred tax liabilities	(47,937		)		(67,003		)
	Total deferred tax liabilities	(49,815		)		(69,461		)
	Net deferred tax assets (liabilities)	$	19,670			$	(28,754	)
Schedule of unrecognized tax benefits roll forward	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
	Balance at December 31, 2010	$	3,651
	Additions for tax positions of the current year	9,039
	Additions for tax positions of prior year	2,316
	Changes in judgment	(584		)
	Reductions for tax positions of prior years for:
	Settlements during the period	(3,184		)
	Lapses of applicable statute of limitations	(211		)
	Balance at December 31, 2011	11,027
	Additions for tax positions of the current year	126
	Additions for tax positions of prior year	245
	Changes in judgment	(2,312		)
	Reductions for tax positions of prior years for:
	Settlements during the period	(274		)
	Lapses of applicable statute of limitations	(456		)
	Balance at December 31, 2012	8,356
	Additions for tax positions of the current year	456
	Additions for tax positions of acquired companies	910
	Reductions for tax positions of prior years for:
	Settlements during the period	(1,898		)
	Lapses of applicable statute of limitations	(148		)
	Balance at December 31, 2013	$	7,676

Business_Segment_Information_T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment net revenues by major payer source	'
	Segment net revenues by major payer source were as follows (in millions):
		Home Health		Hospice				Community Care			Total
	For the year ended December 31, 2013
	Medicare	$	787.3	$	667.9			$	—		$	1,455.20
	Medicaid and Local Government	43.8		28.3				44.5			116.6
	Commercial Insurance and Other:
	Paid at episodic rates	59.6		—				—			59.6
	Other	75.1		19				1.1			95.2
	Total net revenues	$	965.8	$	715.2			$	45.6		$	1,726.60
	For the year ended December 31, 2012
	Medicare	$	749	$	715.5			$	—		$	1,464.60
	Medicaid and Local Government	46.8		27.7				—			74.4
	Commercial Insurance and Other:
	Paid at episodic rates	85.2		—				—			85.2
	Other	67		21.6				—			88.6
	Total net revenues	$	948	$	764.8			$	—		$	1,712.80
	For the year ended December 31, 2011
	Medicare	$	799.2	$	729.1			$	—		$	1,528.30
	Medicaid and Local Government	52.3		30.8				—			83.1
	Commercial Insurance and Other:
	Paid at episodic rates	77.7		—				—			77.7
	Other	83.4		26.3				—			109.7
	Total net revenues	$	1,012.60	$	786.2			$	—		$	1,798.80
Segment information about the Company's operations	'
	Segment information about the Company's operations is as follows (in thousands):
		Home Health				Hospice					Community Care		Total
	For the year ended December 31, 2013 (Restated)
	Net revenue	$	965,848			$	715,190				$	45,606	$	1,726,644
	Operating contribution	$	113,809	-1		$	78,810			-1	$	6,385	$	199,004
	Corporate expenses												(96,146		)	-1
	Goodwill, intangibles and other long-lived asset impairment												(612,380		)	-3
	Depreciation and amortization												(24,621		)
	Interest expense and other, net												(110,384		)	-2
	(Loss) from continuing operations before income taxes and equity in earnings of affiliate												$	(644,527	)
	Segment assets	$	406,367			$	348,445			-3	172,308		$	927,120
	Corporate assets												326,348			-3
	Total assets												$	1,253,468
	For the year ended December 31, 2012 (Revised)
	Net revenue	$	948,019			$	764,785				$	—	$	1,712,804
	Operating contribution	$	125,445	-1		$	133,133			-1	$	—	$	258,578
	Corporate expenses												(83,700		)	-1
	Goodwill, intangibles and other long-lived asset impairment												(19,132		)	-3
	Depreciation and amortization												(26,581		)
	Gain on sale of businesses												8,014
	Interest expense and other, net												(89,947		)	-2
	Income from continuing operations before income taxes and equity in loss of affiliate												$	47,232
	Segment assets	$	242,603	-3		$	855,614			-3	$	—	$	1,098,217
	Corporate assets												409,829
	Total assets												$	1,508,046
	For the year ended December 31, 2011 (Revised)
	Net revenue	$	1,012,566			$	786,212				$	—	$	1,798,778
	Operating contribution	$	126,194	-1		$	139,723			-1	$	—	$	265,917
	Corporate expenses												(115,861		)	-1
	Goodwill, intangibles and other long-lived asset impairment												(643,305		)	-3
	Dividend income												8,590			-4
	Depreciation and amortization												(31,032		)
	Gain on sale of assets and businesses, net												1,061
	Interest expense and other, net												(88,610		)	-2
	(Loss) from continuing operations before income taxes and equity in earnings of affiliate												$	(603,240	)
	Segment assets	$	239,751	-3		$	902,397			-3	$	—	$	1,142,148
	Corporate assets												385,292			-3
	Total assets												$	1,527,440
Charges reflecting for segment reporting purposes	'
	The charges were reflected as follows for segment reporting purposes (in millions):
		2013		2012				2011
	Home Health	$	3.3	$	5.6			$	7.7
	Hospice	8.2		0.4				3.7
	Corporate expenses	16		(0.3		)		37.7
	Total	$	27.5	$	5.7			$	49.1
	-2	For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Company’s interest rate swaps in connection with the refinancing of the Company’s Term Loan A and Term Loan B under the Company’s former credit agreement. See Note 13 for additional information.
	-3	The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.
	For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.
	For the year ended December 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of December 31, 2011, as a result of the impairment.
	-4	For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Company’s combined common and preferred ownership of CareCentrix.

Supplemental_Guarantor_and_Non1

Supplemental Guarantor and Non-Guarantor Financial Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Guarantor and Non-Guarantor Financial Information [Abstract]	'
Condensed Consolidating Balance Sheet	'
	Condensed Consolidating Balance Sheet
	31-Dec-13
	(In thousands)
	As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	55,076			$	—		$	31,881		$	—		$	86,957
	Receivables, net	—				284,379			34,136			(28,610		)	289,905
	Deferred tax assets, net	—				25,845			2,308			—			28,153
	Prepaid expenses and other current assets	—				50,890			13,856			—			64,746
	Total current assets	55,076				361,114			82,181			(28,610		)	469,761
	Notes receivable from CareCentrix	—				28,471			—			—			28,471
	Fixed assets, net	—				48,824			551			—			49,375
	Intangible assets, net	—				253,682			2,600			—			256,282
	Goodwill	—				384,017			6,064			—			390,081
	Investment in subsidiaries	790,589				28,382			—			(818,971		)	—
	Other assets	28,266				40,370			11			—			68,647
	Total assets	$	873,931			$	1,144,860		$	91,407		$	(847,581	)	$	1,262,617
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	45,325			$	—		$	—		$	—		$	45,325
	Accounts payable	—				15,377			282			—			15,659
	Other current liabilities	—				283,228			59,868			(28,610		)	314,486
	Total current liabilities	45,325				298,605			60,150			(28,610		)	375,470
	Long-term debt	1,124,432				—			—			—			1,124,432
	Deferred tax liabilities, net	—				9,825			—			—			9,825
	Other liabilities	7,243				45,841			—			—			53,084
	Total Gentiva shareholders’ equity	(303,069		)		790,589			28,382			(818,971		)	(303,069		)
	Noncontrolling interests	—				—			2,875			—			2,875
	Total equity	(303,069		)		790,589			31,257			(818,971		)	(300,194		)
	Total liabilities and equity	$	873,931			$	1,144,860		$	91,407		$	(847,581	)	$	1,262,617
	Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Intangible assets, net	$	—			$	(2,555	)	$	—		$	—		$	(2,555	)
	Goodwill	—				(6,594		)	—			—			(6,594		)
	Investment in subsidiaries	(7,807		)		—			—			7,807			—
	Total assets	(7,807		)		(9,149		)	—			7,807			(9,149		)
	Deferred tax liabilities, net	—				(1,342		)	—			—			(1,342		)
	Total Gentiva shareholders’ equity	(7,807		)		(7,807		)	—			7,807			(7,807		)
	Total equity	(7,807		)		(7,807		)	—			7,807			(7,807		)
	Total liabilities and equity	(7,807		)		(9,149		)	—			7,807			(9,149		)
	Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Cash and cash equivalents	$	312			$	—		$	(312	)	$	—		$	—
	Receivables, net	—				258			(258		)	—			—
	Prepaid expenses and other current assets	—				2,081			(2,081		)	—			—
	Total current assets	312				2,339			(2,651		)	—			—
	Fixed assets, net	—				31			(31		)	—			—
	Goodwill	—				2,457			(2,457		)	—			—
	Investment in subsidiaries	(312		)		(4,889		)	—			5,201			—
	Other assets	—				5			(5		)	—			—
	Total assets	—				(57		)	(5,144		)	5,201			—
	Other current liabilities	—				255			(255		)	—			—
	Total current liabilities	—				255			(255		)	—			—
	Total Gentiva shareholders’ equity					(312		)	(4,889		)	5,201			—
	Total equity	—				(312		)	(4,889		)	5,201			—
	Total liabilities and equity	—				(57		)	(5,144		)	5,201			—
	As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	55,388			$	—		$	31,569		$	—		$	86,957
Receivables, net	—				284,637			33,878			(28,610		)	289,905
Deferred tax assets, net	—				25,845			2,308			—			28,153
Prepaid expenses and other current assets	—				52,971			11,775			—			64,746
Total current assets	55,388				363,453			79,530			(28,610		)	469,761
Notes receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				48,855			520			—			49,375
Intangible assets, net	—				251,127			2,600			—			253,727
Goodwill	—				379,880			3,607			—			383,487
Investment in subsidiaries	782,470				23,493			—			(805,963		)	—
Other assets	28,266				40,375			6			—			68,647
Total assets	866,124				1,135,654			86,263			(834,573		)	1,253,468
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	45,325			$	—		$	—		$	—		$	45,325
Accounts payable	—				15,377			282			—			15,659
Other current liabilities	—				283,483			59,613			(28,610		)	314,486
Total current liabilities	45,325				298,860			59,895			(28,610		)	375,470
Long-term debt	1,124,432				—			—			—			1,124,432
Deferred tax liabilities, net	—				8,483			—			—			8,483
Other liabilities	7,243				45,841			—			—			53,084
Total Gentiva shareholders’ equity	(310,876		)		782,470			23,493			(805,963		)	(310,876		)
Noncontrolling interests	—				—			2,875			—			2,875
Total equity	(310,876		)		782,470			26,368			(805,963		)	(308,001		)
Total liabilities and equity	$	866,124			$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
Condensed Consolidating Balance Sheet
31-Dec-12
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
ASSETS
Current assets:
Cash and cash equivalents	$	166,140			$	—		$	40,912		$	—		$	207,052
Receivables, net	—				245,191			19,744			(13,855		)	251,080
Deferred tax assets, net	—				10,280			1,983			—			12,263
Prepaid expenses and other current assets	—				36,899			8,733			—			45,632
Total current assets	166,140				292,370			71,372			(13,855		)	516,027
Note receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				41,066			348			—			41,414
Intangible assets, net	—				193,513			100			—			193,613
Goodwill	—				650,300			6,064			—			656,364
Investment in subsidiaries	1,002,204				27,210			—			(1,029,414		)	—
Other assets	44,219				30,820			6			—			75,045
Total assets	$	1,212,563			$	1,263,750		$	77,890		$	(1,043,269	)	$	1,510,934
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	25,000			$	—		$	—		$	—		$	25,000
Accounts payable	—				27,300			—			(13,855		)	13,445
Other current liabilities	—				202,321			49,133			—			251,454
Total current liabilities	25,000				229,621			49,133			(13,855		)	289,899
Long-term debt	910,182				—			—			—			910,182
Deferred tax liabilities, net	—				42,165			—			—			42,165
Other liabilities	—				33,979			9			—			33,988
Total Gentiva shareholders’ equity	277,381				957,985			27,210			(1,029,414		)	233,162
Noncontrolling interests	—				—			1,538			—			1,538
Total equity	277,381				957,985			28,748			(1,029,414		)	234,700
Total liabilities and equity	$	1,212,563			$	1,263,750		$	77,890		$	(1,043,269	)	$	1,510,934
Revision Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Intangible assets, net	$	—			$	(2,888	)	$	—		$	—		$	(2,888	)
Total assets	—				(2,888		)	—			—			(2,888		)
Deferred tax liabilities, net	—				(1,148		)	—			—			(1,148		)
Total Gentiva shareholders’ equity	—				(1,740		)	—			—			(1,740		)
Total equity	—				(1,740		)	—			—			(1,740		)
Total liabilities and equity	—				(2,888		)	—			—			(2,888		)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations (Revised)			Consolidated
	Services, Inc. (Revised				Subsidiaries (Revised)			Subsidiaries						Total (Revised)
ASSETS
Current assets:
Cash and cash equivalents	$	166,140			$	—		$	40,912		$	—		$	207,052
Receivables, net	—				245,191			19,744			(13,855		)	251,080
Deferred tax assets, net	—				10,280			1,983			—			12,263
Prepaid expenses and other current assets	—				36,899			8,733			—			45,632
Total current assets	166,140				292,370			71,372			(13,855		)	516,027
Note receivable from CareCentrix	—				28,471			—			—			28,471
Fixed assets, net	—				41,066			348			—			41,414
Intangible assets, net	—				190,625			100			—			190,725
Goodwill	—				650,300			6,064			—			656,364
Investment in subsidiaries	1,002,204				27,210			—			(1,029,414		)	—
Other assets	44,219				30,820			6			—			75,045
Total assets	$	1,212,563			$	1,260,862		$	77,890		$	(1,043,269	)	$	1,508,046
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	25,000			$	—		$	—		$	—		$	25,000
Accounts payable	—				27,300			—			(13,855		)	13,445
Other current liabilities	—				202,321			49,133			—			251,454
Total current liabilities	25,000				229,621			49,133			(13,855		)	289,899
Long-term debt	910,182				—			—			—			910,182
Deferred tax liabilities, net	—				41,017			—			—			41,017
Other liabilities	—				33,979			9			—			33,988
Total Gentiva shareholders’ equity	277,381				956,245			27,210			(1,029,414		)	231,422
Noncontrolling interests	—				—			1,538			—			1,538
Total equity	277,381				956,245			28,748			(1,029,414		)	232,960
Total liabilities and equity	$	1,212,563			$	1,260,862		$	77,890		$	(1,043,269	)	$	1,508,046
Condensed Consolidating Statement of Comprehensive Income	'
	Condensed Consolidating Statement of Comprehensive Income
	For the Year Ended December 31, 2013
	(In thousands)
	As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Net revenues	$	—			$	1,676,888		$	64,989		$	(15,233	)	$	1,726,644
	Cost of services sold	—				905,261			52,152			(15,233		)	942,180
	Gross profit	—				771,627			12,837			—			784,464
	Selling, general and administrative expenses	—				(682,262		)	(19,454		)	—			(701,716		)
	Goodwill, intangibles and other long-lived asset impairment	—				(610,436		)	—			—			(610,436		)
	Interest (expense) and other, net	(110,477		)		—			93			—			(110,384		)
	Equity in earnings of subsidiaries	(530,697		)		(4,561		)	—			535,258			—
	(Loss) income before income taxes	(641,174		)		(525,632		)	(6,524		)	535,258			(638,072		)
	Income tax benefit (expense)	42,180				(5,065		)	2,450			—			39,565
	Net (loss) income	(598,994		)		(530,697		)	(4,074		)	535,258			(598,507		)
	Noncontrolling interests	—				—			(487		)	—			(487		)
	Net (loss) income attributable to Gentiva shareholders	(598,994		)		(530,697		)	(4,561		)	535,258			(598,994		)
	Comprehensive (loss) income	(598,994		)		(530,697		)	(4,074		)	535,258			(598,507		)
	Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Selling, general and administrative expenses	$	—			$	(4,511	)	$	—		$	—		$	(4,511	)
	Goodwill, intangibles and other long-lived asset impairment	—				(1,944		)	—			—			(1,944		)
	Equity in earnings of subsidiaries	(6,067		)		—			—			6,067			—
	(Loss) income before income taxes	(6,067		)		(6,455		)	—			6,067			(6,455		)
	Income tax benefit (expense)	—				388			—			—			388
	Net (loss) income	(6,067		)		(6,067		)	—			6,067			(6,067		)
	Net (loss) income attributable to Gentiva shareholders	(6,067		)		(6,067		)	—			6,067			(6,067		)
	Comprehensive (loss) income	(6,067		)		(6,067		)	—			6,067			(6,067		)
	Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Net revenues	$	—			$	1,004		$	(1,004	)	$	—		$	—
	Cost of services sold	—				538			(538		)	—			—
	Gross profit	—				466			(466		)	—			—
	Selling, general and administrative expenses	—				(224		)	224			—			—
	(Loss) income before income taxes	—				242			(242		)	—			—
	Income tax benefit (expense)	—				(93		)	93			—			—
	Net (loss) income	—				149			(149		)	—			—
	Net (loss) income attributable to Gentiva shareholders	—				149			(149		)	—			—
	Comprehensive (loss) income	—				145			(145		)	—			—
	As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Net revenues	$	—			$	1,677,892		$	63,985		$	(15,233	)	$	1,726,644
	Cost of services sold	—				905,799			51,614			(15,233		)	942,180
	Gross profit	—				772,093			12,371			—			784,464
	Selling, general and administrative expenses	—				(686,997		)	(19,230		)	—			(706,227		)
	Goodwill, intangibles and other long-lived asset impairment	—				(612,380		)	—			—			(612,380		)
	Interest (expense) and other, net	(110,477		)		—			93			—			(110,384		)
	Equity in earnings of subsidiaries	(536,764		)		(4,710		)	—			541,474			—
	(Loss) income before income taxes	(647,241		)		(531,994		)	(6,766		)	541,474			(644,527		)
	Income tax benefit (expense)	42,180				(4,770		)	2,543			—			39,953
	Net (loss) income	(605,061		)		(536,764		)	(4,223		)	541,474			(604,574		)
	Noncontrolling interests	—				—			(487		)	—			(487		)
	Net (loss) income attributable to Gentiva shareholders	(605,061		)		(536,764		)	(4,710		)	541,474			(605,061		)
	Comprehensive (loss) income	(605,061		)		(536,764		)	(4,223		)	541,474			(604,574		)
	Condensed Consolidating Statement of Comprehensive Income
	For the Year Ended December 31, 2012
	(In thousands)
		Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Net revenues	$	—			$	1,666,368		$	61,656		$	(15,220	)	$	1,712,804
	Cost of services sold	—				884,903			39,058			(15,220		)	908,741
	Gross profit	—				781,465			22,598			—			804,063
	Selling, general and administrative expenses	—				(638,975		)	(16,791		)	—			(655,766		)
Goodwill, intangibles and other long-lived asset impairment	—				(19,132		)	—			—			(19,132		)
Gain on sale of assets and businesses, net	—				8,014			—			—			8,014
Interest (expense) and other, net	(90,054		)		—			107			—			(89,947		)
Equity in earnings of subsidiaries	79,622				3,038			—			(82,660		)	—
(Loss) income before income taxes and equity in net (loss) earnings of CareCentrix	(10,432		)		134,410			5,914			(82,660		)	47,232
Income tax benefit (expense)	37,228				(52,487		)	(1,992		)	—			(17,251		)
Equity in net (loss) earnings of CareCentrix	—				(2,301		)	—			—			(2,301		)
Net income	26,796				79,622			3,922			(82,660		)	27,680
Noncontrolling interests	—				—			(884		)	—			(884		)
Net income attributable to Gentiva shareholders	$	26,796			$	79,622		$	3,038		$	(82,660	)	$	26,796
Comprehensive income	$	26,796			$	79,622		$	3,922		$	(82,660	)	$	27,680
Condensed Consolidating Statement of Comprehensive Income
For the Year Ended December 31, 2011
(In thousands)
As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
Net revenues	$	—			$	1,757,459		$	52,404		$	(11,085	)	$	1,798,778
Cost of services sold	—				921,826			37,714			(11,085		)	948,455
Gross profit	—				835,633			14,690			—			850,323
Selling, general and administrative expenses	—				(715,343		)	(15,064		)	—			(730,407		)
Goodwill, intangibles and other long-lived asset impairment	—				(643,305		)	—			—			(643,305		)
Gain on sale of assets and businesses, net	—				1,061			—			—			1,061
Dividend income	—				8,590			—			—			8,590
Interest (expense) and other, net	(88,665		)		—			55			—			(88,610		)
Equity in earnings of subsidiaries	(380,176		)		221			—			379,955			—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(468,841		)		(513,143		)	(319		)	379,955			(602,348		)
Income tax benefit (expense)	18,316				56,637			815			—			75,768
Equity in net earnings of CareCentrix	—				68,381			—			—			68,381
(Loss) income from continuing operations	(450,525		)		(388,125		)	496			379,955			(458,199		)
Discontinued operations, net of tax	—				7,949			366			—			8,315
Net (loss) income	(450,525		)		(380,176		)	862			379,955			(449,884		)
Noncontrolling interests	—				—			(641		)	—			(641		)
Net (loss) income attributable to Gentiva shareholders	$	(450,525	)		$	(380,176	)	$	221		$	379,955		$	(450,525	)
Comprehensive (loss) income	$	(451,003	)		$	(380,176	)	$	862		$	379,955		$	(450,362	)
Other Restatement Adjustments	Gentiva Health			Guarantor			Non-Guarantor		Eliminations		Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries				Total
Selling, general and administrative expenses	—			(892	)		—		—		(892	)
Equity in earnings of subsidiaries	(537	)		—			—		537		—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(537	)		(892	)		—		537		(892	)
Income tax benefit (expense)	—			355			—		—		355
(Loss) income from continuing operations	(537	)		(537	)		—		537		(537	)
Net (loss) income	(537	)		(537	)		—		537		(537	)
Net (loss) income attributable to Gentiva shareholders	(537	)		(537	)		—		537		(537	)
Comprehensive (loss) income	(537	)		(537	)		—		537		(537	)
As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations (Revised)			Consolidated
	Services, Inc. (Revised)				Subsidiaries (Revised)			Subsidiaries						Total (Revised)
Net revenues	$	—			$	1,757,459		$	52,404		$	(11,085	)	$	1,798,778
Cost of services sold	—				921,826			37,714			(11,085		)	948,455
Gross profit	—				835,633			14,690			—			850,323
Selling, general and administrative expenses	—				(716,235		)	(15,064		)	—			(731,299		)
Goodwill, intangibles and other long-lived asset impairment	—				(643,305		)	—			—			(643,305		)
Gain on sale of assets and businesses, net	—				1,061			—			—			1,061
Dividend income	—				8,590			—			—			8,590
Interest (expense) and other, net	(88,665		)		—			55			—			(88,610		)
Equity in earnings of subsidiaries	(380,713		)		221			—			380,492			—
Loss from continuing operations before income taxes and equity in net earnings of CareCentrix	(469,378		)		(514,035		)	(319		)	380,492			(603,240		)
Income tax benefit (expense)	18,316				56,992			815			—			76,123
Equity in net earnings of CareCentrix	—				68,381			—			—			68,381
(Loss) income from continuing operations	(451,062		)		(388,662		)	496			380,492			(458,736		)
Discontinued operations, net of tax	—				7,949			366			—			8,315
Net (loss) income	(451,062		)		(380,713		)	862			380,492			(450,421		)
Noncontrolling interests	—				—			(641		)	—			(641		)
Net (loss) income attributable to Gentiva shareholders	$	(451,062	)		$	(380,713	)	$	221		$	380,492		$	(451,062	)
Comprehensive (loss) income	$	(451,540	)		$	(380,713	)	$	862		$	380,492		$	(450,899	)
Condensed Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows
	For the Year Ended December 31, 2013
	(In thousands)
	As Reported	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	OPERATING ACTIVITIES:
	Net cash (used in) provided by operating activities	$	(29,406	)		$	80,742		$	(10,194	)	$	(4,037	)	$	37,105
	INVESTING ACTIVITIES:
	Purchase of fixed assets	—				(18,690		)	(385		)	—			(19,075		)
	Proceeds from sale of businesses	—				508			—			—			508
	Proceeds from the sale of assets	—				203			—			—			203
	(Payments to) proceeds from affiliates	—				(7,400		)	—			7,400			—
	Acquisition of businesses	—				(356,935		)	(2,500		)	—			(359,435		)
	Net cash (used in) provided by investing activities	—				(382,314		)	(2,885		)	7,400			(377,799		)
	FINANCING ACTIVITIES:
	Proceeds from issuance of common stock	3,231				—			—			—			3,231
	Windfall tax benefits associated with equity-based compensation	119				—			—			—			119
	Payment of contingent consideration accrued at acquisition date	—				(1,675		)	—			—			(1,675		)
	Proceeds from issuance of debt	817,525				—			—			—			817,525
	Borrowings under revolving credit facility	27,000				—			—			—			27,000
	Intercompany dividend	—				—			(2,300		)	2,300			—
	Repayment of long-term debt	(610,182		)		—			—			—			(610,182		)
	Debt issuance costs	(15,187		)		—			—			—			(15,187		)
	Investment in affiliate	—				—			5,000			(5,000		)	—
	Minority interest capital contribution	—				—			1,600			—			1,600
	Majority interest capital contribution	—				—			2,400			(2,400		)	—
	Distribution to minority interests	—				—			(750		)	—			(750		)
	Distribution to majority interests	—				—			(1,737		)	1,737			—
	Other	(889		)		(28		)	(165		)	—			(1,082		)
	Net payments related to intercompany financing	(303,275		)		303,275			—			—			—
	Net cash provided by (used in) financing activities	(81,658		)		301,572			4,048			(3,363		)	220,599
	Net change in cash and cash equivalents	(111,064		)		—			(9,031		)	—			(120,095		)
	Cash and cash equivalents at beginning of period	166,140				—			40,912			—			207,052
	Cash and cash equivalents at end of period	$	55,076			$	—		$	31,881		$	—		$	86,957
	Other Restatement Adjustments	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	Net cash (used in) provided by operating activities	$	—			$	235		$	(235	)	$	—		$	—
	Purchase of fixed assets	—				(16		)	16			—			—
	Net cash (used in) provided by investing activities	—				(16		)	16			—			—
	Net payments related to intercompany financing	312				(219		)	(93		)	—			—
	Net cash provided by (used in) financing activities	312				(219		)	(93		)	—			—
	Net change in cash and cash equivalents	312				—			(312		)	—			—
	Cash and cash equivalents at end of period	312				—			(312		)	—			—
	As Restated	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.				Subsidiaries			Subsidiaries						Total
	OPERATING ACTIVITIES:
	Net cash (used in) provided by operating activities	$	(29,406	)		$	80,977		$	(10,429	)	$	(4,037	)	$	37,105
	INVESTING ACTIVITIES:
	Purchase of fixed assets	—				(18,706		)	(369		)	—			(19,075		)
	Proceeds from sale of businesses	—				508			—			—			508
	Proceeds from the sale of assets	—				203			—			—			203
	(Payments to) proceeds from affiliates	—				(7,400		)	—			7,400			—
	Acquisition of businesses	—				(356,935		)	(2,500		)	—			(359,435		)
	Net cash (used in) provided by investing activities	—				(382,330		)	(2,869		)	7,400			(377,799		)
	FINANCING ACTIVITIES:
	Proceeds from issuance of common stock	3,231				—			—			—			3,231
	Windfall tax benefits associated with equity-based compensation	119				—			—			—			119
	Payment of contingent consideration accrued at acquisition date	—				(1,675		)	—			—			(1,675		)
	Proceeds from issuance of debt	817,525				—			—			—			817,525
	Borrowings under revolving credit facility	27,000				—			—			—			27,000
	Intercompany dividend	—				—			(2,300		)	2,300			—
	Repayment of long-term debt	(610,182		)		—			—			—			(610,182		)
	Debt issuance costs	(15,187		)		—			—			—			(15,187		)
Investment in affiliate	—				—			5,000			(5,000		)	—
Minority interest capital contribution	—				—			1,600			—			1,600
Majority interest capital contribution	—				—			2,400			(2,400		)	—
Distribution to minority interests	—				—			(750		)	—			(750		)
Distribution to majority interests	—				—			(1,737		)	1,737			—
Other	(889		)		(28		)	(165		)	—			(1,082		)
Net payments related to intercompany financing	(302,963		)		303,056			(93		)	—			—
Net cash provided by (used in) financing activities	(81,346		)		301,353			3,955			(3,363		)	220,599
Net change in cash and cash equivalents	(110,752		)		—			(9,343		)	—			(120,095		)
Cash and cash equivalents at beginning of period	166,140				—			40,912			—			207,052
Cash and cash equivalents at end of period	$	55,388			$	—		$	31,569		$	—		$	86,957
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2012
(In thousands)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(18,089	)		$	138,316		$	5,741		$	—		$	125,968
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(11,609		)	(170		)	—			(11,779		)
Proceeds from sale of businesses	—				9,220			—			—			9,220
Acquisition of businesses	—				(22,335		)	—			—			(22,335		)
Net cash used in investing activities	—				(24,724		)	(170		)	—			(24,894		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,980				—			—			—			3,980
Windfall tax benefits associated with equity-based compensation	88				—			—			—			88
Repayment of long-term debt	(52,943		)		—			—			—			(52,943		)
Debt issuance costs	(4,125		)		—			—			—			(4,125		)
Repurchase of common stock	(4,974		)		—			—			—			(4,974		)
Repayment of capital lease obligations	(135		)		—			—			—			(135		)
Other	4,673				(28		)	(5,470		)	—			(825		)
Net payments related to intercompany financing	113,564				(113,564		)	—			—			—
Net cash provided by (used in) financing activities	60,128				(113,592		)	(5,470		)	—			(58,934		)
Net change in cash and cash equivalents	42,039				—			101			—			42,140
Cash and cash equivalents at beginning of period	124,101				—			40,811			—			164,912
Cash and cash equivalents at end of period	$	166,140			$	—		$	40,912		$	—		$	207,052
Condensed Consolidating Statement of Cash Flows
For the Year Ended December 31, 2011
(In thousands)
	Gentiva Health				Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.				Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(46,730	)		$	51,221		$	650		$	—		$	5,141
INVESTING ACTIVITIES:
Purchase of fixed assets	—				(19,053		)	(178		)	—			(19,231		)
Proceeds from sale of businesses	—				146,261			54			—			146,315
Acquisition of businesses	—				(320		)	—			—			(320		)
Net cash provided by (used in) investing activities	—				126,888			(124		)	—			126,764
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	7,901				—			—			—			7,901
Windfall tax benefits associated with equity-based compensation	192				—			—			—			192
Repayment of long-term debt	(63,438		)		—			—			—			(63,438		)
Debt issuance costs	(15,460		)		—			—			—			(15,460		)
Repayment of capital lease obligations	(267		)		—			—			—			(267		)
Other	—				(22		)	(651		)	—			(673		)
Net payments related to intercompany financing	178,087				(178,087		)	—			—			—
Net cash provided by (used in) financing activities	107,015				(178,109		)	(651		)	—			(71,745		)
Net change in cash and cash equivalents	60,285				—			(125		)	—			60,160
Cash and cash equivalents at beginning of period	63,816				—			40,936			—			104,752
Cash and cash equivalents at end of period	$	124,101			$	—		$	40,811		$	—		$	164,912

Quarterly_Financial_Informatio1

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of quarterly financial information	'
	(in thousands, except per share amounts)
	Year ended December 31, 2013 (As Reported)	First					Second				Third					Fourth
		Quarter					Quarter				Quarter					Quarter
	Net revenues	$	415,591				$	414,424			$	410,492				$	486,137
	Gross profit	194,018					195,477				190,014					204,955
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	(212,472		)	(2	)	11,392				6,852					(443,844		)	-2
	(Loss) net income attributable to Gentiva shareholders (1)	(207,177		)	(2	)	6,347				3,720					(401,884		)	-2
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	(6.73	)			$	0.21			$	0.12				$	(11.46	)
	Diluted	$	(6.73	)			$	0.2			$	0.12				$	(11.46	)
	Weighted average shares outstanding:
	Basic	30,785					30,941				31,037					35,054
	Diluted	30,785					31,239				31,532					35,054
	Year ended December 31, 2013 (Restatement and Revision Adjustments)	First					Second				Third					Fourth
		Quarter (Revised)					Quarter (Revised)				Quarter (Revised)					Quarter (Restated)
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	13,648					(351		)		(258		)			(19,494		)
	(Loss) net income attributable to Gentiva shareholders (1)	13,039					(213		)		(157		)			(18,736		)
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	0.42				$	(0.01	)		$	—				$	(0.54	)
	Diluted	$	0.42				$	—			$	(0.01	)			$	(0.54	)
	Year ended December 31, 2013 (As Restated and Revised)	First					Second				Third					Fourth
		Quarter (Revised)					Quarter (Revised)				Quarter (Revised)					Quarter (Restated)
	Net revenues	$	415,591				$	414,424			$	410,492				$	486,137
	Gross profit	194,018					195,477				190,014					204,955
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix	(198,824		)	(2	)	11,041				6,594					(463,338		)	-2
	(Loss) net income attributable to Gentiva shareholders (1)	(194,138		)	(2	)	6,134				3,563					(420,620		)	-2
	Earnings Per Share:
	Net (loss) income attributable to Gentiva shareholders:
	Basic	$	(6.31	)			$	0.2			$	0.12				$	(12.00	)
	Diluted	$	(6.31	)			$	0.2			$	0.11				$	(12.00	)
	Weighted average shares outstanding:
	Basic	30,785					30,941				31,037					35,054
	Diluted	30,785					31,239				31,532					35,054
	Year ended December 31, 2012	First					Second				Third					Fourth
		Quarter					Quarter				Quarter					Quarter
	Net revenues	$	435,652				$	427,691			$	424,444				$	425,017
	Gross profit	202,791					204,954				200,555					195,763
	Income (loss) before income taxes and equity in net earnings (loss) of CareCentrix	7,582					23,818			-3	(2,678		)	(2	)	18,510			-3
	Net income (loss) attributable to Gentiva shareholders (1)	4,840					13,909			-3	(523		)	(2	)	8,570			(3),(4)
	Earnings Per Share:
	Net income (loss) attributable to Gentiva shareholders:
	Basic	$	0.16				$	0.46			$	(0.02	)			$	0.28
	Diluted	$	0.16				$	0.46			$	(0.02	)			$	0.28
	Weighted average shares outstanding:
	Basic	30,724					30,338				30,423					30,548
	Diluted	30,959					30,446				30,423					30,891
	(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):
		First				Second				Third				Fourth
		Quarter				Quarter				Quarter				Quarter
	Year ended December 31, 2013	$	141			$	744			$	1,699			$	24,955
	Year ended December 31, 2012	$	5,391			$	25			$	53			$	201

Background_and_Basis_of_Presen2

Background and Basis of Presentation Background and Basis of Presentation (Details) (USD $)	12 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Oct. 18, 2013	Oct. 18, 2013	Sep. 30, 2013	Aug. 23, 2013	Apr. 30, 2013	Aug. 31, 2012	Aug. 31, 2012	Jul. 22, 2012	Apr. 29, 2011
		Harden Healthcare Holdings Inc. [Member]	Harden Healthcare Holdings Inc. [Member]	Appalachian Regional Health Systems [Member]	Wake Forest Baptist Health Care at Home, LLC [Member]	Hope Hospice Inc [Member]	Family Home Care [Member]	North Mississippi Hospice [Member]	Advocate Hospice Llc [Member]	Odyssey HealthCare of Augusta, LLC [Member]
			UNITED STATES	NORTH CAROLINA	NORTH CAROLINA	INDIANA	WASHINGTON & IDAHO [Domain]	MISSISSIPPI	INDIANA	GEORGIA
Significant Acquisitions and Disposals [Line Items]	'	'	'	'	'	'	'	'	'	'
Business Acquisition, Name of Acquired Entity	'	'	'Harden Healthcare Holdings, Inc	'Appalachian Regional Health Systems	'Wake Forest Baptist Health Care at Home, LLC	'Hope Hospice, Inc.	'Family Home Care Corporation	'North Mississippi Hospice	'Advocate Hospice	'Odyssey HealthCare of Augusta, LLC
Business Acquisition, Effective Date of Acquisition	'	'	18-Oct-13	30-Sep-13	23-Aug-13	30-Apr-13	31-Aug-12	31-Aug-12	22-Jul-12	29-Apr-11
Purchase price	$6.10	$426.80	$426.80	$2.70	$2.40	$1	$12.30	$4.70	$5.50	$0.30

Background_and_Basis_of_Presen3

Background and Basis of Presentation (Details 2) (USD $)	0 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2012	31-May-12	Jun. 30, 2012	Dec. 31, 2011
	Banner Health [Member]	Healthcare Partners [Member]	Home Health and Hospice [Member]	Home Health certain Utah Michigan Nevada and Brookly NY Branches [Member]
			LOUISIANA
Significant Acquisitions and Disposals [Line Items]	'	'	'	'
Total consideration from sale of business	$3.50	$0.30	$6.40	$1.60

Background_and_Basis_of_Presen4

Background and Basis of Presentation (Details 3) (Discontinued Operations [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Oct. 14, 2011	Sep. 10, 2011
	Homemaker Services Agency [Member]	Rehab Without Walls [Member]
Significant Acquisitions and Disposals [Line Items]	'	'
Total consideration from sale of business	$2.40	$9.80

Background_and_Basis_of_Presen5

Background and Basis of Presentation (Details Textual) (USD $)	12 Months Ended		0 Months Ended				0 Months Ended
	Dec. 31, 2013	Dec. 31, 2011	Oct. 18, 2013	Oct. 18, 2013	Oct. 18, 2013	Oct. 18, 2013	Oct. 18, 2013
			Harden Healthcare Holdings Inc. [Member]	Term Loan B [Member]	Term Loan C [Member]	Revolving Credit Facility [Member]	UNITED STATES
							Harden Healthcare Holdings Inc. [Member]
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'
Purchase price	$6,100,000	'	$426,800,000	'	'	'	$426,800,000
Cost of acquired entity, cash paid	'	'	365,000,000	'	'	'	'
Issuance of stock in connection with Harden acquisition, value	53,750,000	'	53,800,000	'	'	'	'
Contingent consideration arrangements, range of outcomes, value, high	'	'	9,500,000	'	'	'	'
Contingent consideration, liability	'	'	8,100,000	'	'	'	'
Debt instrument, face amount	'	'	'	670,000,000	155,000,000	'	'
Line of credit facility, maximum borrowing capacity	'	'	'	'	'	100,000,000	'
Number of other acquisitions completed	3	'	'	'	'	'	'
Accumulated and unpaid dividends on the preferred shares	'	8,600,000	'	'	'	'	'
Equity method investment, realized gain on disposal	'	$67,100,000	'	'	'	'	'

Restatement_and_Revision_of_Pr2

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Intangible assets, net	$253,727	$190,725	'	'
Goodwill	383,487	656,364	641,669	'
Assets	1,253,468	1,508,046	1,527,440	'
Deferred tax liabilities, net	8,483	41,017	'	'
Accumulated deficit	-758,136	-153,075	'	'
Total Gentiva shareholders' equity	-310,876	231,422	'	'
Total Equity	-308,001	232,960	200,791	637,029
Liabilities and Equity	1,253,468	1,508,046	'	'
Scenario, Previously Reported [Member]	'	'	'	'
Intangible assets, net	256,282	193,613	'	'
Goodwill	390,081	656,364	'	'
Assets	1,262,617	1,510,934	'	'
Deferred tax liabilities, net	9,825	42,165	'	'
Accumulated deficit	-750,329	-151,335	'	'
Total Gentiva shareholders' equity	-303,069	233,162	'	'
Total Equity	-300,194	234,700	202,531	638,232
Liabilities and Equity	1,262,617	1,510,934	'	'
Revision Adjustment [Member]	'	'	'	'
Intangible assets, net	'	-2,888	'	'
Goodwill	0	'	'	'
Assets	0	-2,888	'	'
Deferred tax liabilities, net	'	-1,148	'	'
Accumulated deficit	'	-1,740	'	'
Total Gentiva shareholders' equity	0	-1,740	'	'
Total Equity	0	-1,740	-1,740	-1,203
Liabilities and Equity	0	-2,888	'	'
Restatement Adjustment [Member]	'	'	'	'
Intangible assets, net	-2,555	'	'	'
Goodwill	-6,594	'	'	'
Assets	-9,149	'	'	'
Deferred tax liabilities, net	-1,342	'	'	'
Accumulated deficit	-7,807	'	'	'
Total Gentiva shareholders' equity	-7,807	'	'	'
Total Equity	-7,807	-1,740	'	'
Liabilities and Equity	($9,149)	'	'	'

Restatement_and_Revision_of_Pr3

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements (Details 2) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Selling, General and Administrative Expense

'

'

'

'

'

'

'

'

'

($706,227)

($655,766)

($731,299)

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

-643,300

-612,380

[1]

-19,132

[1]

-643,305

[1]

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix

-463,338

[2]

6,594

11,041

-198,824

[2]

18,510

[3]

-2,678

[2]

23,818

[3]

7,582

'

-644,527

47,232

-603,240

income tax benefit

'

'

'

'

'

'

'

'

'

39,953

-17,251

76,123

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-604,574

27,680

-458,736

Net (loss) income

-420,620

[2],[4]

3,563

[4]

6,134

[4]

-194,138

[2],[4]

8,570

[3],[4],[5]

-523

[2],[4]

13,909

[3],[4]

4,840

[4]

'

-604,574

27,680

-450,421

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-604,574

27,680

-450,899

Income (Loss) from Continuing Operations, Per Basic Share

'

'

'

'

'

'

'

'

'

($18.94)

$0.88

($15.14)

Earnings Per Share, Basic attributable to Gentiva shareholders

($12)

$0.12

$0.20

($6.31)

$0.28

($0.02)

$0.46

$0.16

'

($18.94)

$0.88

($14.86)

(Loss) income from continuing operations attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

($18.94)

$0.87

($15.14)

Earnings Per Share, Diluted

($12)

$0.11

$0.20

($6.31)

$0.28

($0.02)

$0.46

$0.16

'

($18.94)

$0.87

($14.86)

Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Selling, General and Administrative Expense

'

'

'

'

'

'

'

'

'

-701,716

'

-730,407

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-610,436

'

-643,305

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix

-443,844

6,852

11,392

-212,472

'

'

'

'

'

-638,072

'

-602,348

income tax benefit

'

'

'

'

'

'

'

'

'

39,565

'

75,768

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-598,507

'

-458,199

Net (loss) income

-401,884

3,720

6,347

-207,177

'

'

'

'

'

-598,507

'

-449,884

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-598,994

'

-450,525

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-598,507

'

-450,362

Income (Loss) from Continuing Operations, Per Basic Share

'

'

'

'

'

'

'

'

'

($18.75)

'

($15.13)

Earnings Per Share, Basic attributable to Gentiva shareholders

($11.46)

$0.12

$0.21

($6.73)

'

'

'

'

'

($18.75)

'

($14.85)

(Loss) income from continuing operations attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

($18.75)

'

($15.13)

Earnings Per Share, Diluted

($11.46)

$0.12

$0.20

($6.73)

'

'

'

'

'

($18.75)

'

($14.85)

Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Selling, General and Administrative Expense

'

'

'

'

'

'

'

'

'

-4,511

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-1,944

'

'

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix

-19,494

-258

-351

13,648

'

'

'

'

'

-6,455

'

'

income tax benefit

'

'

'

'

'

'

'

'

'

388

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-6,067

'

'

Net (loss) income

-18,736

-157

-213

13,039

'

'

'

'

'

-6,067

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-6,067

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-6,067

'

'

Income (Loss) from Continuing Operations, Per Basic Share

'

'

'

'

'

'

'

'

'

($0.19)

'

'

Earnings Per Share, Basic attributable to Gentiva shareholders

($0.54)

$0

($0.01)

$0.42

'

'

'

'

'

($0.19)

'

'

(Loss) income from continuing operations attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

($0.19)

'

'

Earnings Per Share, Diluted

($0.54)

($0.01)

$0

$0.42

'

'

'

'

'

($0.19)

'

'

Revision Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Selling, General and Administrative Expense

'

'

'

'

'

'

'

'

'

0

'

-892

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

'

-892

income tax benefit

'

'

'

'

'

'

'

'

'

0

'

355

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

0

'

-537

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-537

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

0

'

-537

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

$0

'

($537)

Income (Loss) from Continuing Operations, Per Basic Share

'

'

'

'

'

'

'

'

'

'

'

($0.01)

Earnings Per Share, Basic attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

'

'

($0.01)

(Loss) income from continuing operations attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

'

'

($0.01)

Earnings Per Share, Diluted

'

'

'

'

'

'

'

'

'

'

'

($0.01)

[1]

The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.

[2]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[3]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[4]

(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):B FirstQuarterB SecondQuarterB ThirdQuarterB FourthQuarterYear ended DecemberB 31, 2013$141B $744B $1,699B $24,955Year ended DecemberB 31, 2012$5,391B $25B $53B $201

[5]

In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

Restatement_and_Revision_of_Pr4

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements (Details 3) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Total Equity

($308,001)

'

'

'

$232,960

'

'

'

($308,001)

$232,960

$200,791

$637,029

Net (loss) income

-420,620

[1],[2]

3,563

[1]

6,134

[1]

-194,138

[1],[2]

8,570

[1],[3],[4]

-523

[1],[2]

13,909

[1],[3]

4,840

[1]

-604,574

27,680

-450,421

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

-604,574

27,680

-450,899

'

Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

-300,194

'

'

'

234,700

'

'

'

-300,194

234,700

202,531

638,232

Net (loss) income

-401,884

3,720

6,347

-207,177

'

'

'

'

-598,507

'

-449,884

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

-598,507

'

-450,362

'

Revision Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

0

'

'

'

-1,740

'

'

'

0

-1,740

-1,740

-1,203

Net (loss) income

'

'

'

'

'

'

'

'

'

'

-537

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

0

'

-537

'

Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

-7,807

'

'

'

-1,740

'

'

'

-7,807

-1,740

'

'

Net (loss) income

-18,736

-157

-213

13,039

'

'

'

'

-6,067

'

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

-6,067

'

'

'

Retained Earnings (Deficit) [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

-758,136

'

'

'

-153,075

'

'

'

-758,136

-153,075

-179,871

271,191

Net (loss) income

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

'

Retained Earnings (Deficit) [Member] | Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

-750,329

'

'

'

-151,335

'

'

'

-750,329

-151,335

-178,131

272,394

Net (loss) income

'

'

'

'

'

'

'

'

-598,994

'

-450,525

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

-598,994

'

-450,525

'

Retained Earnings (Deficit) [Member] | Revision Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

'

'

'

'

'

'

'

'

'

'

-1,740

-1,203

Net (loss) income

'

'

'

'

'

'

'

'

'

'

-537

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

'

-537

'

Retained Earnings (Deficit) [Member] | Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Total Equity

-7,807

'

'

'

-1,740

'

'

'

-7,807

-1,740

'

'

Net (loss) income

'

'

'

'

'

'

'

'

-6,067

'

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

($6,067)

'

'

'

[1]

(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):B FirstQuarterB SecondQuarterB ThirdQuarterB FourthQuarterYear ended DecemberB 31, 2013$141B $744B $1,699B $24,955Year ended DecemberB 31, 2012$5,391B $25B $53B $201

[2]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[3]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[4]

In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

Restatement_and_Revision_of_Pr5

Restatement and Revision of Previously Reported Consolidated Financial Statements Restatement and Revision of Previously Reported Consolidated Financial Statements (Details4) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Net (loss) income

($420,620)

[1],[2]

$3,563

[1]

$6,134

[1]

($194,138)

[1],[2]

$8,570

[1],[3],[4]

($523)

[1],[2]

$13,909

[1],[3]

$4,840

[1]

($604,574)

$27,680

($450,421)

Depreciation and amortization

'

'

'

'

'

'

'

'

24,621

26,580

31,032

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

612,380

19,132

643,305

Deferred income tax (benefit) expense

'

'

'

'

'

'

'

'

-37,048

23,513

-86,367

Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-401,884

3,720

6,347

-207,177

'

'

'

'

-598,507

'

-449,884

Depreciation and amortization

'

'

'

'

'

'

'

'

20,110

'

30,140

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

610,436

'

'

Deferred income tax (benefit) expense

'

'

'

'

'

'

'

'

-36,660

'

-86,012

Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-18,736

-157

-213

13,039

'

'

'

'

-6,067

'

'

Depreciation and amortization

'

'

'

'

'

'

'

'

4,511

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

1,944

'

'

Deferred income tax (benefit) expense

'

'

'

'

'

'

'

'

-388

'

'

Revision Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

'

'

-537

Depreciation and amortization

'

'

'

'

'

'

'

'

'

'

892

Deferred income tax (benefit) expense

'

'

'

'

'

'

'

'

'

'

($355)

[1]

(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):B FirstQuarterB SecondQuarterB ThirdQuarterB FourthQuarterYear ended DecemberB 31, 2013$141B $744B $1,699B $24,955Year ended DecemberB 31, 2012$5,391B $25B $53B $201

[2]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[3]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[4]

In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Textual) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Continuing Operations [Member]

Continuing Operations [Member]

Continuing Operations [Member]

Discontinued Operations [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Non-profit hospice [Member]

Non-profit hospice [Member]

CareCentrix [Member]

CareCentrix [Member]

PRRB Appeal [Member]

PRRB Appeal [Member]

Claims incurred prior to March 15, 2002 [Member]

Claims incurred after March 15, 2002 [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Home Health [Member]

Home Health [Member]

Schedule of Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidation for ownership percentage

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

$43,864,000

$37,444,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Hospice programs exceeding Medicare Payment Cap

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Medicare Hospice Cap (income) expense

'

'

'

'

'

'

'

-4,600,000

4,400,000

4,300,000

'

'

'

'

'

'

'

'

'

'

Medicare Hospice Cap liabilities

'

'

'

'

'

'

'

6,500,000

15,900,000

'

'

'

'

'

'

'

'

'

'

'

Accounts Receivable Small Balance Write-off Limit

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Provision for doubtful accounts

6,730,000

4,066,000

8,541,000

6,700,000

4,100,000

8,400,000

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts receivables, allowance for doubtful accounts

10,680,000

8,777,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Workers compensation and professional and general liability expenses

'

'

'

33,900,000

21,000,000

15,100,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Threshold for establishing case loss reserves on open claims

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Malpractice insurance, deductible

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

1,000,000

'

'

Malpractice Insurance, Annual Coverage Limit

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Health and welfare benefits stop loss coverage

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee health and welfare expenses

'

'

'

86,600,000

87,500,000

93,000,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Director's and Officer liability insurance deductible

60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating funds

'

'

'

'

'

'

'

'

'

'

5,500,000

5,400,000

'

'

'

'

'

'

'

'

Dividend income

0

0

8,590,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity method investment, realized gain on disposal

'

'

67,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost method investments

'

'

'

'

'

'

'

'

'

'

'

'

900,000

900,000

'

'

'

'

'

'

Assets held in rabbi trust

34,682,000

27,739,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance costs

28,300,000

44,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred debt issuance costs, write off

16,085,000

461,000

3,559,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,100,000

500,000

Capitalized debt issuance costs

24,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Medicaid daily nursing home rate

'

'

'

'

'

'

'

95.00%

'

'

'

'

'

'

'

'

'

'

'

'

Patient service revenue adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($4,000,000)

($4,000,000)

'

'

'

'

[1]

For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Companybs combined common and preferred ownership of CareCentrix.

Acquisitions_and_Dispositions_1

Acquisitions and Dispositions (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 18, 2013
In Thousands, unless otherwise specified				Harden Healthcare Holdings Inc. [Member]
Business Acquisition [Line Items]	'	'	'	'
Cash	'	'	'	$10,203
Accounts receivable	'	'	'	46,195
Deferred Tax Assets Current	'	'	'	13,589
Prepaid expense and other current assets	'	'	'	1,890
Fixed assets, net	'	'	'	9,476
Identifiable intangible assets	'	'	'	71,215
Goodwill	383,487	656,364	641,669	331,167
Other assets	'	'	'	2,889
Total assets acquired	'	'	'	486,624
Accounts payable and accrued liabilities	'	'	'	58,563
Other current liabilities	'	'	'	8,720
Deferred tax liabilities noncurrent	'	'	'	590
Total liabilities assumed	'	'	'	67,873
Net assets acquired	'	'	'	$418,751

Acquisitions_and_Dispositions_2

Acquisitions and Dispositions (Details 1) (USD $)

12 Months Ended

0 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Trade Names [Member]

Trade Names [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Medicare licenses and certificates of need [Member]

Home Health [Member]

Home Health [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Community Care [Member]

Community Care [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Trade Names [Member]

Covenants not to compete [Member]

Medicare licenses and certificates of need [Member]

Trade Names [Member]

Covenants not to compete [Member]

Medicare licenses and certificates of need [Member]

Trade Names [Member]

Covenants not to compete [Member]

Medicare licenses and certificates of need [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangibles

'

'

'

'

'

$13,772

'

'

$2,018

'

'

'

'

$1,052

$490

'

'

$798

$499

'

'

$11,922

$1,029

'

Indefinite-Lived Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

55,425

'

'

'

18,001

'

'

'

11,413

'

'

'

26,011

Identifiable intangible assets

'

'

'

'

$71,215

'

'

'

'

'

'

'

$19,543

'

'

'

$12,710

'

'

'

$38,962

'

'

'

Useful life

'5 years

'10 years

'2 years

'5 years

'

'

'5 years

'10 years

'

'2 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisitions_and_Dispositions_3

Acquisitions and Dispositions (Details 2) (Harden Healthcare Holdings Inc. [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Harden Healthcare Holdings Inc. [Member]	'	'
Business Acquisition [Line Items]	'	'
Net revenues	$2,105,562	$2,188,915
Net (loss) income attributable to Gentiva shareholders	($618,592)	$40,748
Earnings per common share, Basic	($17.29)	$1.15
Earnings per common share, Diluted	($17.29)	$1.15
Weighted average shares outstanding, Basic	35,786	35,321
Weighted average shares outstanding, Diluted	35,786	35,499

Acquisitions_and_Dispositions_4

Acquisitions and Dispositions (Details 3) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'	'
Goodwill	$383,487	$656,364	$641,669
Series of Individually Immaterial Business Acquisitions [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Fixed assets, net	21	509	'
Identifiable intangible assets	3,062	9,205	'
Goodwill	2,871	14,695	'
Other assets	128	66	'
Total assets acquired	6,082	24,475	'
Accounts payable and accrued liabilities	1,444	1,955	'
Total liabilities assumed	1,444	1,955	'
Net assets acquired	$4,638	$22,520	'

Acquisitions_and_Dispositions_5

Acquisitions and Dispositions (Details 4) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified	Series of Individually Immaterial Business Acquisitions [Member]	Series of Individually Immaterial Business Acquisitions [Member]	Series of Individually Immaterial Business Acquisitions [Member]	Series of Individually Immaterial Business Acquisitions [Member]	Series of Individually Immaterial Business Acquisitions [Member]	Series of Individually Immaterial Business Acquisitions [Member]	Minimum [Member]	Minimum [Member]
			Covenants not to compete [Member]	Covenants not to compete [Member]	Medicare licenses and certificates of need [Member]	Medicare licenses and certificates of need [Member]	Covenants not to compete [Member]	Customer Relationships [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Finite-Lived Intangibles	'	'	$203	$0	'	'	'	'
Indefinite-Lived Intangible Assets	'	'	'	'	3,062	9,002	'	'
Identifiable intangible assets	$3,062	$9,205	'	'	'	'	'	'
Useful life	'	'	'5 years	'	'	'	'2 years	'5 years

Acquisitions_and_Dispositions_6

Acquisitions and Dispositions (Details 5) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011
In Thousands, unless otherwise specified			Home Health and Hospice [Member]	Home Health and Hospice [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Accounts receivable, net	'	'	$561	$526
Fixed assets, net	'	'	271	338
Disposal Group, Including Discontinued Operation, Intangible Assets, Net	'	'	1,356	1,356
Other assets	'	'	485	640
Total assets	'	'	2,673	2,860
Medicare liabilities	-23,894	-27,122	-86	-18
Other accrued Expenses	'	'	-405	-41
Total liabilities	'	'	-491	-59
Total	'	'	$2,182	$2,801

Acquisitions_and_Dispositions_7

Acquisitions and Dispositions (Details 6) (Homemaker Services Agency and Rehab Without Walls [Member], USD $)	Dec. 31, 2011
In Thousands, unless otherwise specified
Homemaker Services Agency and Rehab Without Walls [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Fixed assets, net	$183
Other assets	109
Total non-current assets	292
Total assets	$292

Acquisitions_and_Dispositions_8

Acquisitions and Dispositions (Details 7) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Discontinued operations, net of tax	$0	$0	$8,315
Homemaker Services Agency and Rehab Without Walls [Member]	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Net revenues	'	'	22,819
Income before income taxes	'	'	2,430
Gain on sale of business	'	'	11,475
Income tax expense	'	'	-5,590
Discontinued operations, net of tax	'	'	$8,315

Acquisitions_and_Dispositions_9

Acquisitions and Dispositions (Details Textual) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 30, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 18, 2013

Dec. 31, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Sep. 30, 2013

Aug. 23, 2013

Apr. 30, 2013

Aug. 31, 2012

Dec. 31, 2013

Aug. 31, 2012

Jul. 22, 2012

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2012

Apr. 29, 2011

Sep. 10, 2011

Oct. 14, 2011

Dec. 31, 2012

Aug. 23, 2013

Aug. 23, 2013

Banner Health [Member]

MP Healthcare Partners [Member]

Home Health [Member]

Home Health [Member]

Home Health [Member]

Home Health [Member]

Home Health and Hospice [Member]

Home Health and Hospice [Member]

Home Health and Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Community Care [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Appalachian Regional Health Systems [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Hope Hospice Inc [Member]

Family Home Care [Member]

North Mississippi Hospice [Member]

North Mississippi Hospice [Member]

Advocate Hospice Llc [Member]

Advocate Hospice Llc [Member]

Advocate Hospice Llc [Member]

Advocate Hospice Llc [Member]

Odyssey HealthCare of Augusta, LLC [Member]

Discontinued Operations [Member]

Discontinued Operations [Member]

Discontinued Operations [Member]

Cash [Member]

Other Assets [Member]

Louisiana [Member]

Louisiana [Member]

Louisiana [Member]

UNITED STATES

Home Health [Member]

Hospice [Member]

Community Care [Member]

NORTH CAROLINA

NORTH CAROLINA

INDIANA

WASHINGTON & IDAHO [Domain]

MISSISSIPPI

INDIANA

INDIANA

INDIANA

INDIANA

GEORGIA

Rehab Without Walls [Member]

Homemaker Services Agency [Member]

Homemaker Services Agency [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Branch

Branch

NORTH CAROLINA

NORTH CAROLINA

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Name of Acquired Entity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Harden Healthcare Holdings, Inc

'

'

'

'Appalachian Regional Health Systems

'Wake Forest Baptist Health Care at Home, LLC

'Hope Hospice, Inc.

'Family Home Care Corporation

'

'North Mississippi Hospice

'Advocate Hospice

'

'

'

'Odyssey HealthCare of Augusta, LLC

'

'

'

'

'

Business Acquisition, Effective Date of Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18-Oct-13

'

'

'

30-Sep-13

23-Aug-13

30-Apr-13

31-Aug-12

'

31-Aug-12

22-Jul-12

'

'

'

29-Apr-11

'

'

'

'

'

Purchase price

'

'

'

'

'

'

'

'

$6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$426,800,000

'

$426,800,000

'

'

'

$2,700,000

$2,400,000

$1,000,000

$12,300,000

'

$4,700,000

$5,500,000

'

'

'

$300,000

'

'

'

'

'

Cost of acquired entity, cash paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

365,000,000

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock in connection with Harden acquisition, value

'

'

'

'

'

'

'

'

53,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration arrangements, range of outcomes, value, high

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,500,000

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

Contingent consideration, liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,100,000

'

'

'

'

'

'

'

'

'

'

'

-1,900,000

'

'

-1,100,000

'

'

'

'

'

'

Change in Amount of Contingent Consideration, Liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-900,000

800,000

'

'

'

'

'

'

Goodwill

383,487,000

'

'

'

656,364,000

'

'

'

383,487,000

656,364,000

641,669,000

'

'

123,400,000

9,000,000

'

'

'

'

'

143,600,000

647,400,000

'

'

116,500,000

'

'

331,167,000

'

'

111,700,000

103,000,000

116,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition,Goodwill, Expected tax Deductible Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net revenues

486,137,000

410,492,000

414,424,000

415,591,000

425,017,000

424,444,000

427,691,000

435,652,000

1,726,644,000

1,712,804,000

1,798,778,000

'

'

965,848,000

948,019,000

1,012,566,000

'

'

'

'

715,190,000

764,785,000

786,212,000

'

45,606,000

0

0

'

92,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

-605,061,000

26,796,000

-451,062,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average cash interest rate on outstanding borrowings

7.70%

'

'

'

8.20%

'

'

'

7.70%

8.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Pro Forma, Effective Tax Rate

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Interest in Subsidiaries and Affiliates

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200,000

200,000

Escrow Fund Liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

Reduction in Escrow Fund Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

Payments for Previous Acquisition

'

'

'

'

'

'

'

'

1,675,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

1,500,000

'

'

'

'

'

'

'

Noncontrolling Interest, Ownership Percentage by Parent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dispositions [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total consideration from sale of business

'

'

'

'

'

'

'

'

'

'

'

3,500,000

300,000

'

'

'

'

'

'

6,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,800,000

2,400,000

'

'

'

Gain (loss) on sale of business

'

'

'

'

2,600,000

'

5,400,000

'

0

8,014,000

1,061,000

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of branches sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of businesses

'

'

'

'

'

'

'

'

508,000

9,220,000

146,315,000

'

'

'

'

'

'

'

5,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,200,000

2,000,000

'

'

'

Receivables from business dispositions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Escrow fund

'

'

'

'

10,600,000

'

'

'

'

10,600,000

10,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

400,000

'

'

'

Reduction in escrow fund receivable

'

'

'

'

'

'

'

'

'

$700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$300,000

'

'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Financial assets measured at fair value on a recurring basis	'	'	'
Assets held in rabbi trust	$34,682	$27,739	'
Level 3 [Member] | Accrued Liabilities [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	8,110	1,100	0
Recurring [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	58,377	81,824	'
Liabilities fair value	42,792	28,839	'
Recurring [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	23,695	54,085	'
Recurring [Member] | Accrued Liabilities [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	8,110	1,100	'
Recurring [Member] | Rabbi Trust [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	5,737	5,698	'
Recurring [Member] | Rabbi Trust [Member] | Mutual funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	28,945	22,041	'
Recurring [Member] | Level 1 [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	58,377	81,824	'
Liabilities fair value	34,682	27,739	'
Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	23,695	54,085	'
Recurring [Member] | Level 1 [Member] | Payables To Plan Participant [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	34,682	27,739	'
Recurring [Member] | Level 1 [Member] | Accrued Liabilities [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	0	0	'
Recurring [Member] | Level 1 [Member] | Rabbi Trust [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	5,737	5,698	'
Recurring [Member] | Level 1 [Member] | Rabbi Trust [Member] | Mutual funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	28,945	22,041	'
Recurring [Member] | Level 2 [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Liabilities fair value	0	0	'
Recurring [Member] | Level 2 [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Recurring [Member] | Level 2 [Member] | Payables To Plan Participant [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	0	0	'
Recurring [Member] | Level 2 [Member] | Accrued Liabilities [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	0	0	'
Recurring [Member] | Level 2 [Member] | Rabbi Trust [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Recurring [Member] | Level 2 [Member] | Rabbi Trust [Member] | Mutual funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Recurring [Member] | Level 3 [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Liabilities fair value	8,110	1,100	'
Recurring [Member] | Level 3 [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Recurring [Member] | Level 3 [Member] | Payables To Plan Participant [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	0	0	'
Recurring [Member] | Level 3 [Member] | Accrued Liabilities [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Liabilities fair value	8,110	1,100	'
Recurring [Member] | Level 3 [Member] | Rabbi Trust [Member] | Money Market Funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	0	0	'
Recurring [Member] | Level 3 [Member] | Rabbi Trust [Member] | Mutual funds [Member]	'	'	'
Financial assets measured at fair value on a recurring basis	'	'	'
Assets fair value	$0	$0	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2013		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
		Fair Value, Inputs, Level 3 [Member]		Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]
				Advocate Hospice Llc [Member]	Advocate Hospice Llc [Member]	Harden Healthcare Holdings Inc. [Member]	Accrued Liabilities [Member]	Accrued Liabilities [Member]	Accrued Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'		'	'	'	'	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	'	'		'	'	'	$8,110,000	$1,100,000	$0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	'	'		900,000	1,100,000	8,081,000	'	'	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	'	-2,062,000		'	'	'	'	'	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	'	91,000	[1]	'	'	'	'	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	'	'		'	'	'	8,110,000	1,100,000	0
Sensitivity Analysis of Fair Value, Transferor's Interests in Transferred Financial Assets, Impact of 20 Percent Adverse Change in Discount Rate	$200,000	'		'	'	'	'	'	'
[1]	(1)Accretion of the present value of the contingent liability is recorded in interest expense and other on the Company's consolidated statements of comprehensive (loss) income. A 1 percent change in the discount rate would have an impact on the fair value of the contingent liability of approximately $0.2 million.

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Carrying Amount [Member]	'	'
Assets:	'	'
Note receivable from CareCentrix	$25,000	$25,000
Seller financing note receivable from CareCentrix	3,471	3,471
Liabilities:	'	'
Long-term obligation	1,177,000	935,182
Estimate Fair Value [Member]	'	'
Assets:	'	'
Note receivable from CareCentrix	26,403	25,220
Seller financing note receivable from CareCentrix	3,471	3,471
Liabilities:	'	'
Long-term obligation	$1,183,863	$912,818

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments (Details Textual) (Details) (USD $)	6 Months Ended
	Jun. 30, 2011	Dec. 31, 2013	Nov. 15, 2011	Mar. 09, 2011
			Interest Rate Cap [Member]	Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'
Derivative, notional amount	'	'	$220,000,000	$300,000,000
Loss on derivative	300,000	'	'	'
Derivative Asset	'	$0	'	'

Net_Revenues_and_Accounts_Rece2

Net Revenues and Accounts Receivable (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	$486,137	$410,492	$414,424	$415,591	$425,017	$424,444	$427,691	$435,652	$1,726,644	$1,712,804	$1,798,778
Home Health [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	965,800	948,000	1,012,600
Hospice [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	715,200	764,800	786,200
Medicare [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	1,455,200	1,464,600	1,528,300
Medicare [Member] | Home Health [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	787,300	749,000	799,200
Medicare [Member] | Hospice [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	667,900	715,500	729,100
Medicaid and Local Government [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	116,600	74,400	83,100
Medicaid and Local Government [Member] | Home Health [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	43,800	46,800	52,300
Medicaid and Local Government [Member] | Hospice [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	28,300	27,700	30,800
Commercial Insurance and Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	154,800	173,800	187,400
Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	59,600	85,200	77,700
Commercial Insurance and Other [Member] | Commercial Insurance Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	95,200	88,600	109,700
Commercial Insurance and Other [Member] | Home Health [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	59,600	85,200	77,700
Commercial Insurance and Other [Member] | Home Health [Member] | Commercial Insurance Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	75,100	67,000	83,400
Commercial Insurance and Other [Member] | Hospice [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	0	0	0
Commercial Insurance and Other [Member] | Hospice [Member] | Commercial Insurance Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Net revenues by major payer classification	'	'	'	'	'	'	'	'	'	'	'
Net revenues	'	'	'	'	'	'	'	'	$19,000	$21,600	$26,300

Net_Revenues_and_Accounts_Rece3

Net Revenues and Accounts Receivable (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	$300,585	$259,857
Less: Allowance for doubtful accounts	-10,680	-8,777
Net Accounts Receivable	289,905	251,080
Medicare [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	214,366	192,541
Medicaid and Local Government [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	48,183	31,259
Commercial Insurance and Other [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	$38,036	$36,057

Net_Revenues_and_Accounts_Rece4

Net Revenues and Accounts Receivable (Details Textual) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Medicare Cap Year 2013 [Member]

Medicare Cap Year 2014 [Member]

Prior Year Medicare Cap Settlement [Member]

Prior Year Medicare Cap Settlement [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

PRRB Appeal [Member]

PRRB Appeal [Member]

Eligibility Review [Member]

Eligibility Review [Member]

Schedule of Health Care Revenue Adjustment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Medicare Hospice Cap (income) expense

'

'

$1,900,000

$200,000

($6,100,000)

($1,500,000)

'

'

($4,600,000)

$4,400,000

$4,300,000

'

'

Hospice programs exceeding Medicare Payment Cap

'

'

5

2

'

'

'

'

2

'

'

'

'

Medicare Hospice Cap liabilities

'

'

'

'

'

'

'

'

6,500,000

15,900,000

'

'

'

Commercials Insurance self pay accounts receivables related to patient

2,400,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

Patient service revenue adjustments

'

'

'

'

'

'

-4,000,000

-4,000,000

'

'

'

12,000,000

4,900,000

Allowance for credit losses

$0

$0

'

'

'

'

'

'

'

'

'

'

'

Investment_in_and_Notes_Receiv1

Investment in and Notes Receivable from CareCentrix (Details Textual) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Aug. 24, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'	'
Accumulated and unpaid dividends on the preferred shares	'	'	'	'	$8,600,000
Equity method investment, realized gain on disposal	'	'	'	'	67,100,000
Escrow fund receivable	'	10,600,000	'	10,600,000	10,600,000
Promissory note	'	'	25,000,000	'	'
Investment maturity date	19-Mar-17	'	19-Mar-17	'	'
Increase (decrease) in notes receivable	'	6,500,000	'	'	'
Fixed interest rate on promissory note	'	'	10.00%	'	'
Investment income, nonoperating	'	'	2,500,000	2,500,000	2,500,000
Reduction in escrow fund receivable	'	'	'	700,000	'
Seller financing note receivable	9,900,000	3,400,000	3,400,000	3,400,000	'
Interest rate on promissory note, thereafter	18.00%	'	'	'	'
Equity in net (loss) earnings of CareCentrix	'	'	0	-2,301,000	68,381,000
Allowance for credit losses	'	0	0	0	'
CareCentrix [Member]	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'	'
Cost method investments	'	$900,000	$900,000	$900,000	'

Fixed_Assets_Net_Details

Fixed Assets, Net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	$137,409	$124,064
Less accumulated depreciation	-88,034	-82,650
Fixed assets, net	49,375	41,414
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	768	1,451
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'30 years	'
Fixed assets, gross	4,587	6,107
Computer Equipment and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	70,131	65,718
Computer Equipment and Software [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'3 years	'
Computer Equipment and Software [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'7 years	'
Home Medical Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'4 years	'
Fixed assets, gross	5,356	5,179
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'5 years	'
Fixed assets, gross	35,028	24,556
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	18,121	18,250
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'5 years	'
Fixed assets, gross	2,153	2,692
Automobiles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, useful lives	'5 years	'
Fixed assets, gross	$1,265	$111

Fixed_Assets_Net_Details_Textu

Fixed Assets, Net (Details Textual) (USD $)	12 Months Ended			3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2011
				Software Development [Member]	Software Development [Member]	Software Development [Member]	Real Estate [Member]	Real Estate [Member]
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'
Depreciation	$15,300,000	$16,600,000	$17,200,000	'	'	'	'	'
Deferred software development cost	1,500,000	2,000,000	'	'	'	'	'	'
Asset impairment charges	$612,380,000	$19,132,000	$643,305,000	$1,600,000	$1,600,000	$40,300,000	$1,900,000	$900,000

Goodwill_and_Identifiable_Inta2

Goodwill and Identifiable Intangible Assets (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

In Thousands, unless otherwise specified

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Medicare licenses and certificates of need [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Trade Names [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Trade Names [Member]

Amortized intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

'

'

'

'

'

'

'

'

$8,735

$2,888

$714

$0

$8,021

$2,888

$0

$0

$19,369

$17,352

$2,157

$1,667

$16,183

$15,685

$1,029

$0

$28,106

$28,106

$27,196

$27,196

$910

$910

$0

$0

$48,717

$34,945

$19,267

$18,215

$17,528

$16,730

$11,922

$0

'

'

'

'

'

'

Less: accumulated amortization

'

'

'

'

'

'

'

'

-7,400

-2,888

-588

0

-6,812

-2,888

0

0

-17,364

-15,562

-1,553

-1,449

-15,720

-14,113

-91

0

-20,478

-18,041

-19,997

-17,651

-481

-390

0

0

-15,982

-15,402

-11,992

-11,794

-3,763

-3,608

-227

0

'

'

'

'

'

'

Finite Lived Intangible Assets, Accumulated Impairment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-27

-27

-27

-27

0

0

0

0

-19,543

-19,543

-6,421

-6,421

-13,122

-13,122

0

0

'

'

'

'

'

'

Finite-Lived Intangible Assets, Net

24,133

11,828

8,756

9,736

2,744

2,092

12,633

0

1,335

0

126

0

1,209

0

0

0

2,005

1,790

604

218

463

1,572

938

0

7,601

10,038

7,172

9,518

429

520

0

0

13,192

0

854

0

643

0

11,695

0

'

'

'

'

'

'

Finite-Lived Intangible Asset, useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'10 years

'10 years

'2 years

'5 years

'5 years

Indefinite-lived intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-Lived Intangible Assets

'

'

'

'

'

'

'

'

376,729

324,088

245,086

225,227

105,632

98,861

26,011

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite Lived Intangible Assets, Accumulated Impairment

'

'

'

'

'

'

'

'

-147,135

-145,191

-144,672

-144,672

-2,463

-519

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite Lived Intangible Assets, Net

'

'

'

'

'

'

'

'

229,594

178,897

100,414

80,555

103,169

98,342

26,011

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, net

$253,727

$190,725

$109,170

$90,291

$105,913

$100,434

$38,644

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill_and_Identifiable_Inta3

Goodwill and Identifiable Intangible Assets (Details 1) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill [Roll Forward]	'	'	'	'
Goodwill, Gross	'	$1,447,440	$1,113,401	$1,098,706
Goodwill, Impaired, Accumulated Impairment Loss	'	-1,063,953	-457,037	-457,037
Goodwill	'	383,487	656,364	641,669
Goodwill, Acquired During Period	'	334,039	14,695	'
Goodwill, Impairment Loss	-207,200	-606,916	'	'
Home Health [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, Gross	'	386,719	272,389	267,058
Goodwill, Impaired, Accumulated Impairment Loss	'	-263,370	-263,370	-263,370
Goodwill	'	123,400	9,000	'
Goodwill, Acquired During Period	'	114,330	5,331	'
Goodwill, Impairment Loss	'	0	'	'
Hospice [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, Gross	'	944,187	841,012	831,648
Goodwill, Impaired, Accumulated Impairment Loss	'	-800,583	-193,667	-193,667
Goodwill	'	143,600	647,400	'
Goodwill, Acquired During Period	'	103,175	9,364	'
Goodwill, Impairment Loss	-207,200	-606,916	'	-457,000
Community Care [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, Gross	'	116,534	0	0
Goodwill	'	116,500	'	'
Goodwill, Acquired During Period	'	$116,534	$0	'

Goodwill_and_Identifiable_Inta4

Goodwill and Identifiable Intangible Assets (Details Textual) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Dec. 31, 2013

Dec. 31, 2011

Home Health [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Impairment of Intangible Assets [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Licensing Agreements [Member]

Licensing Agreements [Member]

Home Health [Member]

Hospice [Member]

Community Care [Member]

Goodwill [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate

9.90%

'

'

'

'

'

'

'

'

10.60%

11.60%

'

9.50%

'

9.50%

11.20%

'

'

'

'

'

'

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

$643,300,000

$612,380,000

[1]

$19,132,000

[1]

$643,305,000

[1]

'

$408,400,000

'

$399,700,000

'

'

$193,700,000

'

'

'

'

'

'

'

'

'

Goodwill

383,487,000

'

656,364,000

'

641,669,000

383,487,000

656,364,000

641,669,000

123,400,000

9,000,000

'

143,600,000

'

143,600,000

647,400,000

'

116,500,000

'

331,167,000

111,700,000

103,000,000

116,500,000

'

'

Indefinite-lived intangible assets, period increase (decrease)

'

'

'

'

'

-1,400,000

-1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Impairment Loss

'

207,200,000

'

'

'

606,916,000

'

'

0

'

'

'

207,200,000

606,916,000

'

457,000,000

'

'

'

'

'

'

'

'

Number of states requiring CON licenses

'

'

'

'

'

'

'

'

17

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

900,000

Goodwill impairment test, net book value of reporting unit

'

'

'

'

'

'

'

'

'

'

220,200,000

'

555,000,000

'

'

772,800,000

'

'

'

'

'

'

'

'

Number of branches divested

'

'

'

'

'

'

'

'

46

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

9,300,000

10,000,000

13,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense for 2014

7,100,000

'

'

'

'

7,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense for 2015

4,100,000

'

'

'

'

4,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense for 2016

3,100,000

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense for 2017

2,400,000

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense for 2018

1,600,000

'

'

'

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of intangible assets, finite-lived

'

210,700,000

'

'

'

'

19,100,000

'

6,000,000

'

'

'

'

13,100,000

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets (Excluding Goodwill)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-145,100,000

'

'

'

'

'

'

2,000,000

'

Gain (loss) on sale of business

'

'

2,600,000

5,400,000

'

0

8,014,000

1,061,000

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

Operating expenses

'

'

'

'

'

$706,227,000

$655,766,000

$731,299,000

'

'

'

'

'

'

'

'

'

$400,000

'

'

'

'

'

'

Business Acquisition,Goodwill, Expected tax Deductible Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

[1]

The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.

Cost_Savings_Initiatives_Acqui2

Cost Savings Initiatives, Acquisition and Integration Activities and Legal Settlements (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance	'	'	'	$2,696	'	'	'	$38,379	$2,696	$38,379	$19,377
Charge	24,955	1,699	744	141	201	53	25	5,391	27,539	5,670	49,138
Cash Expenditure	'	'	'	'	'	'	'	'	-13,075	-40,994	-28,335
Non-cash expenditures	'	'	'	'	'	'	'	'	-735	-359	-1,801
Restructuring Reserve,Reclassification	'	'	'	'	'	'	'	'	0	'	'
Ending Balance	16,425	'	'	'	2,696	'	'	'	16,425	2,696	38,379
Cost Savings and Other Restructuring [Member]	'	'	'	'	'	'	'	'	'	'	'
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance	'	'	'	1,685	'	'	'	8,671	1,685	8,671	2,893
Charge	'	'	'	'	'	'	'	'	8,742	'	'
Cash Expenditure	'	'	'	'	'	'	'	'	-3,525	-8,544	-7,680
Non-cash expenditures	'	'	'	'	'	'	'	'	-656	-143	-1,801
Restructuring Reserve,Reclassification	'	'	'	'	'	'	'	'	476	'	'
Ending Balance	6,722	'	'	'	1,685	'	'	'	6,722	1,685	8,671
Acquisition & Integration [Member]	'	'	'	'	'	'	'	'	'	'	'
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance	'	'	'	1,011	'	'	'	3,708	1,011	3,708	3,984
Charge	'	'	'	'	'	'	'	'	18,797	-989	7,879
Cash Expenditure	'	'	'	'	'	'	'	'	-9,550	-1,492	-8,155
Non-cash expenditures	'	'	'	'	'	'	'	'	-79	-216	0
Restructuring Reserve,Reclassification	'	'	'	'	'	'	'	'	-476	'	'
Ending Balance	9,703	'	'	'	1,011	'	'	'	9,703	1,011	3,708
Legal Settlements [Member]	'	'	'	'	'	'	'	'	'	'	'
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance	'	'	'	0	'	'	'	26,000	0	26,000	12,500
Charge	'	'	'	'	'	'	'	'	0	4,958	26,000
Cash Expenditure	'	'	'	'	'	'	'	'	0	-30,958	-12,500
Non-cash expenditures	'	'	'	'	'	'	'	'	0	0	0
Restructuring Reserve,Reclassification	'	'	'	'	'	'	'	'	0	'	'
Ending Balance	$0	'	'	'	$0	'	'	'	$0	$0	$26,000

Cost_Savings_Initiatives_Acqui3

Cost Savings Initiatives, Acquisition and Integration Activities and Legal Settlements (Details Textual) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

$24,955,000

$1,699,000

$744,000

$141,000

$201,000

$53,000

$25,000

$5,391,000

$27,539,000

$5,670,000

$49,138,000

'

Restructuring reserve

16,425,000

'

'

'

2,696,000

'

'

'

16,425,000

2,696,000

38,379,000

19,377,000

Non-cash compensation expense

'

'

'

'

'

'

'

'

'

'

400,000

'

Cost Savings Initiative [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

'

'

'

'

'

'

'

'

8,742,000

'

'

'

Restructuring reserve

6,722,000

'

'

'

1,685,000

'

'

'

6,722,000

1,685,000

8,671,000

2,893,000

Acquisition Integration [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

'

'

'

'

'

'

'

'

18,797,000

-989,000

7,879,000

'

Restructuring reserve

9,703,000

'

'

'

1,011,000

'

'

'

9,703,000

1,011,000

3,708,000

3,984,000

Legal Settlements [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

'

'

'

'

'

'

'

'

0

4,958,000

26,000,000

'

Restructuring reserve

0

'

'

'

0

'

'

'

0

0

26,000,000

12,500,000

2013 initiatives [Member] | Cost Savings Initiative [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

'

'

'

'

'

'

'

'

8,700,000

'

'

'

Number of branches closed, consolidated or divested

'

'

'

'

'

'

'

'

77

'

'

'

2011 and 2012 initiatives [Member] | Cost Savings Initiative [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Charge

'

'

'

'

'

'

'

'

$100,000

$1,701,000

$15,259,000

'

2011 and 2012 initiatives [Member] | Home Health [Member] | Cost Savings Initiative [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of branches closed, consolidated or divested

'

'

'

'

'

'

'

'

'

'

46

'

2011 and 2012 initiatives [Member] | Hospice [Member] | Cost Savings Initiative [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of branches closed, consolidated or divested

'

'

'

'

'

'

'

'

'

'

13

'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Computations of the basic and diluted per share amounts	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	'	'	'	'	($605,061)	$26,796	($451,062)
Basic weighted average common shares outstanding	35,054	31,037	30,941	30,785	30,548	30,423	30,338	30,724	31,954	30,509	30,336
Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	'	'	'	'	'	'	'	'	0	178	0
Diluted weighted average common shares outstanding	35,054	31,532	31,239	30,785	30,891	30,423	30,446	30,959	31,954	30,687	30,336
Basic earnings per common share:	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income attributable to Gentiva shareholders	($12)	$0.12	$0.20	($6.31)	$0.28	($0.02)	$0.46	$0.16	($18.94)	$0.88	($14.86)
Diluted earnings per common share:	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) attributable to Gentiva shareholders	($12)	$0.11	$0.20	($6.31)	$0.28	($0.02)	$0.46	$0.16	($18.94)	$0.87	($14.86)
Statement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total anti-dilutive shares	'	'	'	'	'	'	'	'	826	3,232	2,865
Stock Options [Member]	'	'	'	'	'	'	'	'	'	'	'
Statement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total anti-dilutive shares	'	'	'	'	'	'	'	'	595	2,813	2,388
Performance Shares [Member]	'	'	'	'	'	'	'	'	'	'	'
Statement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total anti-dilutive shares	'	'	'	'	'	'	'	'	0	89	129
Restricted Stock [Member]	'	'	'	'	'	'	'	'	'	'	'
Statement [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total anti-dilutive shares	'	'	'	'	'	'	'	'	231	330	348

Earnings_Per_Share_Details_Tex

Earnings Per Share (Details Textual)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'	'
Anit-dilutive shares excluded from EPS	826	3,232	2,865

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Long-term debt	'	'
Total debt	$1,169,757	$935,182
Less: current portion of long-term debt	-45,325	-25,000
Total long-term debt	1,124,432	910,182
Senior Subordinated Notes [Member]	'	'
Long-term debt	'	'
Senior Notes, Noncurrent	325,000	325,000
Revolving Credit Facility [Member]	'	'
Long-term debt	'	'
Line of Credit Facility, Amount Outstanding	27,000	0
Term Loan A, Dated August 17, 2010 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	0	143,750
Term Loan B, Dated August 17, 2010 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	0	466,432
Term Loan B, dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	663,492	0
Term Loan C, Dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	$154,265	$0

LongTerm_Debt_Details_1

Long-Term Debt (Details 1)	Dec. 31, 2013
Eurodollar Rate [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	1.00%
Revolver, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Revolver, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Revolver, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%
Revolver, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.25%
Term Loan B, dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	5.25%
Term Loan B, dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	5.25%
Term Loan B, dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Term Loan B, dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Term Loan C, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Term Loan C, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Term Loan C, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%
Term Loan C, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%

LongTerm_Debt_Details_2

Long-Term Debt (Details 2)	12 Months Ended
	Dec. 31, 2013
Long-term Debt, Unclassified [Abstract]	'
Maximum Leverage Ratio effective for fiscal quarters ending March 31, 2014 to March 31, 2015	6.75%
Maximum Leverage Ratio effective for fiscal quarters ending June 30, 2015 to March 31, 2016	6.50%
Maximum Leverage Ratio effective for fiscal quarters ending June 30, 2016 to March 31, 2017	6.25%
Maximum Leverage Ratio effective for fiscal quarters ending June 30, 2017 to December 31, 2017	6.00%
Maximum Leverage Ratio effective for fiscal quarter ending March 31, 2018 and each fiscal quarter thereafter	5.75%

LongTerm_Debt_Details_3

Long-Term Debt (Details 3)	12 Months Ended
	Dec. 31, 2013
Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest	'
2014	105.75%
2015	102.88%
2016 and thereafter	100.00%

LongTerm_Debt_Details_Textual

Long-Term Debt (Details Textual) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Oct. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Federal Funds [Member]

Eurodollar Rate [Member]

Eurodollar Rate [Member]

Base Rate [Member]

Loans Payable [Member]

Loans Payable [Member]

Senior Subordinated Notes [Member]

Senior Notes [Member]

Term Loan B, dated October 18, 2013 [Member]

Term Loan C, Dated October 18, 2013 [Member]

Revolver, Dated October 18, 2013 [Member]

Revolver, Dated October 18, 2013 [Member]

Revolver, Dated October 18, 2013 [Member]

Revolver, Dated October 18, 2013 [Member]

Term Loan A, Dated August 17, 2010 [Member]

Term Loan B, Dated August 17, 2010 [Member]

Revolver, Dated August 17, 2010 [Member]

Minimum [Member]

Minimum [Member]

Loans Payable [Member]

Loans Payable [Member]

Letter of Credit [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Same-Day Borrowing [Member]

Loans Payable [Member]

Loans Payable [Member]

Revolving Credit Facility [Member]

Long-Term Debt (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$670,000,000

$155,000,000

'

'

'

'

$200,000,000

$550,000,000

'

Line of credit facility, maximum borrowing capacity

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

80,000,000

100,000,000

100,000,000

15,000,000

'

'

110,000,000

Repayments of Debt

'

'

'

'

'

'

'

'

'

'

585,182,000

'

'

'

'

'

'

'

'

'

118,750,000

466,432,000

'

Deferred debt issuance costs, write off

16,085,000

461,000

3,559,000

19,100,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of debt issuance costs

24,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18-Oct-18

'

'

'

'

Outstanding letter of credit

52,000,000

45,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unused and available borrowing capacity under the Credit Agreement

'

'

'

21,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity, repayments of principal in 2014

'

'

'

'

'

'

'

'

'

'

'

18,325,000

'

'

6,700,000

11,625,000

'

'

'

'

'

'

'

Maturity, repayments of principal in 2015

'

'

'

'

'

'

'

'

'

'

'

26,075,000

'

'

6,700,000

'

'

'

'

'

'

'

'

Maturity, repayments of principal in 2016

'

'

'

'

'

'

'

'

'

'

'

29,900,000

'

'

6,700,000

'

'

'

'

'

'

'

'

Maturity, repayments of principal in 2017

'

'

'

'

'

'

'

'

'

'

'

37,700,000

'

'

6,700,000

'

'

'

'

'

'

'

'

Maturity, repayments of principal in 2018

'

'

'

'

'

'

'

'

'

'

'

76,450,000

'

325,000,000

6,700,000

'

'

'

'

'

'

'

'

Maturity, repayments of principal thereafter

'

'

'

'

'

'

'

'

'

'

'

$636,500,000

'

'

$636,500,000

'

'

'

'

'

'

'

'

Weighted average cash interest rate on outstanding borrowings

7.70%

8.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Excess Cash Flow With Two Step Downs Based on Company Leverage Ratio

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

0.50%

1.00%

1.25%

2.25%

'

'

11.50%

'

6.50%

5.75%

'

4.69%

4.69%

'

6.25%

6.50%

'

Line of Credit Facility, Unused Commitment Fee Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

Consolidated Leverage Ratio

5.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pledge of Capital Stock to Lenders Percentage

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Redemption Price Terms

'

'

'

'

'

'

'

'

'

'

'

'

'Gentiva may redeem the Senior Notes, in whole or in part, at any time prior to the first interest payment of 2014, at a price equal to 100 percent of the principal amount of the Senior Notes redeemed plus an applicable make-whole premium based on the present value of the remaining payments discounted at the treasury rate plus 50 basis points plus accrued and unpaid interest, if any, to the date of redemption.

'

'

'

'

'

'

'

'

'

'

Shareholders_Equity_Details_Te

Shareholdersb Equity (Details Textual) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 13, 2012
Equity (Textual) [Abstract]	'	'
Preferred stock	25,000,000	'
Preferred stock, par value	$0.01	'
Senior note governing repurchases of the Company's common stock limitations per year	$7.50	'
Limitations per year for leverage ratio less than or equal to 3.5:1	25	'
Consolidated leverage ratio	'less than or equal to 3.5:1.0	'
2012 Repurchase Program [Member]	'	'
Equity (Textual) [Abstract]	'	'
Repurchase limitations	'	5,000,000
Remaining authorization to repurchase common stock under	$1.50	'
Common Stock [Member]	'	'
Equity (Textual) [Abstract]	'	'
Issuance of stock in connection with Harden acquisition, shares	4,812,414	'
Cumulative Preferred Stock [Member]	'	'
Equity (Textual) [Abstract]	'	'
Preferred stock	1,000	'

EquityBased_Compensation_Plans2

Equity-Based Compensation Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Weighted-average fair values of the Company's stock options granted	'	'	'
Weighted average fair value of options granted	$6.02	$4.32	$3.46
Risk-free interest rate	'	'	0.91%
Expected volatility	'	'	60.00%
Contractual life	'7 years	'7 years	'7 years
Expected dividend yield	0.00%	0.00%	0.00%
Maximum [Member]	'	'	'
Weighted-average fair values of the Company's stock options granted	'	'	'
Risk-free interest rate	0.54%	0.95%	'
Expected volatility	79.00%	65.00%	'
Expected life	'5 years 5 months	'5 years 5 months	'6 years 6 months
Minimum [Member]	'	'	'
Weighted-average fair values of the Company's stock options granted	'	'	'
Risk-free interest rate	0.29%	0.77%	'
Expected volatility	76.00%	64.00%	'
Expected life	'3 years 5 months	'3 years 5 months	'4 years 6 months

EquityBased_Compensation_Plans3

Equity-Based Compensation Plans (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of options, Beginning balance	3,752,418
Weighted Average Exercise Price, Beginning balance	$15.99
Number of Options, Granted	642,700
Weighted Average Exercise Price, Granted	$10.74
Number of Options, Exercised	-97,455
Weighted Average Exercise Price, Exercised	$5.60
Number of Options, Cancelled	-292,074
Weighted Average Exercise Price, Cancelled	$15.98
Number of options, Ending balance	4,005,589
Weighted Average Exercise Price, Ending balance	$15.40
Weighted Average Remaining Contractual Life-Years	'4 years 5 months
Aggregate intrinsic value, Ending Balance	$8,651,115
Number of Options, Exercisable options	2,829,292
Weighted Average Exercise Price, Exercisable options	$17.58
Weighted Average Remaining Contractual Term, Exercisable options	'3 years 11 months
Aggregate intrinsic value, Exercisable options	4,771,998
Number of Options, Expected to vest	1,139,228
Weighted Average Exercise Price, Expected to vest	$10.19
Weighted Average Remaining Contractual Term, Expected to vest options	'5 years 6 months
Aggregate Intrinsic Value, Expected to vest	$3,785,503

EquityBased_Compensation_Plans4

Equity-Based Compensation Plans (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Performance Shares 2010 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Requisite Service Period	'	'	'	'3 years
Percent allocated to performance year one	33.00%	'	'	'
Percent allocated to performance year two	33.00%	'	'	'
Percent allocated to performance year three	33.00%	'	'	'
Performance percent target achieved year one	'	'	'	150.00%
Performance percent target achieved year two	'	'	150.00%	'
Performance percent target achieved year three	'	0.00%	'	'
Summary of performance share unit	'	'	'	'
Number of Shares, Beginning balance	33,700	'	'	'
Number of Performance Share Units, Cancelled	0	'	'	'
Change in performance expectations	0	'	'	'
Number of Performance Share Units Issued in Period	-33,700	'	'	'
Number of Share Units, Ending balance	0	33,700	'	'
Performance Shares 2011 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Requisite Service Period	'	'	'3 years	'
Percent allocated to performance year one	90.00%	'	'	'
Percent allocated to performance year three	10.00%	'	'	'
Performance percent target achieved year one	'	'	200.00%	'
Performance percent target achieved year three	0.00%	'	'	'
Summary of performance share unit	'	'	'	'
Number of Shares, Beginning balance	166,750	'	'	'
Number of Performance Share Units, Cancelled	-1,800	'	'	'
Change in performance expectations	-6,650	'	'	'
Number of Performance Share Units Issued in Period	-158,300	'	'	'
Number of Share Units, Ending balance	0	'	'	'
Performance Shares [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Requisite Service Period	'3 years	'	'	'
Summary of performance share unit	'	'	'	'
Number of Shares, Beginning balance	200,450	'	'	'
Weighted Average Exercise Price, Beginning balance	26.31	'	'	'
Number of Performance Share Units, Cancelled	-1,800	'	'	'
Weighted Average Exercise Price, Cancelled	26.67	'	'	'
Change in performance expectations	-6,650	'	'	'
Change in performance expectations, weighted average	26.58	'	'	'
Number of Performance Share Units Issued in Period	-192,000	'	'	'
Weighted Average Exercise Price, Issued	26.29	'	'	'
Number of Share Units, Ending balance	0	'	'	'
Weighted Average Exercise Price, Ending balance	0	'	'	'
Minimum [Member] | Performance Shares 2010 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	'	0.00%
Minimum [Member] | Performance Shares 2011 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	0.00%	'
Maximum [Member] | Performance Shares 2010 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	'	150.00%
Maximum [Member] | Performance Shares 2011 Award [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	200.00%	'

EquityBased_Compensation_Plans5

Equity-Based Compensation Plans Equity-Based Compensation Plans (Details 3) (USD $)	12 Months Ended				9 Months Ended	12 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2013
	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]
			Minimum [Member]	Maximum [Member]				Minimum [Member]	Maximum [Member]	Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Requisite Service Period	'	'3 years	'	'	'3 years	'	'	'	'	'
Long-Term Incentive Award, Settled in Cash	$2,519,276	$1,293,687	'	'	'	$1,005,832	$0	'	'	'
long-term incentive, settled in cash, earned	1,225,589	'	'	'	'	1,005,832	'	'	'	'
Long-Term Incentives, Settled in Cash, Issued	$0	'	'	'	'	$0	'	'	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	0.00%	200.00%	'	'	'	0.00%	240.00%	240.00%
Percent allocated to performance year one	'	50.00%	'	'	'	60.00%	'	'	'	'
Percent allocated to performance year three	'	50.00%	'	'	'	40.00%	'	'	'	'
Percent allocated to performance year two	'	0.00%	'	'	'	0.00%	'	'	'	'
Performance percent target achieved year one	'	85.00%	'	'	'	0.00%	'	'	'	'

EquityBased_Compensation_Plans6

Equity-Based Compensation Plans (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of restricted Stock activity	'	'	'
Number of Options, Expected to vest	1,139,228	'	'
Weighted Average Exercise Price, Expected to vest	$10.19	'	'
Aggregate Intrinsic Value, Expected to vest	$3,785,503	'	'
Restricted Stock [Member]	'	'	'
Summary of restricted Stock activity	'	'	'
Number of Shares, Beginning balance	364,650	'	'
Weighted Average Exercise Price, Beginning balance	$25.25	'	'
Number of Restricted Shares, Granted	338,300	'	'
Weighted Average Exercise Price, Granted	$11.37	'	'
Number of Restricted Shares, Exercised	-39,750	'	'
Weighted Average Exercise Price, Exercised	$26.06	'	'
Number of Performance Share Units, Cancelled	-27,800	'	'
Weighted Average Exercise Price, Cancelled	$14.70	'	'
Number of Share Units, Ending balance	635,400	'	'
Weighted Average Exercise Price, Ending balance	$18.27	'	'
Aggregate Intrinsic Value, Ending Balance	7,885,314	3,700,000	2,500,000
Number of Options, Expected to vest	602,343	'	'
Weighted Average Exercise Price, Expected to vest	$18.53	'	'
Aggregate Intrinsic Value, Expected to vest	$7,475,074	'	'

EquityBased_Compensation_Plans7

Equity-Based Compensation Plans (Details Textual) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9-May-13

Jan. 03, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

10-May-12

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

2004 Plan [Member]

Stock option grants in 2011 and 2012 [Member]

Stock option grants in 2006 through 2010 [Member]

Performance Cash Award 2013 [Member]

Employee Stock Option Market vesting feature [Member]

Stock Options [Member]

Stock Options [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Cash Award [Member]

Performance Cash Award [Member]

Restricted Stock Units R S U [Member]

Restricted Stock Units R S U [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Selling General and Administrative Expenses [Member]

Selling General and Administrative Expenses [Member]

Selling General and Administrative Expenses [Member]

Market Vesting Feature Stock Price Threshold 1 [Member]

Market Vesting Feature Stock Price Threshold 2 [Member]

Market Vesting Feature Stock Price Threshold 3 [Member]

Annual Vesting [Member]

Clif Vesting after Second Year [Member]

Annual Vesting Years Three and Four [Member]

Performance Cash Award 2013 [Member]

Performance Cash Award 2013 [Member]

Employee Stock Option Market vesting feature [Member]

Performance Shares [Member]

Restricted Stock Units R S U [Member]

Performance Cash Award 2013 [Member]

Employee Stock Option Market vesting feature [Member]

Restricted Stock Units R S U [Member]

Employee Stock Option Market vesting feature [Member]

Employee Stock Option Market vesting feature [Member]

Employee Stock Option Market vesting feature [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock option grants in 2011 and 2012 [Member]

Stock option grants in 2006 through 2010 [Member]

Stock option grants in 2006 through 2010 [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Options, Granted

'

'

642,700

'

'

'

'

'

'

'

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by award type, market condition target

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14

$16

$18

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

50.00%

25.00%

Weighted Average Exercise Price, Granted

'

'

$10.74

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

$6.02

$4.32

$3.46

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.87

'

'

'

'

'

$5.22

'

'

'

'

'

'

'

'

'

'

Equity-Based Compensation Plans (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorization of additional shares under ESPP

'

'

7,800,000

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award Maximum

'

'10 years

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

1,850,597

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity-based compensation expense

'

'

$8,210,000

$7,645,000

$7,548,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,200,000

$7,600,000

$7,500,000

'

'

'

'

'

'

Non-cash compensation expense

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options

'

'

600,000

300,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense

'

'

3,400,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option vesting period

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'5 years

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Award Type, Performance Cash Award, Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200,000

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Options, Exercised

'

'

-97,455

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense recognized over a weighted-average period

'

'

'

'

'

'

'

'

'

'

'

'1 year 5 months

'1 year 4 months

'

'1 year

'1 year 7 months

'2 years

'

'

'2 years

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Vested Options

'

'

4,000,000

4,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Performance awards target achievement range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

240.00%

240.00%

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

Intrinsic Value of restricted stock awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,885,314

3,700,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost total

'

'

'

'

'

'

'

'

'

'

'

'

'

0

1,500,000

3,300,000

2,600,000

4,900,000

4,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increasing in aggregate number of shares of common stock available for issuance

'

'

'

'

'

350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock available for issuance

'

'

650,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance

'

'

206,837

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock & Deferred Compensation Plan for Non-Employee

'

'

67,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average fair value

'

'

$11.29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Approximate cash payment to each non-employee for insufficient deferred stock units

'

'

28,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share units outstanding under the plan

'

'

332,776

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Stock Purchase Plan, Annual FMV Limit

'

'

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Stock Purchase Plan, Annual Compensation Limit Percentage

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Offering Period of Employee Stock Purchase Plan

'

'

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ESPP under which the offering purchase price of shares

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Share Available, Employee Stock Purchase Plans

'

'

2,067,483

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued under ESPP

'

'

269,156

403,292

407,091

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount on company issued common stock under its ESPP

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

60.00%

'

'

'

'

'

67.00%

'

'

'

'

'

'

'

'

'

'

'

79.00%

65.00%

'

'

'

'

'

76.00%

64.00%

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

0.91%

'

'

'

'

'

0.60%

'

'

'

'

'

'

'

'

'

'

'

0.54%

0.95%

'

'

'

'

'

0.29%

0.77%

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

0.00%

0.00%

0.00%

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

'

'

'

'

'

'

'

'three-year period

'four-year period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Requisite Service Period

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal_Matters_Details_Textual

Legal Matters (Details Textual) (USD $)	0 Months Ended	12 Months Ended		36 Months Ended	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 29, 2011	Dec. 31, 2013	Oct. 25, 2011	Dec. 31, 2006	Sep. 30, 2013	Dec. 31, 2013
	Plaintiffs	Plaintiffs	Plaintiffs		PRRB Appeal [Member]	PRRB Appeal [Member]
					Home Health [Member]	Home Health [Member]
Legal Matters [Line Items]	'	'	'	'	'	'
Patient service revenue adjustments	'	'	'	'	($4)	($4)
Number of plaintiffs	'	5	'	'	'	'
Settlement of damages claims	'	5	'	'	'	'
Former employees of Generations Healthcare	2	'	'	'	'	'
Shareholder class actions filed against company	'	'	5	'	'	'
Aggregate adjustment to allowable costs	'	'	'	$15.90	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Oct. 18, 2013

Common Stock [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Capstar Partners, LLC [Member]

Capstar Investment Partners, L.P [Member]

Capstar Investment Partners, L.P [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Director [Member]

Director [Member]

Director [Member]

Maximum [Member]

Minimum [Member]

Five Trusts [Member]

Two Entities [Member]

Five Trusts [Member]

Two Entities [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Cost of acquired entity, cash paid

'

'

'

'

'

'

'

'

$365,000,000

$890,000

$890,000

$3,600,000

Issuance of stock in connection with Harden acquisition, value

53,750,000

481,000

'

'

'

'

'

'

53,800,000

'

'

'

Contingent consideration arrangements, range of outcomes, value, high

'

'

'

'

'

'

'

'

9,500,000

'

'

'

Contingent consideration, liability

'

'

'

'

'

'

'

'

8,100,000

'

'

'

Issuance of stock in connection with Harden acquisition, shares

'

4,812,414

'

'

'

481,288

484,715

1,955,905

'

'

'

'

Related Party Transaction, Number of Payments under Contingent Liability Arrangements

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

Related party contingent liability arrangements

'

'

$1,000,000

$750,000

$0

'

'

'

'

'

'

'

Commitments_Details

Commitments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Total Commitment, 2013	$50,738
Sublease Rentals, 2013	525
Net, 2013	50,213
Total Commitment, 2014	38,205
Sublease Rentals, 2014	237
Net, 2014	37,968
Total Commitment, 2015	27,387
Sublease Rentals, 2015	69
Net, 2015	27,318
Total Commitment, 2016	19,259
Sublease Rentals, 2016	37
Net, 2016	19,222
Total Commitment, 2017	13,398
Sublease Rentals, 2017	28
Net, 2017	13,370
Total Commitment, Thereafter	13,785
Sublease Rentals, Thereafter	0
Net, Thereafter	$13,785

Committments_Detail_Textual_De

Committments (Detail Textual) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Continuing Operations [Member]	'	'	'
Operating Leased Assets [Line Items]	'	'	'
Operating leases, rent expense, net	$45.90	$45.30	$47.90
Discontinued Operations [Member]	'	'	'
Operating Leased Assets [Line Items]	'	'	'
Operating leases, rent expense, net	'	'	$0.60

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	($3,968)	($7,784)	$7,784
State and local	1,063	1,522	2,460
Current income tax (benefit) expense	-2,905	-6,262	10,244
Deferred:	'	'	'
Federal	-30,655	20,211	-71,267
State and local	-6,393	3,302	-15,100
Deferred income tax expense (benefit)	-37,048	23,513	-86,367
Income tax (expense) benefit	($39,953)	$17,251	($76,123)

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory tax rate	35.00%	35.00%	35.00%
Impairment	-29.20%	0.00%	-23.60%
State income taxes, net of Federal benefit	0.60%	4.60%	1.70%
Change in tax reserve	-0.10%	-3.40%	-0.50%
Net change in state valuation allowance	0.00%	-0.60%	-0.10%
Other	-0.10%	0.90%	0.10%
Effective tax rate	6.20%	36.50%	12.60%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Reserves and allowances	$18,840	$8,833
Payroll and related accruals	5,343	5,953
State net operating loss carryforwards	6,216	0
Other	409	446
Less: valuation allowance	-777	-511
Total current deferred tax assets	30,031	14,721
Equity compensation	17,376	16,940
Deferred rent	2,241	2,935
Net operating loss carryforwards, federal	12,141	0
Deferred Tax Assets, Capital Loss Carryforwards	232	0
Federal tax credit carryforwards	4,408	4,809
Other	5,920	3,669
Less: valuation allowance	-2,864	-2,367
Total noncurrent deferred tax assets	39,454	25,986
Total deferred tax assets	69,485	40,707
Prepaid assets and other	-1,873	-2,458
Deferred Tax Liabilities, Other, Current	-5	0
Deferred Tax Liabilities, Gross, Current	-1,878	-2,458
Fixed assets	-2,684	-1,409
Intangible assets	-39,202	-50,398
Developed software	-3,568	-4,559
Financing fees	-1,940	-10,637
Deferred Tax Liabilities, Other, Non Current	-543	0
Total non-current deferred tax liabilities	-47,937	-67,003
Total deferred tax liabilities	-49,815	-69,461
Net deferred tax liabilities	$19,670	($28,754)

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Beginning balance	$8,356	$11,027	$3,651
Additions for tax positions of the current year	456	126	9,039
Additions for tax positions of prior year	'	245	2,316
Additions for tax positions of acquired companies	910	'	'
Changes in judgment	'	-2,312	-584
Settlements during the period	-1,898	-274	-3,184
Lapses of applicable statute of limitations	-148	-456	-211
Ending balance	$7,676	$8,356	$11,027

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]	'	'	'	'
Deferred tax assets, current	$28,153,000	$12,263,000	'	'
Deferred tax liabilities, net	-8,483,000	-41,017,000	'	'
Tax Credit Carryforward, Amount	4,400,000	'	'	'
Operating loss carryforwards, valuation allowance	3,400,000	'	'	'
State net operating loss carryforwards	6,216,000	0	'	'
Federal tax credit carryforwards	4,408,000	4,809,000	'	'
Unrecognized Tax Benefits	7,676,000	8,356,000	11,027,000	3,651,000
Unrecognized tax benefits, interest on income taxes accrued	1,400,000	600,000	'	'
Net operating loss carryforwards, federal	12,141,000	0	'	'
Deferred Tax Assets, Capital Loss Carryforwards	232,000	0	'	'
Capital Loss Carryforward [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Operating Loss Carryforwards	700,000	'	'	'
Operating loss carryforwards, valuation allowance	200,000	'	'	'
Domestic Tax Authority [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Operating Loss Carryforwards	34,700,000	'	'	'
State and Local Jurisdiction [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Operating Loss Carryforwards	133,000,000	'	'	'
Harden Healthcare Holdings Inc. [Member] | State and Local Jurisdiction [Member]	'	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'	'
Operating Loss Carryforwards	$15,600,000	'	'	'

Benefit_Plans_for_Employee_Det

Benefit Plans for Employee (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation and Retirement Disclosure [Abstract]	'	'	'
Assets held in rabbi trust	$34,682,000	$27,739,000	'
Defined Benefit Plan, Contributions by Employer	$8,000,000	$7,600,000	$9,100,000

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	$486,137	$410,492	$414,424	$415,591	$425,017	$424,444	$427,691	$435,652	$1,726,644	$1,712,804	$1,798,778
Medicare [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	1,455,200	1,464,600	1,528,300
Medicaid and Local Government [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	116,600	74,400	83,100
Commercial Insurance and Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	154,800	173,800	187,400
Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	59,600	85,200	77,700
Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	95,200	88,600	109,700
Home Health [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	965,800	948,000	1,012,600
Home Health [Member] | Medicare [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	787,300	749,000	799,200
Home Health [Member] | Medicaid and Local Government [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	43,800	46,800	52,300
Home Health [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	59,600	85,200	77,700
Home Health [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	75,100	67,000	83,400
Hospice [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	715,200	764,800	786,200
Hospice [Member] | Medicare [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	667,900	715,500	729,100
Hospice [Member] | Medicaid and Local Government [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	28,300	27,700	30,800
Hospice [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	0	0	0
Hospice [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	19,000	21,600	26,300
Community Care [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	45,600	0	0
Community Care [Member] | Medicare [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	0	0	0
Community Care [Member] | Medicaid and Local Government [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	44,500	0	0
Community Care [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	0	0	0
Community Care [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment net revenues by major payer source	'	'	'	'	'	'	'	'	'	'	'
Total net revenues	'	'	'	'	'	'	'	'	$1,100	$0	$0

Business_Segment_Information_D1

Business Segment Information (Details 1) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

$486,137

$410,492

$414,424

$415,591

$425,017

$424,444

$427,691

$435,652

'

$1,726,644

$1,712,804

$1,798,778

Operating contribution

'

'

'

'

'

'

'

'

'

199,004

258,578

265,917

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

-643,300

-612,380

[1]

-19,132

[1]

-643,305

[1]

Depreciation and amortization

'

'

'

'

'

'

'

'

'

-24,621

-26,581

-31,032

Gain on sale of assets and businesses, net

'

'

'

'

2,600

'

5,400

'

'

0

8,014

1,061

Dividend income

'

'

'

'

'

'

'

'

'

0

0

8,590

[2]

Interest expense and other, net

'

'

'

'

'

'

'

'

'

-110,384

[3]

-89,947

[3]

-88,610

[3]

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix

-463,338

[4]

6,594

11,041

-198,824

[4]

18,510

[5]

-2,678

[4]

23,818

[5]

7,582

'

-644,527

47,232

-603,240

Total assets

1,253,468

'

'

'

1,508,046

'

'

'

1,527,440

1,253,468

1,508,046

1,527,440

Home Health [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

965,848

948,019

1,012,566

Operating contribution

'

'

'

'

'

'

'

'

'

113,809

[6]

125,445

[6]

126,194

[6]

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

'

-408,400

'

Total assets

406,367

'

'

'

242,603

[1]

'

'

'

239,751

[1]

406,367

242,603

[1]

239,751

[1]

Hospice [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

715,190

764,785

786,212

Operating contribution

'

'

'

'

'

'

'

'

'

78,810

[6]

133,133

[6]

139,723

[6]

Goodwill, intangibles and other long-lived asset impairment

-399,700

'

'

'

'

'

'

'

'

'

-193,700

'

Total assets

348,445

[1]

'

'

'

855,614

[1]

'

'

'

902,397

[1]

348,445

[1]

855,614

[1]

902,397

[1]

Community Care [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

45,606

0

0

Operating contribution

'

'

'

'

'

'

'

'

'

6,385

0

0

Total assets

172,308

'

'

'

0

'

'

'

0

172,308

0

0

Home Health and Hospice [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Total assets

927,120

'

'

'

1,098,217

'

'

'

1,142,148

927,120

1,098,217

1,142,148

Corporate [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment information about the Company's operations

'

'

'

'

'

'

'

'

'

'

'

'

Corporate Expenses

'

'

'

'

'

'

'

'

'

-96,146

[6]

-83,700

[6]

-115,861

[6]

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

'

-41,200

'

Total assets

$326,348

[1]

'

'

'

$409,829

'

'

'

$385,292

[1]

$326,348

[1]

$409,829

$385,292

[1]

[1]

The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.

[2]

For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Companybs combined common and preferred ownership of CareCentrix.

[3]

For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Companybs interest rate swaps in connection with the refinancing of the Companybs Term Loan A and Term Loan B under the Companybs former credit agreement. See Note 13 for additional information.

[4]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[5]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[6]

For the years ended December 31, 2013,B 2012 and 2011, the Company recorded charges relating to cost savings initiatives and other restructuring costs, acquisition and integration costs and legal settlements of $27.5 million, $5.7 million and $49.1 million, respectively. See Note 11 for additional information.The charges were reflected as follows for segment reporting purposes (in millions):B 2013B 2012B 2011Home Health$3.3B $5.6B $7.7Hospice8.2B 0.4B 3.7Corporate expenses16.0B (0.3)B 37.7Total$27.5B $5.7B $49.1

Business_Segment_Information_D2

Business Segment Information (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Charges reflecting for segment reporting purposes	'	'	'
Restructuring, settlement and impairment provisions	$27.50	$5.70	$49.10
Home Health [Member]	'	'	'
Charges reflecting for segment reporting purposes	'	'	'
Restructuring, settlement and impairment provisions	3.3	5.6	7.7
Hospice [Member]	'	'	'
Charges reflecting for segment reporting purposes	'	'	'
Restructuring, settlement and impairment provisions	8.2	0.4	3.7
Corporate expenses [Member]	'	'	'
Charges reflecting for segment reporting purposes	'	'	'
Restructuring, settlement and impairment provisions	$16	($0.30)	$37.70

Business_Segment_Information_D3

Business Segment Information (Details Textual) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Interest Rate Swap [Member]

Home Health [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Corporate expenses [Member]

Corporate expenses [Member]

Corporate expenses [Member]

Corporate expenses [Member]

Land and Building [Member]

Software Development [Member]

Software Development [Member]

Software Development [Member]

Goodwill [Member]

Intangible Assets [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

State

State

State

State

Hospice [Member]

Hospice [Member]

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of states in certified providers serving

'

'

'

'

'

'

38

'

'

30

'

30

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring, settlement and impairment provisions

'

'

$27,500,000

$5,700,000

$49,100,000

'

$3,300,000

$5,600,000

$7,700,000

'

'

$8,200,000

$400,000

$3,700,000

'

'

$16,000,000

($300,000)

$37,700,000

'

'

'

'

'

'

'

'

Interest expense and other, net

'

'

-110,384,000

[1]

-89,947,000

[1]

-88,610,000

[1]

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Write off of debt issuance cost

'

'

16,085,000

461,000

3,559,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,100,000

500,000

Goodwill, Impairment Loss

207,200,000

'

606,916,000

'

'

'

0

'

'

'

207,200,000

606,916,000

'

457,000,000

'

'

'

'

'

'

'

'

'

399,700,000

'

'

'

Impairment of intangible assets, finite-lived

210,700,000

'

'

19,100,000

'

'

6,000,000

'

'

'

'

13,100,000

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

612,380,000

19,132,000

643,305,000

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

1,900,000

1,600,000

1,600,000

40,300,000

'

'

'

'

Goodwill and Intangible Asset Impairment

'

643,300,000

612,380,000

[2]

19,132,000

[2]

643,305,000

[2]

'

'

408,400,000

'

399,700,000

'

'

193,700,000

'

'

'

'

41,200,000

'

'

'

'

'

'

'

'

'

Dividend income

'

'

$0

$0

$8,590,000

[3]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Companybs interest rate swaps in connection with the refinancing of the Companybs Term Loan A and Term Loan B under the Companybs former credit agreement. See Note 13 for additional information.

[2]

The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.

[3]

For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Companybs combined common and preferred ownership of CareCentrix.

Supplemental_Guarantor_and_Non2

Supplemental Guarantor and Non-Guarantor Financial Information (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Current assets:	'	'	'	'
Cash and cash equivalents	$86,957	$207,052	$164,912	$104,752
Receivables, net	289,905	251,080	'	'
Deferred tax assets, current	28,153	12,263	'	'
Prepaid expenses and other current assets	64,746	45,632	'	'
Total current assets	469,761	516,027	'	'
Note receivable from CareCentrix	28,471	28,471	'	'
Fixed assets, net	49,375	41,414	'	'
Intangible assets, net	253,727	190,725	'	'
Goodwill	383,487	656,364	641,669	'
Investments in subsidiaries	0	0	'	'
Other assets	68,647	75,045	'	'
Total assets	1,253,468	1,508,046	1,527,440	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	45,325	25,000	'	'
Accounts payable	15,659	13,445	'	'
Other current liabilities	314,486	251,454	'	'
Total current liabilities	375,470	289,899	'	'
Long-term debt	1,124,432	910,182	'	'
Deferred tax liabilities, net	8,483	41,017	'	'
Other liabilities	53,084	33,988	'	'
Total Gentiva shareholders' equity	-310,876	231,422	'	'
Noncontrolling interests	2,875	1,538	'	'
Total equity	-308,001	232,960	200,791	637,029
Liabilities and Equity	1,253,468	1,508,046	'	'
Gentiva Health Services, Inc. [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	55,388	166,140	124,101	63,816
Receivables, net	0	0	'	'
Deferred tax assets, current	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	55,388	166,140	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investments in subsidiaries	782,470	1,002,204	'	'
Other assets	28,266	44,219	'	'
Total assets	866,124	1,212,563	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	45,325	25,000	'	'
Accounts payable	0	0	'	'
Other current liabilities	0	0	'	'
Total current liabilities	45,325	25,000	'	'
Long-term debt	1,124,432	910,182	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	7,243	0	'	'
Total Gentiva shareholders' equity	-310,876	277,381	'	'
Noncontrolling interests	0	0	'	'
Total equity	-310,876	277,381	'	'
Liabilities and Equity	866,124	1,212,563	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	0	0
Receivables, net	284,637	245,191	'	'
Deferred tax assets, current	25,845	10,280	'	'
Prepaid expenses and other current assets	52,971	36,899	'	'
Total current assets	363,453	292,370	'	'
Note receivable from CareCentrix	28,471	28,471	'	'
Fixed assets, net	48,855	41,066	'	'
Intangible assets, net	251,127	190,625	'	'
Goodwill	379,880	650,300	'	'
Investments in subsidiaries	23,493	27,210	'	'
Other assets	40,375	30,820	'	'
Total assets	1,135,654	1,260,862	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	15,377	27,300	'	'
Other current liabilities	283,483	202,321	'	'
Total current liabilities	298,860	229,621	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	8,483	41,017	'	'
Other liabilities	45,841	33,979	'	'
Total Gentiva shareholders' equity	782,470	956,245	'	'
Noncontrolling interests	0	0	'	'
Total equity	782,470	956,245	'	'
Liabilities and Equity	1,135,654	1,260,862	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	31,569	40,912	40,811	40,936
Receivables, net	33,878	19,744	'	'
Deferred tax assets, current	2,308	1,983	'	'
Prepaid expenses and other current assets	11,775	8,733	'	'
Total current assets	79,530	71,372	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	520	348	'	'
Intangible assets, net	2,600	100	'	'
Goodwill	3,607	6,064	'	'
Investments in subsidiaries	0	0	'	'
Other assets	6	6	'	'
Total assets	86,263	77,890	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	282	0	'	'
Other current liabilities	59,613	49,133	'	'
Total current liabilities	59,895	49,133	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	9	'	'
Total Gentiva shareholders' equity	23,493	27,210	'	'
Noncontrolling interests	2,875	1,538	'	'
Total equity	26,368	28,748	'	'
Liabilities and Equity	86,263	77,890	'	'
Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	0	0
Receivables, net	-28,610	-13,855	'	'
Deferred tax assets, current	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	-28,610	-13,855	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investments in subsidiaries	-805,963	-1,029,414	'	'
Other assets	0	0	'	'
Total assets	-834,573	-1,043,269	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	-13,855	'	'
Other current liabilities	-28,610	0	'	'
Total current liabilities	-28,610	-13,855	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	0	'	'
Total Gentiva shareholders' equity	-805,963	-1,029,414	'	'
Noncontrolling interests	0	0	'	'
Total equity	-805,963	-1,029,414	'	'
Liabilities and Equity	-834,573	-1,043,269	'	'
Scenario, Previously Reported [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	86,957	207,052	'	'
Receivables, net	289,905	251,080	'	'
Deferred tax assets, current	28,153	12,263	'	'
Prepaid expenses and other current assets	64,746	45,632	'	'
Total current assets	469,761	516,027	'	'
Note receivable from CareCentrix	28,471	28,471	'	'
Fixed assets, net	49,375	41,414	'	'
Intangible assets, net	256,282	193,613	'	'
Goodwill	390,081	656,364	'	'
Investments in subsidiaries	0	0	'	'
Other assets	68,647	75,045	'	'
Total assets	1,262,617	1,510,934	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	45,325	25,000	'	'
Accounts payable	15,659	13,445	'	'
Other current liabilities	314,486	251,454	'	'
Total current liabilities	375,470	289,899	'	'
Long-term debt	1,124,432	910,182	'	'
Deferred tax liabilities, net	9,825	42,165	'	'
Other liabilities	53,084	33,988	'	'
Total Gentiva shareholders' equity	-303,069	233,162	'	'
Noncontrolling interests	2,875	1,538	'	'
Total equity	-300,194	234,700	202,531	638,232
Liabilities and Equity	1,262,617	1,510,934	'	'
Scenario, Previously Reported [Member] | Gentiva Health Services, Inc. [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	55,076	166,140	'	'
Receivables, net	0	0	'	'
Deferred tax assets, current	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	55,076	166,140	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investments in subsidiaries	790,589	1,002,204	'	'
Other assets	28,266	44,219	'	'
Total assets	873,931	1,212,563	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	45,325	25,000	'	'
Accounts payable	0	0	'	'
Other current liabilities	0	0	'	'
Total current liabilities	45,325	25,000	'	'
Long-term debt	1,124,432	910,182	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	7,243	0	'	'
Total Gentiva shareholders' equity	-303,069	277,381	'	'
Noncontrolling interests	0	0	'	'
Total equity	-303,069	277,381	'	'
Liabilities and Equity	873,931	1,212,563	'	'
Scenario, Previously Reported [Member] | Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	'	'
Receivables, net	284,379	245,191	'	'
Deferred tax assets, current	25,845	10,280	'	'
Prepaid expenses and other current assets	50,890	36,899	'	'
Total current assets	361,114	292,370	'	'
Note receivable from CareCentrix	28,471	28,471	'	'
Fixed assets, net	48,824	41,066	'	'
Intangible assets, net	253,682	193,513	'	'
Goodwill	384,017	650,300	'	'
Investments in subsidiaries	28,382	27,210	'	'
Other assets	40,370	30,820	'	'
Total assets	1,144,860	1,263,750	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	15,377	27,300	'	'
Other current liabilities	283,228	202,321	'	'
Total current liabilities	298,605	229,621	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	9,825	42,165	'	'
Other liabilities	45,841	33,979	'	'
Total Gentiva shareholders' equity	790,589	957,985	'	'
Noncontrolling interests	0	0	'	'
Total equity	790,589	957,985	'	'
Liabilities and Equity	1,144,860	1,263,750	'	'
Scenario, Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	31,881	40,912	'	'
Receivables, net	34,136	19,744	'	'
Deferred tax assets, current	2,308	1,983	'	'
Prepaid expenses and other current assets	13,856	8,733	'	'
Total current assets	82,181	71,372	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	551	348	'	'
Intangible assets, net	2,600	100	'	'
Goodwill	6,064	6,064	'	'
Investments in subsidiaries	0	0	'	'
Other assets	11	6	'	'
Total assets	91,407	77,890	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	282	0	'	'
Other current liabilities	59,868	49,133	'	'
Total current liabilities	60,150	49,133	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	9	'	'
Total Gentiva shareholders' equity	28,382	27,210	'	'
Noncontrolling interests	2,875	1,538	'	'
Total equity	31,257	28,748	'	'
Liabilities and Equity	91,407	77,890	'	'
Scenario, Previously Reported [Member] | Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	'	'
Receivables, net	-28,610	-13,855	'	'
Deferred tax assets, current	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	-28,610	-13,855	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investments in subsidiaries	-818,971	-1,029,414	'	'
Other assets	0	0	'	'
Total assets	-847,581	-1,043,269	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	-13,855	'	'
Other current liabilities	-28,610	0	'	'
Total current liabilities	-28,610	-13,855	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	0	'	'
Total Gentiva shareholders' equity	-818,971	-1,029,414	'	'
Noncontrolling interests	0	0	'	'
Total equity	-818,971	-1,029,414	'	'
Liabilities and Equity	-847,581	-1,043,269	'	'
Restatement Adjustment [Member]	'	'	'	'
Current assets:	'	'	'	'
Intangible assets, net	-2,555	'	'	'
Goodwill	-6,594	'	'	'
Investments in subsidiaries	0	'	'	'
Total assets	-9,149	'	'	'
Current liabilities:	'	'	'	'
Deferred tax liabilities, net	-1,342	'	'	'
Total Gentiva shareholders' equity	-7,807	'	'	'
Total equity	-7,807	-1,740	'	'
Liabilities and Equity	-9,149	'	'	'
Restatement Adjustment [Member] | Gentiva Health Services, Inc. [Member]	'	'	'	'
Current assets:	'	'	'	'
Intangible assets, net	0	'	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	-7,807	'	'	'
Total assets	-7,807	'	'	'
Current liabilities:	'	'	'	'
Deferred tax liabilities, net	0	'	'	'
Total Gentiva shareholders' equity	-7,807	'	'	'
Total equity	-7,807	'	'	'
Liabilities and Equity	-7,807	'	'	'
Restatement Adjustment [Member] | Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Intangible assets, net	-2,555	'	'	'
Goodwill	-6,594	'	'	'
Investments in subsidiaries	0	'	'	'
Total assets	-9,149	'	'	'
Current liabilities:	'	'	'	'
Deferred tax liabilities, net	-1,342	'	'	'
Total Gentiva shareholders' equity	-7,807	'	'	'
Total equity	-7,807	'	'	'
Liabilities and Equity	-9,149	'	'	'
Restatement Adjustment [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Intangible assets, net	0	'	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	0	'	'	'
Total assets	0	'	'	'
Current liabilities:	'	'	'	'
Deferred tax liabilities, net	0	'	'	'
Total Gentiva shareholders' equity	0	'	'	'
Total equity	0	'	'	'
Liabilities and Equity	0	'	'	'
Restatement Adjustment [Member] | Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Intangible assets, net	0	'	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	7,807	'	'	'
Total assets	7,807	'	'	'
Current liabilities:	'	'	'	'
Deferred tax liabilities, net	0	'	'	'
Total Gentiva shareholders' equity	7,807	'	'	'
Total equity	7,807	'	'	'
Liabilities and Equity	7,807	'	'	'
Revision Adjustment [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	'	'	'
Receivables, net	0	'	'	'
Prepaid expenses and other current assets	0	'	'	'
Total current assets	0	'	'	'
Fixed assets, net	0	'	'	'
Intangible assets, net	'	-2,888	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	0	'	'	'
Other assets	0	'	'	'
Total assets	0	-2,888	'	'
Current liabilities:	'	'	'	'
Other current liabilities	0	'	'	'
Total current liabilities	0	'	'	'
Deferred tax liabilities, net	'	-1,148	'	'
Total Gentiva shareholders' equity	0	-1,740	'	'
Total equity	0	-1,740	-1,740	-1,203
Liabilities and Equity	0	-2,888	'	'
Revision Adjustment [Member] | Gentiva Health Services, Inc. [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	312	'	'	'
Receivables, net	0	'	'	'
Prepaid expenses and other current assets	0	'	'	'
Total current assets	312	'	'	'
Fixed assets, net	0	'	'	'
Intangible assets, net	'	0	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	-312	'	'	'
Other assets	0	'	'	'
Total assets	0	0	'	'
Current liabilities:	'	'	'	'
Other current liabilities	0	'	'	'
Total current liabilities	0	'	'	'
Deferred tax liabilities, net	'	0	'	'
Total Gentiva shareholders' equity	'	0	'	'
Total equity	0	0	'	'
Liabilities and Equity	0	0	'	'
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	'	'	'
Receivables, net	258	'	'	'
Prepaid expenses and other current assets	2,081	'	'	'
Total current assets	2,339	'	'	'
Fixed assets, net	31	'	'	'
Intangible assets, net	'	-2,888	'	'
Goodwill	2,457	'	'	'
Investments in subsidiaries	-4,889	'	'	'
Other assets	5	'	'	'
Total assets	-57	-2,888	'	'
Current liabilities:	'	'	'	'
Other current liabilities	255	'	'	'
Total current liabilities	255	'	'	'
Deferred tax liabilities, net	'	-1,148	'	'
Total Gentiva shareholders' equity	-312	-1,740	'	'
Total equity	-312	-1,740	'	'
Liabilities and Equity	-57	-2,888	'	'
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	-312	'	'	'
Receivables, net	-258	'	'	'
Prepaid expenses and other current assets	-2,081	'	'	'
Total current assets	-2,651	'	'	'
Fixed assets, net	-31	'	'	'
Intangible assets, net	'	0	'	'
Goodwill	-2,457	'	'	'
Investments in subsidiaries	0	'	'	'
Other assets	-5	'	'	'
Total assets	-5,144	0	'	'
Current liabilities:	'	'	'	'
Other current liabilities	-255	'	'	'
Total current liabilities	-255	'	'	'
Deferred tax liabilities, net	'	0	'	'
Total Gentiva shareholders' equity	-4,889	0	'	'
Total equity	-4,889	0	'	'
Liabilities and Equity	-5,144	0	'	'
Revision Adjustment [Member] | Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	'	'	'
Receivables, net	0	'	'	'
Prepaid expenses and other current assets	0	'	'	'
Total current assets	0	'	'	'
Fixed assets, net	0	'	'	'
Intangible assets, net	'	0	'	'
Goodwill	0	'	'	'
Investments in subsidiaries	5,201	'	'	'
Other assets	0	'	'	'
Total assets	5,201	0	'	'
Current liabilities:	'	'	'	'
Other current liabilities	0	'	'	'
Total current liabilities	0	'	'	'
Deferred tax liabilities, net	'	0	'	'
Total Gentiva shareholders' equity	5,201	0	'	'
Total equity	5,201	0	'	'
Liabilities and Equity	$5,201	$0	'	'

Supplemental_Guarantor_and_Non3

Supplemental Guarantor and Non-Guarantor Financial Information (Details 1) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

$486,137

$410,492

$414,424

$415,591

$425,017

$424,444

$427,691

$435,652

'

$1,726,644

$1,712,804

$1,798,778

Cost of services sold

'

'

'

'

'

'

'

'

'

942,180

908,741

948,455

Gross profit

204,955

190,014

195,477

194,018

195,763

200,555

204,954

202,791

'

784,464

804,063

850,323

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-706,227

-655,766

-731,299

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

-643,300

-612,380

[1]

-19,132

[1]

-643,305

[1]

Gain on sale of assets and businesses, net

'

'

'

'

2,600

'

5,400

'

'

0

8,014

1,061

Dividend income

'

'

'

'

'

'

'

'

'

0

0

8,590

[2]

Interest expense and other, net

'

'

'

'

'

'

'

'

'

-110,384

[3]

-89,947

[3]

-88,610

[3]

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

0

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

-463,338

[4]

6,594

11,041

-198,824

[4]

18,510

[5]

-2,678

[4]

23,818

[5]

7,582

'

-644,527

47,232

-603,240

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

39,953

-17,251

76,123

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

-2,301

68,381

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-604,574

27,680

-458,736

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

0

0

8,315

Net (loss) income

-420,620

[4],[6]

3,563

[6]

6,134

[6]

-194,138

[4],[6]

8,570

[5],[6],[7]

-523

[4],[6]

13,909

[5],[6]

4,840

[6]

'

-604,574

27,680

-450,421

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

-487

-884

-641

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-604,574

27,680

-450,899

Gentiva Health Services, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

0

0

0

Cost of services sold

'

'

'

'

'

'

'

'

'

0

0

0

Gross profit

'

'

'

'

'

'

'

'

'

0

0

0

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

0

0

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

0

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

0

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

'

-90,054

-88,665

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

-536,764

79,622

-380,713

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-647,241

-10,432

-469,378

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

42,180

37,228

18,316

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

0

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

0

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-451,062

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-605,061

26,796

-451,062

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-605,061

26,796

-451,540

Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

1,677,892

1,666,368

1,757,459

Cost of services sold

'

'

'

'

'

'

'

'

'

905,799

884,903

921,826

Gross profit

'

'

'

'

'

'

'

'

'

772,093

781,465

835,633

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-686,997

-638,975

-716,235

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-612,380

-19,132

-643,305

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

8,014

1,061

Dividend income

'

'

'

'

'

'

'

'

'

'

'

8,590

Interest expense and other, net

'

'

'

'

'

'

'

'

'

0

0

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

-4,710

3,038

221

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-531,994

134,410

-514,035

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

-4,770

-52,487

56,992

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

-2,301

68,381

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-536,764

79,622

-388,662

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

7,949

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-380,713

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-536,764

79,622

-380,713

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-536,764

79,622

-380,713

Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

63,985

61,656

52,404

Cost of services sold

'

'

'

'

'

'

'

'

'

51,614

39,058

37,714

Gross profit

'

'

'

'

'

'

'

'

'

12,371

22,598

14,690

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-19,230

-16,791

-15,064

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

0

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

0

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

93

107

55

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

0

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-6,766

5,914

-319

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

2,543

-1,992

815

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

0

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-4,223

3,922

496

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

366

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

862

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

-487

-884

-641

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-4,710

3,038

221

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-4,223

3,922

862

Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

-15,233

-15,220

-11,085

Cost of services sold

'

'

'

'

'

'

'

'

'

-15,233

-15,220

-11,085

Gross profit

'

'

'

'

'

'

'

'

'

0

0

0

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

0

0

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

0

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

0

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

0

0

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

541,474

-82,660

380,492

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

541,474

-82,660

380,492

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

0

0

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

0

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

541,474

-82,660

380,492

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

0

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

380,492

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

0

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

541,474

-82,660

380,492

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

541,474

-82,660

380,492

Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

1,726,644

'

1,798,778

Cost of services sold

'

'

'

'

'

'

'

'

'

942,180

'

948,455

Gross profit

'

'

'

'

'

'

'

'

'

784,464

'

850,323

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-701,716

'

-730,407

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-610,436

'

-643,305

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

'

1,061

Dividend income

'

'

'

'

'

'

'

'

'

'

'

8,590

Interest expense and other, net

'

'

'

'

'

'

'

'

'

-110,384

'

-88,610

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

'

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

-443,844

6,852

11,392

-212,472

'

'

'

'

'

-638,072

'

-602,348

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

39,565

'

75,768

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

'

68,381

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-598,507

'

-458,199

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

8,315

Net (loss) income

-401,884

3,720

6,347

-207,177

'

'

'

'

'

-598,507

'

-449,884

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

-487

'

-641

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-598,994

'

-450,525

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-598,507

'

-450,362

Scenario, Previously Reported [Member] | Gentiva Health Services, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

0

'

0

Cost of services sold

'

'

'

'

'

'

'

'

'

0

'

0

Gross profit

'

'

'

'

'

'

'

'

'

0

'

0

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

0

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

'

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

-110,477

'

-88,665

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

-530,697

'

-380,176

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-641,174

'

-468,841

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

42,180

'

18,316

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-598,994

'

-450,525

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

0

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-450,525

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

'

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-598,994

'

-450,525

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-598,994

'

-451,003

Scenario, Previously Reported [Member] | Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

1,676,888

'

1,757,459

Cost of services sold

'

'

'

'

'

'

'

'

'

905,261

'

921,826

Gross profit

'

'

'

'

'

'

'

'

'

771,627

'

835,633

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-682,262

'

-715,343

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-610,436

'

-643,305

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

'

1,061

Dividend income

'

'

'

'

'

'

'

'

'

'

'

8,590

Interest expense and other, net

'

'

'

'

'

'

'

'

'

0

'

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

-4,561

'

221

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-525,632

'

-513,143

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

-5,065

'

56,637

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

'

68,381

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-530,697

'

-388,125

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

7,949

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-380,176

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

'

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-530,697

'

-380,176

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-530,697

'

-380,176

Scenario, Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

64,989

'

52,404

Cost of services sold

'

'

'

'

'

'

'

'

'

52,152

'

37,714

Gross profit

'

'

'

'

'

'

'

'

'

12,837

'

14,690

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-19,454

'

-15,064

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

'

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

93

'

55

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

'

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-6,524

'

-319

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

2,450

'

815

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-4,074

'

496

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

366

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

862

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

-487

'

-641

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-4,561

'

221

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-4,074

'

862

Scenario, Previously Reported [Member] | Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

-15,233

'

-11,085

Cost of services sold

'

'

'

'

'

'

'

'

'

-15,233

'

-11,085

Gross profit

'

'

'

'

'

'

'

'

'

0

'

0

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

0

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

0

Gain on sale of assets and businesses, net

'

'

'

'

'

'

'

'

'

'

'

0

Dividend income

'

'

'

'

'

'

'

'

'

'

'

0

Interest expense and other, net

'

'

'

'

'

'

'

'

'

0

'

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

535,258

'

379,955

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

535,258

'

379,955

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

0

Equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

'

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

535,258

'

379,955

Discontinued operations, net of tax

'

'

'

'

'

'

'

'

'

'

'

0

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

379,955

Less: Net income attributable to noncontrolling interests

'

'

'

'

'

'

'

'

'

0

'

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

535,258

'

379,955

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

535,258

'

379,955

Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-4,511

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-1,944

'

'

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

'

'

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

-19,494

-258

-351

13,648

'

'

'

'

'

-6,455

'

'

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

388

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-6,067

'

'

Net (loss) income

-18,736

-157

-213

13,039

'

'

'

'

'

-6,067

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-6,067

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-6,067

'

'

Restatement Adjustment [Member] | Gentiva Health Services, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

'

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

-6,067

'

'

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-6,067

'

'

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-6,067

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-6,067

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-6,067

'

'

Restatement Adjustment [Member] | Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-4,511

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

-1,944

'

'

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

'

'

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-6,455

'

'

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

388

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-6,067

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-6,067

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-6,067

'

'

Restatement Adjustment [Member] | Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

'

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

0

'

'

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

'

'

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

0

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

0

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

0

'

'

Restatement Adjustment [Member] | Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

'

Goodwill, intangibles and other long-lived asset impairment

'

'

'

'

'

'

'

'

'

0

'

'

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

6,067

'

'

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

6,067

'

'

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

'

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

6,067

'

'

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

6,067

'

'

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

6,067

'

'

Revision Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

0

'

'

Cost of services sold

'

'

'

'

'

'

'

'

'

0

'

'

Gross profit

'

'

'

'

'

'

'

'

'

0

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

-892

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

'

-892

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

355

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

0

'

-537

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-537

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

0

'

-537

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

0

'

-537

Revision Adjustment [Member] | Gentiva Health Services, Inc. [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

0

'

'

Cost of services sold

'

'

'

'

'

'

'

'

'

0

'

'

Gross profit

'

'

'

'

'

'

'

'

'

0

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

-537

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

'

-537

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

0

'

-537

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-537

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

0

'

-537

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

0

'

-537

Revision Adjustment [Member] | Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

1,004

'

'

Cost of services sold

'

'

'

'

'

'

'

'

'

538

'

'

Gross profit

'

'

'

'

'

'

'

'

'

466

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

-224

'

-892

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

242

'

-892

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

-93

'

355

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

149

'

-537

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

-537

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

149

'

-537

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

145

'

-537

Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

-1,004

'

'

Cost of services sold

'

'

'

'

'

'

'

'

'

-538

'

'

Gross profit

'

'

'

'

'

'

'

'

'

-466

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

224

'

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

0

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

-242

'

0

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

93

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

-149

'

0

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

0

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

-149

'

0

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

-145

'

0

Revision Adjustment [Member] | Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Condensed Consolidating Statement of Comprehensive Income

'

'

'

'

'

'

'

'

'

'

'

'

Total net revenues

'

'

'

'

'

'

'

'

'

0

'

'

Cost of services sold

'

'

'

'

'

'

'

'

'

0

'

'

Gross profit

'

'

'

'

'

'

'

'

'

0

'

'

Selling, general and administrative expenses

'

'

'

'

'

'

'

'

'

0

'

0

Equity in earnings (loss) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

537

(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix

'

'

'

'

'

'

'

'

'

0

'

537

Income tax benefit (expense)

'

'

'

'

'

'

'

'

'

0

'

0

Income (Loss) from Continuing Operations

'

'

'

'

'

'

'

'

'

0

'

537

Net (loss) income

'

'

'

'

'

'

'

'

'

'

'

537

Net income (loss) attributable to Gentiva shareholders

'

'

'

'

'

'

'

'

'

0

'

537

Total comprehensive Income (Loss)

'

'

'

'

'

'

'

'

'

$0

'

$537

[1]

The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended DecemberB 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of DecemberB 31, 2011, as a result of the impairment.

[2]

For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Companybs combined common and preferred ownership of CareCentrix.

[3]

For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Companybs interest rate swaps in connection with the refinancing of the Companybs Term Loan A and Term Loan B under the Companybs former credit agreement. See Note 13 for additional information.

[4]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[5]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[6]

(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):B FirstQuarterB SecondQuarterB ThirdQuarterB FourthQuarterYear ended DecemberB 31, 2013$141B $744B $1,699B $24,955Year ended DecemberB 31, 2012$5,391B $25B $53B $201

[7]

In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

Supplemental_Guarantor_and_Non4

Supplemental Guarantor and Non-Guarantor Financial Information (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	$37,105	$125,968	$5,141
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-19,075	-11,779	-19,231
Proceeds from sale of businesses	508	9,220	146,315
Proceeds from sale of assets	203	0	0
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	-359,435	-22,335	-320
Net cash (used in) provided by investing activities	-377,799	-24,894	126,764
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,231	3,980	7,901
Windfall tax benefits associated with equity-based compensation	119	88	192
Payments of contingent consideration accrued at acquisition date	-1,675	0	0
Proceeds from issuance of debt	817,525	0	0
Borrowings under revolving credit facility	27,000	0	0
Intercompany dividend	0	'	'
Repayment of long-term debt	-610,182	-52,943	-63,438
Debt issuance costs	-15,187	-4,125	-15,460
Investment in affiliate	0	'	'
Minority interest capital contribution	1,600	0	0
Majority interest capital contribution	0	'	'
Repurchase of common stock	0	-4,974	0
Repayment of capital lease obligations	'	-135	-267
Distribution to minority interests	-750	-825	-673
Distribution to majority interests	0	'	'
Other	-1,082	-135	-267
Net payments related to intercompany financing	0	0	0
Net cash (used in) provided by financing activities	220,599	-58,934	-71,745
Net change in cash and cash equivalents	-120,095	42,140	60,160
Cash and cash equivalents at beginning of period	207,052	164,912	104,752
Cash and cash equivalents at end of period	86,957	207,052	164,912
Gentiva Health Services, Inc. [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-29,406	-18,089	-46,730
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	0	0
Proceeds from sale of businesses	0	0	0
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	0	0	0
Net cash (used in) provided by investing activities	0	0	0
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,231	3,980	7,901
Windfall tax benefits associated with equity-based compensation	119	88	192
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	817,525	'	'
Borrowings under revolving credit facility	27,000	'	'
Intercompany dividend	0	'	'
Repayment of long-term debt	-610,182	-52,943	-63,438
Debt issuance costs	-15,187	-4,125	-15,460
Investment in affiliate	0	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	0	'	'
Repurchase of common stock	'	-4,974	'
Repayment of capital lease obligations	'	-135	-267
Distribution to minority interests	0	4,673	0
Distribution to majority interests	0	'	'
Other	-889	'	'
Net payments related to intercompany financing	-302,963	113,564	178,087
Net cash (used in) provided by financing activities	-81,346	60,128	107,015
Net change in cash and cash equivalents	-110,752	42,039	60,285
Cash and cash equivalents at beginning of period	166,140	124,101	63,816
Cash and cash equivalents at end of period	55,388	166,140	124,101
Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	80,977	138,316	51,221
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-18,706	-11,609	-19,053
Proceeds from sale of businesses	508	9,220	146,261
Proceeds from sale of assets	203	'	'
(Payments to) proceeds from affiliate	-7,400	'	'
Acquisition of businesses, net of cash acquired	-356,935	-22,335	-320
Net cash (used in) provided by investing activities	-382,330	-24,724	126,888
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	0	0
Windfall tax benefits associated with equity-based compensation	0	0	0
Payments of contingent consideration accrued at acquisition date	-1,675	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	0	'	'
Repayment of long-term debt	0	0	0
Debt issuance costs	0	0	0
Investment in affiliate	0	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	0	'	'
Repurchase of common stock	'	0	'
Repayment of capital lease obligations	'	0	0
Distribution to minority interests	0	-28	-22
Distribution to majority interests	0	'	'
Other	-28	'	'
Net payments related to intercompany financing	303,056	-113,564	-178,087
Net cash (used in) provided by financing activities	301,353	-113,592	-178,109
Net change in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	0	0	0
Non-Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-10,429	5,741	650
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-369	-170	-178
Proceeds from sale of businesses	0	0	54
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	-2,500	0	0
Net cash (used in) provided by investing activities	-2,869	-170	-124
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	0	0
Windfall tax benefits associated with equity-based compensation	0	0	0
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	-2,300	'	'
Repayment of long-term debt	0	0	0
Debt issuance costs	0	0	0
Investment in affiliate	5,000	'	'
Minority interest capital contribution	1,600	'	'
Majority interest capital contribution	2,400	'	'
Repurchase of common stock	'	0	'
Repayment of capital lease obligations	'	0	0
Distribution to minority interests	-750	-5,470	-651
Distribution to majority interests	-1,737	'	'
Other	-165	'	'
Net payments related to intercompany financing	-93	0	0
Net cash (used in) provided by financing activities	3,955	-5,470	-651
Net change in cash and cash equivalents	-9,343	101	-125
Cash and cash equivalents at beginning of period	40,912	40,811	40,936
Cash and cash equivalents at end of period	31,569	40,912	40,811
Eliminations [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-4,037	0	0
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	0	0
Proceeds from sale of businesses	0	0	0
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	7,400	'	'
Acquisition of businesses, net of cash acquired	0	0	0
Net cash (used in) provided by investing activities	7,400	0	0
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	0	0
Windfall tax benefits associated with equity-based compensation	0	0	0
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	2,300	'	'
Repayment of long-term debt	0	0	0
Debt issuance costs	0	0	0
Investment in affiliate	-5,000	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	-2,400	'	'
Repurchase of common stock	'	0	'
Repayment of capital lease obligations	'	0	0
Distribution to minority interests	0	0	0
Distribution to majority interests	1,737	'	'
Other	0	'	'
Net payments related to intercompany financing	0	0	0
Net cash (used in) provided by financing activities	-3,363	0	0
Net change in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of period	0	0	0
Cash and cash equivalents at end of period	0	0	0
Scenario, Previously Reported [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	37,105	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-19,075	'	'
Proceeds from sale of businesses	508	'	'
Proceeds from sale of assets	203	'	'
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	-359,435	'	'
Net cash (used in) provided by investing activities	-377,799	'	'
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,231	'	'
Windfall tax benefits associated with equity-based compensation	119	'	'
Payments of contingent consideration accrued at acquisition date	-1,675	'	'
Proceeds from issuance of debt	817,525	'	'
Borrowings under revolving credit facility	27,000	'	'
Intercompany dividend	0	'	'
Repayment of long-term debt	-610,182	'	'
Debt issuance costs	-15,187	'	'
Investment in affiliate	0	'	'
Minority interest capital contribution	1,600	'	'
Majority interest capital contribution	0	'	'
Distribution to minority interests	-750	'	'
Distribution to majority interests	0	'	'
Other	-1,082	'	'
Net payments related to intercompany financing	0	'	'
Net cash (used in) provided by financing activities	220,599	'	'
Net change in cash and cash equivalents	-120,095	'	'
Cash and cash equivalents at beginning of period	207,052	'	'
Cash and cash equivalents at end of period	86,957	'	'
Scenario, Previously Reported [Member] | Gentiva Health Services, Inc. [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-29,406	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	'	'
Proceeds from sale of businesses	0	'	'
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	0	'	'
Net cash (used in) provided by investing activities	0	'	'
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,231	'	'
Windfall tax benefits associated with equity-based compensation	119	'	'
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	817,525	'	'
Borrowings under revolving credit facility	27,000	'	'
Intercompany dividend	0	'	'
Repayment of long-term debt	-610,182	'	'
Debt issuance costs	-15,187	'	'
Investment in affiliate	0	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	0	'	'
Distribution to minority interests	0	'	'
Distribution to majority interests	0	'	'
Other	-889	'	'
Net payments related to intercompany financing	-303,275	'	'
Net cash (used in) provided by financing activities	-81,658	'	'
Net change in cash and cash equivalents	-111,064	'	'
Cash and cash equivalents at beginning of period	166,140	'	'
Cash and cash equivalents at end of period	55,076	'	'
Scenario, Previously Reported [Member] | Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	80,742	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-18,690	'	'
Proceeds from sale of businesses	508	'	'
Proceeds from sale of assets	203	'	'
(Payments to) proceeds from affiliate	-7,400	'	'
Acquisition of businesses, net of cash acquired	-356,935	'	'
Net cash (used in) provided by investing activities	-382,314	'	'
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	'	'
Windfall tax benefits associated with equity-based compensation	0	'	'
Payments of contingent consideration accrued at acquisition date	-1,675	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	0	'	'
Repayment of long-term debt	0	'	'
Debt issuance costs	0	'	'
Investment in affiliate	0	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	0	'	'
Distribution to minority interests	0	'	'
Distribution to majority interests	0	'	'
Other	-28	'	'
Net payments related to intercompany financing	303,275	'	'
Net cash (used in) provided by financing activities	301,572	'	'
Net change in cash and cash equivalents	0	'	'
Cash and cash equivalents at beginning of period	0	'	'
Cash and cash equivalents at end of period	0	'	'
Scenario, Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-10,194	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-385	'	'
Proceeds from sale of businesses	0	'	'
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	0	'	'
Acquisition of businesses, net of cash acquired	-2,500	'	'
Net cash (used in) provided by investing activities	-2,885	'	'
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	'	'
Windfall tax benefits associated with equity-based compensation	0	'	'
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	-2,300	'	'
Repayment of long-term debt	0	'	'
Debt issuance costs	0	'	'
Investment in affiliate	5,000	'	'
Minority interest capital contribution	1,600	'	'
Majority interest capital contribution	2,400	'	'
Distribution to minority interests	-750	'	'
Distribution to majority interests	-1,737	'	'
Other	-165	'	'
Net payments related to intercompany financing	0	'	'
Net cash (used in) provided by financing activities	4,048	'	'
Net change in cash and cash equivalents	-9,031	'	'
Cash and cash equivalents at beginning of period	40,912	'	'
Cash and cash equivalents at end of period	31,881	'	'
Scenario, Previously Reported [Member] | Eliminations [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-4,037	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	'	'
Proceeds from sale of businesses	0	'	'
Proceeds from sale of assets	0	'	'
(Payments to) proceeds from affiliate	7,400	'	'
Acquisition of businesses, net of cash acquired	0	'	'
Net cash (used in) provided by investing activities	7,400	'	'
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	0	'	'
Windfall tax benefits associated with equity-based compensation	0	'	'
Payments of contingent consideration accrued at acquisition date	0	'	'
Proceeds from issuance of debt	0	'	'
Borrowings under revolving credit facility	0	'	'
Intercompany dividend	2,300	'	'
Repayment of long-term debt	0	'	'
Debt issuance costs	0	'	'
Investment in affiliate	-5,000	'	'
Minority interest capital contribution	0	'	'
Majority interest capital contribution	-2,400	'	'
Distribution to minority interests	0	'	'
Distribution to majority interests	1,737	'	'
Other	0	'	'
Net payments related to intercompany financing	0	'	'
Net cash (used in) provided by financing activities	-3,363	'	'
Net change in cash and cash equivalents	0	'	'
Cash and cash equivalents at beginning of period	0	'	'
Cash and cash equivalents at end of period	0	'	'
Revision Adjustment [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	0	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	'	'
Net cash (used in) provided by investing activities	0	'	'
FINANCING ACTIVITIES:	'	'	'
Net payments related to intercompany financing	0	'	'
Net cash (used in) provided by financing activities	0	'	'
Net change in cash and cash equivalents	0	'	'
Cash and cash equivalents at end of period	0	'	'
Revision Adjustment [Member] | Gentiva Health Services, Inc. [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	0	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	'	'
Net cash (used in) provided by investing activities	0	'	'
FINANCING ACTIVITIES:	'	'	'
Net payments related to intercompany financing	312	'	'
Net cash (used in) provided by financing activities	312	'	'
Net change in cash and cash equivalents	312	'	'
Cash and cash equivalents at end of period	312	'	'
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	235	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	-16	'	'
Net cash (used in) provided by investing activities	-16	'	'
FINANCING ACTIVITIES:	'	'	'
Net payments related to intercompany financing	-219	'	'
Net cash (used in) provided by financing activities	-219	'	'
Net change in cash and cash equivalents	0	'	'
Cash and cash equivalents at end of period	0	'	'
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	-235	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	16	'	'
Net cash (used in) provided by investing activities	16	'	'
FINANCING ACTIVITIES:	'	'	'
Net payments related to intercompany financing	-93	'	'
Net cash (used in) provided by financing activities	-93	'	'
Net change in cash and cash equivalents	-312	'	'
Cash and cash equivalents at end of period	-312	'	'
Revision Adjustment [Member] | Eliminations [Member]	'	'	'
OPERATING ACTIVITIES:	'	'	'
Net cash provided by operating activities	0	'	'
INVESTING ACTIVITIES:	'	'	'
Purchase of fixed assets	0	'	'
Net cash (used in) provided by investing activities	0	'	'
FINANCING ACTIVITIES:	'	'	'
Net payments related to intercompany financing	0	'	'
Net cash (used in) provided by financing activities	0	'	'
Net change in cash and cash equivalents	0	'	'
Cash and cash equivalents at end of period	$0	'	'

Quarterly_Financial_Informatio2

Quarterly Financial Information (Unaudited) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Quarterly Financial Information Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Net revenues

$486,137

$410,492

$414,424

$415,591

$425,017

$424,444

$427,691

$435,652

$1,726,644

$1,712,804

$1,798,778

Gross profit

204,955

190,014

195,477

194,018

195,763

200,555

204,954

202,791

784,464

804,063

850,323

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix, including gain on sale

-463,338

[1]

6,594

11,041

-198,824

[1]

18,510

[2]

-2,678

[1]

23,818

[2]

7,582

-644,527

47,232

-603,240

Net income (loss) attributable to Gentiva shareholders

-420,620

[1],[3]

3,563

[3]

6,134

[3]

-194,138

[1],[3]

8,570

[2],[3],[4]

-523

[1],[3]

13,909

[2],[3]

4,840

[3]

-604,574

27,680

-450,421

Basic:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($12)

$0.12

$0.20

($6.31)

$0.28

($0.02)

$0.46

$0.16

($18.94)

$0.88

($14.86)

Diluted:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($12)

$0.11

$0.20

($6.31)

$0.28

($0.02)

$0.46

$0.16

($18.94)

$0.87

($14.86)

Weighted average shares outstanding:

'

'

'

'

'

'

'

'

'

'

'

Basic

35,054

31,037

30,941

30,785

30,548

30,423

30,338

30,724

31,954

30,509

30,336

Diluted

35,054

31,532

31,239

30,785

30,891

30,423

30,446

30,959

31,954

30,687

30,336

Scenario, Previously Reported [Member]

'

'

'

'

'

'

'

'

'

'

'

Quarterly Financial Information Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Net revenues

'

'

'

'

'

'

'

'

1,726,644

'

1,798,778

Gross profit

'

'

'

'

'

'

'

'

784,464

'

850,323

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix, including gain on sale

-443,844

6,852

11,392

-212,472

'

'

'

'

-638,072

'

-602,348

Net income (loss) attributable to Gentiva shareholders

-401,884

3,720

6,347

-207,177

'

'

'

'

-598,507

'

-449,884

Basic:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($11.46)

$0.12

$0.21

($6.73)

'

'

'

'

($18.75)

'

($14.85)

Diluted:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($11.46)

$0.12

$0.20

($6.73)

'

'

'

'

($18.75)

'

($14.85)

Restatement Adjustment [Member]

'

'

'

'

'

'

'

'

'

'

'

Quarterly Financial Information Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Income (loss) from continuing operations before income taxes and equity in net earnings of CareCentrix, including gain on sale

-19,494

-258

-351

13,648

'

'

'

'

-6,455

'

'

Net income (loss) attributable to Gentiva shareholders

($18,736)

($157)

($213)

$13,039

'

'

'

'

($6,067)

'

'

Basic:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($0.54)

$0

($0.01)

$0.42

'

'

'

'

($0.19)

'

'

Diluted:

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income attributable to Gentiva shareholders

($0.54)

($0.01)

$0

$0.42

'

'

'

'

($0.19)

'

'

[1]

For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $399.7 million and $2.0 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $210.7 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 9 and 10.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[2]

For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[3]

(Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands):B FirstQuarterB SecondQuarterB ThirdQuarterB FourthQuarterYear ended DecemberB 31, 2013$141B $744B $1,699B $24,955Year ended DecemberB 31, 2012$5,391B $25B $53B $201

[4]

In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.

Quarterly_Financial_Informatio3

Quarterly Financial Information (Unaudited) (Details 1) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Restructuring charges	$24,955	$1,699	$744	$141	$201	$53	$25	$5,391	$27,539	$5,670	$49,138

Quarterly_Financial_Informatio4

Quarterly Financial Information (Unaudited) (Details Textual) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 24, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Hospice [Member]

Goodwill [Member]

Intangible Assets [Member]

Schedule of Quarterly Financial Data [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Impairment Loss

$207,200,000

'

'

$606,916,000

'

'

'

$207,200,000

$606,916,000

$457,000,000

$399,700,000

'

Impairment of intangible assets, finite-lived

210,700,000

'

'

'

19,100,000

'

'

'

13,100,000

'

'

2,000,000

Gain on sale of assets and businesses, net

'

2,600,000

5,400,000

0

8,014,000

1,061,000

'

'

'

'

'

'

Increase (decrease) in notes receivable

'

6,500,000

'

'

'

'

'

'

'

'

'

'

Seller financing note receivable

'

$3,400,000

'

$3,400,000

$3,400,000

'

$9,900,000

'

'

'

'

'

SCHEDULE_IIVALUATION_AND_QUALI1

SCHEDULE IIbVALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 03, 2010
Allowance for Doubtful Accounts [Member]	'	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'	'
Balance at beginning of period	$8,777	$11,562	'	$7,654
Additions charged to costs and expenses	6,730	4,066	8,541	'
Deductions	-4,827	-6,851	-4,633	'
Balance at end of period	10,680	8,777	11,562	7,654
Valuation Allowance on Deferred Tax Assets [Member]	'	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'	'
Balance at beginning of period	2,878	4,667	'	13,376
Additions charged to costs and expenses	763	0	258	'
Deductions	0	-1,789	-8,967	'
Balance at end of period	$3,641	$2,878	$4,667	$13,376